var title_f40_18_41248="Wedge shoes";
var content_f40_18_41248=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F53678&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F53678&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 491px\">",
"   <div class=\"ttl\">",
"    Wedge shoes",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 471px; height: 646px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     <p>",
"      &nbsp;",
"     </p>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_18_41248=[""].join("\n");
var outline_f40_18_41248=null;
var title_f40_18_41249="Contents: Gastrointestinal disease";
var content_f40_18_41249=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"mobipreview.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"mobipreview.htm?3/12/3278\">",
"       Gastroenterology and Hepatology",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Gastrointestinal disease",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"mobipreview.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Gastrointestinal disease",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Appendicitis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?30/40/31370\">",
"           Acute appendicitis in adults: Clinical manifestations and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?5/7/5242\">",
"           Acute appendicitis in adults: Management",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Bariatric surgery",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?40/58/41898\">",
"           Complications of bariatric surgery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?32/31/33274\">",
"           Surgical management of severe obesity",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Benign anal disorders",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?33/24/34181\">",
"           Anal fissure: Clinical manifestations, diagnosis, prevention",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?15/1/15384\">",
"           Anal fissure: Medical and surgical management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?14/48/15110\">",
"           Approach to the patient with anal pruritus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?22/38/23144\">",
"           Condylomata acuminata (anogenital warts)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?5/14/5348\">",
"           Overview of hemorrhoids",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?25/40/26246\">",
"           Perianal abscess: Clinical manifestations, diagnosis, treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?15/47/16118\">",
"           Proctalgia fugax",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?5/61/6105\">",
"           Treatment of hemorrhoids",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Clinical pathological cases",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?33/27/34226\">",
"           Clinical pathological cases in gastroenterology: Stomach",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Conscious sedation",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?42/2/43049\">",
"           Alternatives and adjuncts to moderate procedural sedation for gastrointestinal endoscopy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/41/28310\">",
"           Complications of procedural sedation for gastrointestinal endoscopy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?24/22/24936\">",
"           Overview of procedural sedation for gastrointestinal endoscopy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?41/44/42694\">",
"           Sedation-free gastrointestinal endoscopy",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Diverticular disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?41/52/42819\">",
"           Acute diverticulitis complicated by fistula formation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?34/6/34919\">",
"           Clinical manifestations and diagnosis of colonic diverticular disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?37/49/38679\">",
"           Colonic diverticular bleeding",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?19/54/20324\">",
"           Diverticular colitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?35/63/36854\">",
"           Epidemiology and pathophysiology of colonic diverticular disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?7/6/7272\">",
"           Etiology of lower gastrointestinal bleeding in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?11/4/11336\">",
"           Evaluation of occult gastrointestinal bleeding",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?32/8/32901\">",
"           Small bowel diverticula",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?13/8/13450\">",
"           Treatment of acute diverticulitis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Gastrointestinal bleeding",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?8/13/8410\">",
"           Angiodysplasia of the gastrointestinal tract",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?24/2/24616\">",
"           Angiographic control of nonvariceal gastrointestinal bleeding in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/55/28538\">",
"           Approach to acute upper gastrointestinal bleeding in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?30/7/30841\">",
"           Approach to resuscitation and diagnosis of acute lower gastrointestinal bleeding in the adult patient",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?33/56/34695\">",
"           Argon plasma coagulation in the management of gastrointestinal hemorrhage",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?37/49/38679\">",
"           Colonic diverticular bleeding",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?15/10/15528\">",
"           Contact thermal devices, endoscopic hemoclips, and epinephrine injection for ulcer hemostasis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?7/6/7272\">",
"           Etiology of lower gastrointestinal bleeding in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?30/39/31352\">",
"           Evaluation of obscure gastrointestinal bleeding",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?11/4/11336\">",
"           Evaluation of occult gastrointestinal bleeding",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?24/32/25094\">",
"           Fibrin sealant",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?24/24/24968\">",
"           Gastrointestinal manifestations of vasculitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?1/56/1928\">",
"           General principles of the management of variceal hemorrhage",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?30/31/31226\">",
"           Hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu syndrome)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?12/23/12664\">",
"           Major causes of upper gastrointestinal bleeding in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?6/37/6745\">",
"           NSAIDs (including aspirin): Pathogenesis of gastroduodenal toxicity",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?37/31/38393\">",
"           NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?11/58/12197\">",
"           NSAIDs (including aspirin): Secondary prevention of gastroduodenal toxicity",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?26/20/26947\">",
"           NSAIDs (including aspirin): Treatment of gastroduodenal toxicity",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?37/6/37990\">",
"           Overview of Peutz-Jeghers syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?5/14/5348\">",
"           Overview of hemorrhoids",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?24/15/24826\">",
"           Overview of the treatment of bleeding peptic ulcers",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?20/60/21446\">",
"           Prediction of variceal hemorrhage in patients with cirrhosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?17/23/17786\">",
"           Prevention of recurrent variceal hemorrhage in patients with cirrhosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?26/49/27418\">",
"           Primary and pre-primary prophylaxis against variceal hemorrhage in patients with cirrhosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?22/61/23514\">",
"           Treatment of active variceal hemorrhage",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?5/61/6105\">",
"           Treatment of hemorrhoids",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?40/56/41865\">",
"           Uncommon causes of upper gastrointestinal bleeding in adults",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Mesenteric ischemia",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?43/21/44377\">",
"           Acute mesenteric ischemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?26/43/27316\">",
"           Celiac artery compression syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?32/27/33206\">",
"           Chronic mesenteric ischemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?41/20/42313\">",
"           Colonic ischemia",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Miscellaneous",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?25/30/26087\">",
"           A short primer on cost-effectiveness analysis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?40/25/41367\">",
"           Antibiotic prophylaxis for gastrointestinal endoscopic procedures",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?30/22/31077\">",
"           Appendiceal (ileocecal) mucoceles",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?42/55/43897\">",
"           Approach to the adult with chronic diarrhea in developed countries",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?31/62/32746\">",
"           Approach to the patient with colonic polyps",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?14/9/14485\">",
"           Cap polyposis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?30/19/31030\">",
"           Chronic abdominal wall pain",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?18/59/19386\">",
"           Clinical features and diagnosis of Lynch syndrome (hereditary nonpolyposis colorectal cancer)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?24/31/25078\">",
"           Clinical manifestations and diagnosis of familial Mediterranean fever",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?16/39/17016\">",
"           Clinical manifestations and diagnosis of familial adenomatous polyposis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?41/25/42394\">",
"           Colorectal cancer: Epidemiology, risk factors, and protective factors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?40/55/41848\">",
"           Congenital aganglionic megacolon (Hirschsprung disease)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?33/48/34568\">",
"           Cyclic vomiting syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?19/15/19706\">",
"           Cystic fibrosis: Overview of gastrointestinal disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?16/30/16874\">",
"           Differential diagnosis of abdominal pain in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?31/13/31959\">",
"           Endoscopic procedures in patients with disorders of hemostasis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?28/18/28968\">",
"           Endoscopic removal of large colonic polyps",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?42/43/43703\">",
"           Eosinophilic gastroenteritis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?4/35/4661\">",
"           Epidemiology of gastric cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?34/16/35076\">",
"           Epiploic appendagitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?6/6/6246\">",
"           Factitious diarrhea",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?16/14/16618\">",
"           Familial adenomatous polyposis and MUTYH associated polyposis: Screening and management of patients and families",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?21/59/22458\">",
"           Fecal incontinence in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?23/25/23960\">",
"           Fecal microbiota transplantation in the treatment of recurrent Clostridium difficile infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?25/62/26598\">",
"           Gallstone ileus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?7/11/7352\">",
"           Gardner syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?43/47/44793\">",
"           Gastric outlet obstruction in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?16/27/16824\">",
"           Gastrointestinal disorders in athletes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?5/50/5928\">",
"           Gastrointestinal manifestations of systemic lupus erythematosus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?17/14/17638\">",
"           Gastrointestinal sarcoidosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?24/18/24872\">",
"           Intestinal gas and bloating",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?5/32/5641\">",
"           Lactose intolerance",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?29/5/29783\">",
"           Lynch syndrome (hereditary nonpolyposis colorectal cancer): Screening and management of patients and families",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?20/33/21014\">",
"           Management of anticoagulants in patients undergoing endoscopic procedures",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?5/36/5702\">",
"           Management of antiplatelet agents in patients undergoing endoscopic procedures",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?8/3/8247\">",
"           Management of familial Mediterranean fever",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?2/10/2218\">",
"           Management of patients with a colostomy or ileostomy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?31/32/32261\">",
"           Pathophysiology of familial Mediterranean fever",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?7/21/7507\">",
"           Patient information: Gallstones (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?3/9/3224\">",
"           Peutz-Jeghers syndrome and juvenile polyposis: Screening and management of patients and families",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?30/31/31223\">",
"           Pneumatosis intestinalis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?2/33/2586\">",
"           Postoperative ileus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?16/10/16554\">",
"           Probiotics for gastrointestinal diseases",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?38/46/39654\">",
"           Rectal foreign bodies",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?0/38/618\">",
"           Risk factors for gastric cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?14/6/14440\">",
"           Sclerosing mesenteritis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?6/52/6983\">",
"           Screening and prevention of gastric cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?20/40/21125\">",
"           Solitary rectal ulcer syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?29/51/30519\">",
"           Tattooing and other methods for localizing colonic lesions",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?38/25/39319\">",
"           The role of imaging tests in the evaluation of anal abscesses and fistulas",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?31/25/32154\">",
"           Transabdominal ultrasonography of the small and large intestine",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Nausea and vomiting",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?15/47/16120\">",
"           Approach to the adult with nausea and vomiting",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?18/48/19208\">",
"           Characteristics of antiemetic drugs",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?38/61/39894\">",
"           Pathophysiology and prediction of chemotherapy-induced nausea and vomiting",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?38/18/39210\">",
"           Prevention and treatment of chemotherapy-induced nausea and vomiting",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Neuroendocrine tumors",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?17/57/18330\">",
"           Classification, epidemiology, clinical presentation, localization, and staging of pancreatic neuroendocrine tumors (islet-cell tumors)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?0/60/969\">",
"           Clinical characteristics of carcinoid tumors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?8/63/9206\">",
"           Clinical features of the carcinoid syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?11/8/11400\">",
"           Diagnosis of the carcinoid syndrome and tumor localization",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?30/57/31640\">",
"           Glucagonoma and the glucagonoma syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?3/34/3623\">",
"           Somatostatinoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?15/59/16311\">",
"           The VIPoma syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?38/61/39897\">",
"           Treatment and surveillance of non-metastatic carcinoid tumors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?16/31/16888\">",
"           Treatment of the carcinoid syndrome",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Nonesophageal gastrointestinal motility disorders",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?21/50/22311\">",
"           Acute colonic pseudo-obstruction (Ogilvie's syndrome)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?37/52/38727\">",
"           Alosetron hydrochloride (Lotronex) for irritable bowel syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?2/26/2474\">",
"           Chronic intestinal pseudo-obstruction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?21/59/22455\">",
"           Clinical manifestations and diagnosis of irritable bowel syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?34/14/35048\">",
"           Constipation in the older adult",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?24/25/24985\">",
"           Diabetic autonomic neuropathy of the gastrointestinal tract",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?30/53/31574\">",
"           Electrical stimulation for gastroparesis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?42/12/43209\">",
"           Etiology and diagnosis of delayed gastric emptying",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?13/22/13673\">",
"           Etiology and evaluation of chronic constipation in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?12/53/13142\">",
"           Gastric bezoars",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?11/63/12280\">",
"           Gastrointestinal amyloidosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?40/35/41529\">",
"           Gastrointestinal manifestations of systemic sclerosis (scleroderma)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?17/23/17785\">",
"           High resolution manometry",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?8/5/8279\">",
"           Irritable bowel syndrome in patients with inflammatory bowel disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?29/57/30616\">",
"           Management of chronic constipation in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?16/11/16568\">",
"           Motility testing: When does it help?",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?13/62/14312\">",
"           Pathogenesis of delayed gastric emptying",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?12/25/12697\">",
"           Pathophysiology of irritable bowel syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?32/50/33576\">",
"           Treatment of delayed gastric emptying",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?11/9/11415\">",
"           Treatment of gastrointestinal disease in systemic sclerosis (scleroderma)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?39/14/40169\">",
"           Treatment of irritable bowel syndrome",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         NSAIDs",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?6/37/6745\">",
"           NSAIDs (including aspirin): Pathogenesis of gastroduodenal toxicity",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?37/31/38393\">",
"           NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?22/8/22666\">",
"           NSAIDs (including aspirin): Role in prevention of cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?11/58/12197\">",
"           NSAIDs (including aspirin): Secondary prevention of gastroduodenal toxicity",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?26/20/26947\">",
"           NSAIDs (including aspirin): Treatment of gastroduodenal toxicity",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?25/50/26406\">",
"           NSAIDs: Adverse effects on the distal small bowel and colon",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?16/49/17177\">",
"           Nonselective NSAIDs: Overview of adverse effects",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?12/48/13066\">",
"           Overview of selective COX-2 inhibitors",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Nutrition",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?37/21/38232\">",
"           Clinical features and diagnosis of malabsorption",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?2/34/2601\">",
"           Dietary fat",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?32/51/33592\">",
"           Enteral feeding: Gastric versus post-pyloric",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?30/57/31641\">",
"           Healthy diet in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?40/50/41765\">",
"           Mechanisms of nutrient absorption and malabsorption",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/44/28362\">",
"           Nutrition in pregnancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?42/39/43639\">",
"           Nutritional support in advanced lung disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?38/19/39226\">",
"           Overview of dietary trace minerals",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?21/14/21736\">",
"           Overview of vitamin A",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?39/3/39990\">",
"           Overview of vitamin D",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?28/12/28871\">",
"           Overview of vitamin E",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?15/37/15960\">",
"           Overview of vitamin K",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/62/28650\">",
"           Overview of water-soluble vitamins",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?19/63/20473\">",
"           Percutaneous endoscopic gastrostomy (PEG) tubes: Uses and efficacy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?34/7/34937\">",
"           Prevention and management of complications from percutaneous endoscopic gastrostomy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?35/46/36586\">",
"           Vitamin supplementation in disease prevention",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Physiology",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?16/33/16917\">",
"           Overview of gastrointestinal peptides in health and disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?40/15/41205\">",
"           Overview of the development of the gastrointestinal tract",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?32/62/33766\">",
"           Pancreatic polypeptide, peptide YY, and neuropeptide Y",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?34/51/35638\">",
"           Physiology of cholecystokinin",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?25/9/25751\">",
"           Physiology of gastrin",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?4/29/4567\">",
"           Physiology of somatostatin and its analogues",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?41/44/42692\">",
"           Secretin",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?14/27/14776\">",
"           Spatial organization of intestinal microbiota in health and disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?22/8/22660\">",
"           Synthesis, secretion, and regulation of gastrointestinal peptides",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?37/32/38406\">",
"           Vasoactive intestinal polypeptide",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Small bowel obstruction",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?13/46/14058\">",
"           Small bowel obstruction: Causes and management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?8/38/8807\">",
"           Small bowel obstruction: Clinical manifestations and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?36/58/37799\">",
"           Superior mesenteric artery syndrome",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Volvulus",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?8/29/8663\">",
"           Cecal volvulus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?7/22/7527\">",
"           Hiatus hernia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?25/53/26453\">",
"           Sigmoid volvulus",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Zollinger-Ellison syndrome",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?14/10/14504\">",
"           Clinical manifestations and diagnosis of Zollinger-Ellison syndrome (gastrinoma)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?6/51/6968\">",
"           Management and prognosis of the Zollinger-Ellison syndrome (gastrinoma)",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-BED2E7D09F-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f40_18_41249=[""].join("\n");
var outline_f40_18_41249=null;
var title_f40_18_41250="Truncal rash of RMSF";
var content_f40_18_41250=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F67850&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F67850&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Rocky mountain spotted fever",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 385px; height: 252px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Extensive maculopapular and petechial lesions on the trunk and thigh in a patient with Rocky Mountain spotted fever. The rash characteristically begins on the wrists and ankles and spreads centripetally.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Harold G Muchmore. The Skin and Infection: A Color Atlas and Text, Sanders CV, Nesbitt LT Jr (Eds), Williams &amp;Wilkins, Baltimore, 1995.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_18_41250=[""].join("\n");
var outline_f40_18_41250=null;
var title_f40_18_41251="Half-and-half nails";
var content_f40_18_41251=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F85717&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F85717&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Half-and-half nails in chronic renal failure",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 387px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_18_41251=[""].join("\n");
var outline_f40_18_41251=null;
var title_f40_18_41252="Congenital anomalies of the processus vaginalis";
var content_f40_18_41252=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F83047&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F83047&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 478px\">",
"   <div class=\"ttl\">",
"    Congenital anomalies of the processus vaginalis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 458px; height: 563px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Congenital hydrocele.",
"    <br>",
"     (B) Encysted hydrocele of the spermatic cord.",
"     <br>",
"      (C) Preformed hemial sac for indirect inguinal hernia.",
"      <div class=\"footnotes\">",
"      </div>",
"      <div class=\"reference\">",
"       Reproduced with permission from: Snell RS. Clinical Anatomy By Regions, 8th Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2008. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins.",
"      </div>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_18_41252=[""].join("\n");
var outline_f40_18_41252=null;
var title_f40_18_41253="What's new in adult and pediatric emergency medicine";
var content_f40_18_41253=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   What's new in adult and pediatric emergency medicine",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/18/41253/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/18/41253/contributors\">",
"     Jonathan Grayzel, MD, FAAEM",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/18/41253/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?40/18/41253/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 25, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    The following represent additions to UpToDate from the past six months that were considered by the editors and authors to be of particular interest. The most recent What's New entries are at the top of each subsection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     ADULT RESUSCITATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h2\">",
"     Surviving Sepsis Campaign releases new guidelines",
"    </span>",
"   </p>",
"   <p>",
"    The Surviving Sepsis Campaign has&nbsp;published&nbsp;updated guidelines for the management of patients with sepsis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/18/41253/abstract/1\">",
"     1",
"    </a>",
"    ].&nbsp;A notable revision from&nbsp;2008&nbsp;is that the recommended&nbsp;goals for fluid resuscitation in the first six hours are specified:&nbsp;central venous pressure 8 to 12 mmHg, central venous (superior vena cava) or mixed venous oxygen saturation&nbsp;&ge;70 or 65 percent, respectively, mean arterial pressure &ge;65 mmHg, and urine output &ge;0.5",
"    <span class=\"nowrap\">",
"     mL/kg/hour.",
"    </span>",
"    Additional recommendations are to administer an initial fluid challenge in patients with suspected hypovolemia&nbsp;with a&nbsp;minimum of 30",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    of crystalloids and to initiate broad-spectrum antimicrobial therapy within&nbsp;one hour&nbsp;of recognition of septic shock. Further, norepinephrine is preferred as the initial vasopressor&nbsp;agent for septic shock.&nbsp;(See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/51/21306?source=see_link&amp;anchor=H3877337#H3877337\">",
"     \"Evaluation and management of severe sepsis and septic shock in adults\", section on 'Goals of initial resuscitation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Airway management for out-of-hospital cardiac arrest",
"    </span>",
"   </p>",
"   <p>",
"    Airway management using a supraglottic airway or tracheal intubation may not be the best approach for managing cardiac arrest patients in the prehospital setting. This is supported by a prospective, observational nationwide Japanese study involving 649,359 adult patients with sudden cardiac arrest that occurred outside the hospital [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/18/41253/abstract/2\">",
"     2",
"    </a>",
"    ]. The rate of survival with a favorable neurologic outcome was significantly lower among those managed with advanced airway techniques compared with bag-mask ventilation. The association of higher rates of survival with favorable neurologic outcomes and use of bag-mask ventilation&nbsp;was seen across all analyzed subgroups, including adjustments for initial rhythm, return of spontaneous circulation, bystander CPR, and other treatments (eg, epinephrine). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/33/13850?source=see_link&amp;anchor=H4318336#H4318336\">",
"     \"Advanced cardiac life support (ACLS) in adults\", section on 'Airway management during ACLS'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Hydroxyethyl starch solutions in hypovolemia",
"    </span>",
"   </p>",
"   <p>",
"    Concern has been raised about the potential risks of using hydroxyethyl starch solutions for fluid resuscitation. The validity of this concern was demonstrated in a randomized trial, in which 7000 critically-ill patients were randomly assigned to receive 6% hydroxyethyl starch or isotonic saline for all fluid resuscitation until discharge from the intensive care unit, death, or 90 days&nbsp;post randomization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/18/41253/abstract/3\">",
"     3",
"    </a>",
"    ]. More patients in the hydroxyethyl starch group required renal replacement therapy, although no difference was found in the risk of death at 90 days in the two groups. Thus, saline solutions are preferred over hydroxyethyl starch solutions for most critically-ill patients with hypovolemia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/20/13639?source=see_link&amp;anchor=H5#H5\">",
"     \"Treatment of severe hypovolemia or hypovolemic shock in adults\", section on 'Colloid versus crystalloid'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     ENVIRONMENTAL EMERGENCIES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Hot water immersion for jellyfish stings",
"    </span>",
"   </p>",
"   <p>",
"    A systematic review of trials and observational studies found that hot water immersion is more effective for treating pain caused by stings of Physalia species (Man of war) and",
"    <em>",
"     Carybdea alata",
"    </em>",
"    (Hawaiian box jellyfish) than other topical therapies, including cold therapy or application of acetic acid or papain meat tenderizer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/18/41253/abstract/4\">",
"     4",
"    </a>",
"    ]. Hot water immersion may be helpful for stings from other jellyfish as well. However, application of acetic acid to prevent further discharge of venom from adherent nematocysts supersedes hot water immersion in importance for all stings caused by",
"    <em>",
"     Chironex fleckeri",
"    </em>",
"    (Australian box jellyfish) and for life-threatening stings caused by",
"    <em>",
"     C. alata",
"    </em>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/0/43016?source=see_link&amp;anchor=H15#H15\">",
"     \"Jellyfish stings\", section on 'Hot water immersion'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/0/43016?source=see_link&amp;anchor=H12735251#H12735251\">",
"     \"Jellyfish stings\", section on 'Acetic acid'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     GENERAL ADULT EMERGENCY MEDICINE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Control of the agitated patient",
"    </span>",
"   </p>",
"   <p>",
"    The best medication for sedating acutely agitated patients remains a subject of debate, but combination therapy appears to be an effective approach. In a multicenter randomized trial, the combination of either droperidol (5 mg IV) and midazolam or olanzapine (5 mg IV) and midazolam provided more rapid sedation of acutely agitated emergency department patients (n = 336) than midazolam alone (2.5 to 5 mg IV used for all three groups) without an increase in adverse events and with less need for rescue medication [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/18/41253/abstract/5\">",
"     5",
"    </a>",
"    ]. The mean times to sedation were 21.3 minutes for the droperidol group, 14 minutes for the olanzapine group, and 67.8 minutes for the midazolam only (ie, control) group. Further study of intravenous olanzapine and other second-generation antipsychotics is needed before this approach can be widely recommended for the treatment of acute agitation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/22/25962?source=see_link&amp;anchor=H21#H21\">",
"     \"Assessment and management of the acutely agitated or violent adult\", section on 'Combination therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     GENERAL PEDIATRIC EMERGENCY MEDICINE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Topical ivermectin for pediculosis capitis",
"    </span>",
"   </p>",
"   <p>",
"    The emergence of resistance to treatments for pediculosis capitis (head lice) has fueled the desire to identify additional effective treatments for this condition. In two randomized trials, a single 10-minute application of topical ivermectin was superior to a placebo lotion for the eradication of lice [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/18/41253/abstract/6\">",
"     6",
"    </a>",
"    ]. A combined analysis of the trial results revealed that among the index patients (youngest household member with at least three live lice detected on examination), 131 of 138 (95 percent) treated with topical ivermectin and 46 of 147 (31 percent) treated with the placebo lotion were free of live lice on day two. By day 15, live lice were absent in 74 and 18 percent of patients, respectively. Adverse events were infrequent and occurred at similar rates in both groups. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/15/25849?source=see_link&amp;anchor=H2579574#H2579574\">",
"     \"Pediculosis capitis\", section on 'Topical ivermectin'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Injuries in children living with an abused child",
"    </span>",
"   </p>",
"   <p>",
"    Children who live with an abused child are also at high risk for child maltreatment. In a prospective, multicenter observational study of household contacts of abused children, at least one abusive fracture on skeletal survey was found in 12 percent of the 134 household contacts who were two years of age or younger [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/18/41253/abstract/7\">",
"     7",
"    </a>",
"    ]. None of the fractures detected by skeletal survey were clinically suspected or had associated physical findings. This study supports the practice of obtaining skeletal surveys, in addition to careful history and physical examination, for all infants and young children who reside with an abused child. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/19/24890?source=see_link&amp;anchor=H4721692#H4721692\">",
"     \"Physical abuse in children: Diagnostic evaluation and management\", section on 'Identifying injuries in other children at risk'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     PEDIATRIC RESUSCITATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Goal-directed therapy for septic shock",
"    </span>",
"   </p>",
"   <p>",
"    Goal-directed therapy for septic shock refers to an aggressive systematic approach to resuscitation targeted to improvements in physiologic indicators of perfusion and vital organ function within the first six hours. Effective treatment of septic shock requires rapid correction of circulatory dysfunction with continuous monitoring and re-evaluation at frequent intervals and early administration of empiric broad-spectrum antimicrobial therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/18/41253/abstract/1\">",
"     1",
"    </a>",
"    ]. The 2012 Surviving Sepsis Campaign guidelines reaffirms that children with septic shock should receive treatment according to the 2007 American College of Critical Care Medicine (ACCM) (",
"    <a class=\"graphic graphic_algorithm graphicRef80923 \" href=\"mobipreview.htm?28/36/29255\">",
"     algorithm 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/18/41253/abstract/8\">",
"     8",
"    </a>",
"    ]. These guidelines are also largely compatible with the algorithm for pediatric septic shock promoted in the Pediatric Advanced Life Support (PALS) course (",
"    <a class=\"graphic graphic_algorithm graphicRef65304 \" href=\"mobipreview.htm?14/27/14770\">",
"     algorithm 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/33/4634?source=see_link&amp;anchor=H6411279#H6411279\">",
"     \"Septic shock: Rapid recognition and initial resuscitation in children\", section on 'Early goal-directed therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/2/13354?source=see_link&amp;anchor=H18270326#H18270326\">",
"     \"Septic shock: Ongoing management after resuscitation in children\", section on 'Overview'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     PRIMARY CARE ORTHOPEDICS AND SPORTS MEDICINE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Prevention of anterior cruciate ligament (ACL) injury",
"    </span>",
"   </p>",
"   <p>",
"    ACL rupture is&nbsp;a&nbsp;severe and increasingly common&nbsp;injury among female athletes.&nbsp;Although well designed prevention programs have been shown to reduce ACL injury rates, guidelines are not clear about the age at which to introduce such programs.&nbsp;According to a meta-analysis of 14 randomized trials, females in early adolescence, or possibly even preadolescence, may benefit the most from neuromuscular training prevention programs.&nbsp;In this meta-analysis, females in their mid-teens had greater reductions in their rate of ACL injury&nbsp;than females in their late teens&nbsp;or early adulthood&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/18/41253/abstract/9\">",
"     9",
"    </a>",
"    ]. These results suggest that it is important to implement prevention programs before female athletes develop poor mechanics&nbsp;for movements associated with an increased risk of ACL injury. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/24/32138?source=see_link&amp;anchor=H25#H25\">",
"     \"Anterior cruciate ligament injury\", section on 'Neuromuscular training'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     TOXICOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Oxycodone toxicity and QTc prolongation",
"    </span>",
"   </p>",
"   <p>",
"    Opioids are well known to cause depressed mental status and respirations. Additional toxicities may be specific to particular agents. Methadone has been associated with an increase in the QTc interval and torsade des pointes, leading to a safety alert&nbsp;in the U.S. 2006. A new retrospective review of 137 patients with oxycodone overdose found associated bradycardia in 24 patients and prolongation of the QTc interval&nbsp;in 20 of the 116 patients for whom electrocardiograms were available&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/18/41253/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/51/3897?source=see_link&amp;anchor=H11#H11\">",
"     \"Opioid intoxication in adults\", section on 'Electrocardiography'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Patient understanding of acetaminophen dosing",
"    </span>",
"   </p>",
"   <p>",
"    Accidental acetaminophen overdose remains a major cause of morbidity and mortality. According to a prospective study of 500 patients tested about their understanding of acetaminophen dosing at one academic and one community internal medicine practice, up to 46 percent of patients would ingest excessive amounts of acetaminophen because they misunderstand dosing directions or fail to recognize that acetaminophen is found in more than one medication they are using [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/18/41253/abstract/11\">",
"     11",
"    </a>",
"    ]. Such errors occur most often among patients with limited literacy or frequent acetaminophen use. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/43/25274?source=see_link&amp;anchor=H2#H2\">",
"     \"Acetaminophen (paracetamol) poisoning in adults: Pathophysiology, presentation, and diagnosis\", section on 'Epidemiology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Lipid emulsion effects on laboratory testing",
"    </span>",
"   </p>",
"   <p>",
"    Lipid emulsion (LE) therapy is being used with increasing frequency to treat poisoning from lipophilic drugs. Clinicians using LE should be aware that it interferes with some laboratory measurements and therapeutic drug monitoring [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/18/41253/abstract/12\">",
"     12",
"    </a>",
"    ]. As examples, serum glucose concentrations when determined by colorimetric testing and serum magnesium concentrations become inaccurate following the administration of LE, while creatinine and lipase become unmeasurable. Potassium and troponin-I are not affected. Centrifugation of blood samples substantially reduces any interference. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/63/31736?source=see_link&amp;anchor=H6162826#H6162826\">",
"     \"Calcium channel blocker poisoning\", section on 'Lipid emulsion therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Acute kidney injury after synthetic cannabinoid use",
"    </span>",
"   </p>",
"   <p>",
"    Synthetic cannabinoids, including tetrahydrocannabinol [THC], cannabidiol [CBD], and cannabinol [CBN], are analogs of naturally-occurring chemicals found in marijuana. In two small case series, synthetic cannabinoid or &ldquo;Spice&rdquo; use has been associated with reversible acute kidney injury necessitating renal replacement therapy&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/18/41253/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. Pathologically, the injury is characterized by acute tubular necrosis and interstitial nephritis. In some instances, these previously-healthy&nbsp;young adults&nbsp;reported smoking a blueberry- or bubblegum-flavored synthetic cannabinoid. A unique synthetic cannabinoid, 1-((5-fluoropentyl)-1H-indol-3yl) (2,23,3,-tetramethylcyclopropyl) methanone (also called XLR-11) was found in clinical specimens and product samples [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/18/41253/abstract/14\">",
"     14",
"    </a>",
"    ]. However, the specific chemical agent responsible for causing renal toxicity is not known. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/47/1784?source=see_link&amp;anchor=H1913412#H1913412\">",
"     \"Designer drugs of abuse\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     TRAUMA",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Very low risk criteria for pediatric intraabdominal injury",
"    </span>",
"   </p>",
"   <p>",
"    In a&nbsp;multicenter, prospective observational study of&nbsp;over 12,000&nbsp;children with blunt torso trauma, clinical features that predicted a very low risk of intraabominal injury (IAI) requiring intervention (eg, laparotomy, angiographic embolization, blood transfusion, or hospitalization for two nights or longer)&nbsp;were identified&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/18/41253/abstract/15\">",
"     15",
"    </a>",
"    ]:",
"    <br/>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Glasgow coma scale &ge;14",
"     </li>",
"     <li>",
"      No evidence of abdominal wall trauma or seat belt sign",
"     </li>",
"     <li>",
"      No abdominal tenderness",
"     </li>",
"     <li>",
"      No complaints of abdominal pain",
"     </li>",
"     <li>",
"      No vomiting",
"     </li>",
"     <li>",
"      No thoracic wall trauma",
"     </li>",
"     <li>",
"      No decreased breath sounds",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The absolute risk of IAI for the&nbsp;more than 5000&nbsp;children who met all seven of these criteria was 0.1 percent. However, 23 percent of these patients underwent computed tomography (CT)&nbsp;of the abdomen. Thus, implementation of this rule, if validated, has significant potential to reduce the number of abdominal CTs in children.&nbsp;(See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/62/33768?source=see_link&amp;anchor=H13#H13\">",
"     \"Overview of blunt abdominal trauma in children\", section on 'Abdominal CT'",
"    </a>",
"    .)",
"    <br/>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/18/41253/abstract/1\">",
"      Dellinger RP, Levy MM, Rhodes A, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med 2013; 41:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/18/41253/abstract/2\">",
"      Hasegawa K, Hiraide A, Chang Y, Brown DF. Association of prehospital advanced airway management with neurologic outcome and survival in patients with out-of-hospital cardiac arrest. JAMA 2013; 309:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/18/41253/abstract/3\">",
"      Myburgh JA, Finfer S, Bellomo R, et al. Hydroxyethyl starch or saline for fluid resuscitation in intensive care. N Engl J Med 2012; 367:1901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/18/41253/abstract/4\">",
"      Ward NT, Darracq MA, Tomaszewski C, Clark RF. Evidence-based treatment of jellyfish stings in North America and Hawaii. Ann Emerg Med 2012; 60:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/18/41253/abstract/5\">",
"      Chan EW, Taylor DM, Knott JC, et al. Intravenous droperidol or olanzapine as an adjunct to midazolam for the acutely agitated patient: a multicenter, randomized, double-blind, placebo-controlled clinical trial. Ann Emerg Med 2013; 61:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/18/41253/abstract/6\">",
"      Pariser DM, Meinking TL, Bell M, Ryan WG. Topical 0.5% ivermectin lotion for treatment of head lice. N Engl J Med 2012; 367:1687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/18/41253/abstract/7\">",
"      Lindberg DM, Shapiro RA, Laskey AL, et al. Prevalence of abusive injuries in siblings and household contacts of physically abused children. Pediatrics 2012; 130:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/18/41253/abstract/8\">",
"      Brierley J, Carcillo JA, Choong K, et al. Clinical practice parameters for hemodynamic support of pediatric and neonatal septic shock: 2007 update from the American College of Critical Care Medicine. Crit Care Med 2009; 37:666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/18/41253/abstract/9\">",
"      Myer GD, Sugimoto D, Thomas S, Hewett TE. The influence of age on the effectiveness of neuromuscular training to reduce anterior cruciate ligament injury in female athletes: a meta-analysis. Am J Sports Med 2013; 41:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/18/41253/abstract/10\">",
"      Berling I, Whyte IM, Isbister GK. Oxycodone overdose causes naloxone responsive coma and QT prolongation. QJM 2013; 106:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/18/41253/abstract/11\">",
"      Wolf MS, King J, Jacobson K, et al. Risk of unintentional overdose with non-prescription acetaminophen products. J Gen Intern Med 2012; 27:1587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/18/41253/abstract/12\">",
"      Grunbaum AM, Gilfix BM, Gosselin S, Blank DW. Analytical interferences resulting from intravenous lipid emulsion. Clin Toxicol (Phila) 2012; 50:812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/18/41253/abstract/13\">",
"      Bhanushali GK, Jain G, Fatima H, et al. AKI Associated with Synthetic Cannabinoids: A Case Series. Clin J Am Soc Nephrol 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/18/41253/abstract/14\">",
"      Centers for Disease Control and Prevention (CDC). Acute kidney injury associated with synthetic cannabinoid use--multiple states, 2012. MMWR Morb Mortal Wkly Rep 2013; 62:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/18/41253/abstract/15\">",
"      Holmes JF, Lillis K, Monroe D, et al. Identifying Children at Very Low Risk of Clinically Important Blunt Abdominal Injuries. Ann Emerg Med 2013.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8365 Version 2390.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-61.234.146.186-71A5527948-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_18_41253=[""].join("\n");
var outline_f40_18_41253=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      ADULT RESUSCITATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      Surviving Sepsis Campaign releases new guidelines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Airway management for out-of-hospital cardiac arrest",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Hydroxyethyl starch solutions in hypovolemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      ENVIRONMENTAL EMERGENCIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Hot water immersion for jellyfish stings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      GENERAL ADULT EMERGENCY MEDICINE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Control of the agitated patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      GENERAL PEDIATRIC EMERGENCY MEDICINE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Topical ivermectin for pediculosis capitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Injuries in children living with an abused child",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      PEDIATRIC RESUSCITATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Goal-directed therapy for septic shock",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      PRIMARY CARE ORTHOPEDICS AND SPORTS MEDICINE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Prevention of anterior cruciate ligament (ACL) injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      TOXICOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Oxycodone toxicity and QTc prolongation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Patient understanding of acetaminophen dosing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Lipid emulsion effects on laboratory testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Acute kidney injury after synthetic cannabinoid use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      TRAUMA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Very low risk criteria for pediatric intraabdominal injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/8365\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/8365|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?28/36/29255\" title=\"algorithm 1\">",
"      Pediatric sepsis management guidelines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?14/27/14770\" title=\"algorithm 2\">",
"      Pediatric algorithm for septic shock",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/43/25274?source=related_link\">",
"      Acetaminophen (paracetamol) poisoning in adults: Pathophysiology, presentation, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/33/13850?source=related_link\">",
"      Advanced cardiac life support (ACLS) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/24/32138?source=related_link\">",
"      Anterior cruciate ligament injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/22/25962?source=related_link\">",
"      Assessment and management of the acutely agitated or violent adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/63/31736?source=related_link\">",
"      Calcium channel blocker poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/47/1784?source=related_link\">",
"      Designer drugs of abuse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/51/21306?source=related_link\">",
"      Evaluation and management of severe sepsis and septic shock in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/0/43016?source=related_link\">",
"      Jellyfish stings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/51/3897?source=related_link\">",
"      Opioid intoxication in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/62/33768?source=related_link\">",
"      Overview of blunt abdominal trauma in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/15/25849?source=related_link\">",
"      Pediculosis capitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/19/24890?source=related_link\">",
"      Physical abuse in children: Diagnostic evaluation and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/2/13354?source=related_link\">",
"      Septic shock: Ongoing management after resuscitation in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/33/4634?source=related_link\">",
"      Septic shock: Rapid recognition and initial resuscitation in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/20/13639?source=related_link\">",
"      Treatment of severe hypovolemia or hypovolemic shock in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_18_41254="Danaparoid: Drug information";
var content_f40_18_41254=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"12\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Danaparoid: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?35/30/36324?source=see_link\">",
"    see \"Danaparoid: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F156561\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Orgaran&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F156590\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Anticoagulant;",
"     </li>",
"     <li>",
"      Heparinoid",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F156563\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Dosing recommendations per manufacturer labeling unless otherwise noted. Dose expressed as anti-Xa units.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Prevention of DVT following orthopedic, major abdominal, or thoracic surgery:",
"     </b>",
"     SubQ: 750 units twice daily for up to 14 days; it is recommended that patients begin prophylactic therapy preoperatively and receive their last preoperative dose 1-4 hours before surgery.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Prevention of DVT in stroke (nonhemorrhagic):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Initial: I.V.: Up to 1000 units as single dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Maintenance: SubQ: 750 units every 12 hours for 7-14 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Heparin-induced thrombocytopenia (HIT):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Prevention of DVT (with current or past HIT):",
"     </i>",
"     <b>",
"      Note:",
"     </b>",
"     May administer I.V. bolus of 1250 units if clinically necessary (ie, current HIT) or may initiate maintenance regimen without a bolus as follows:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     SubQ:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     &le;90 kg: Current HIT or past HIT: 750 units every 8-12 hours for 7-10 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     &gt;90 kg: Current HIT: 1250 units every 8-12 hours for 7-10 days; Past HIT: 1250 units every 12 hours or 750 units every 8 hours  for 7-10 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Treatment of DVT/PE (see also Linkins, 2012):",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Initial  I.V. bolus: Thrombosis &lt;5 days old:  &le;55 kg: 1250-1500 units; 55-90 kg: 2250-2500 units; &gt;90 kg: 3750 units; followed by a  maintenance I.V. infusion or maintenance SubQ injections.",
"     <b>",
"      Note:",
"     </b>",
"     If thrombosis is &ge;5 days old, administer an I.V. bolus dose of 1250 units followed by maintenance SubQ injections.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Maintenance: I.V. infusion (after I.V. bolus administered): Thrombosis &lt;5 days old: 400 units/hour for 4 hours, then 300 units/hour for 4 hours, then 150-200 units/hour for 5-7 days; adjust rate according to target anti-Xa levels",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <b>",
"      or",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Maintenance: SubQ injections (after I.V. bolus administered):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Thrombosis &lt;5 days old: &le;55 kg: 1500 units every 12 hours; 55-90 kg: 2000 units every 12 hours; &gt;90 kg: 1750 units every 8 hours for 4-7 days.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Thrombosis &ge;5 days old: &le;90 kg: 750 units every 8-12 hours; &gt;90 kg: 750 units every 8 hours or 1250 units every 8-12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      HIT/surgical thromboprophylaxis:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Nonvascular surgery:",
"     </i>",
"     SubQ:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &le;90 kg: 750 units 1-4 hours preoperatively and at &ge;6 hours postop, followed by 750 units every 12 hours beginning day 1 post-op and continued for 7-10 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &gt;90 kg: 750 units 1-4 hours preoperatively and at &ge;6 hours postop, followed by 750 units every 8 hours or 1250 units every 12 hours beginning day 1 post-op and continued for 7-10 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Embolectomy:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     55-90 kg: I.V.: 2250-2500 units as a bolus preoperatively, followed by SubQ: 1250 units every 12 hours beginning &ge;6 hours postop.",
"     <b>",
"      Note:",
"     </b>",
"     After several days of I.V.  therapy, may switch to SubQ: 750 units every 8-12 hours or oral anticoagulant therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &gt;90 kg: I.V.: 2250-2500 units as a bolus preoperatively, followed by 150-200 units/hour beginning &ge;6 hours post-op for 5-7 days.",
"     <b>",
"      Note:",
"     </b>",
"     After several days of I.V. therapy, may switch to SubQ: 750 units every 8-12 hours or oral anticoagulant therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      HIT/cardiac procedures: Note:",
"     </b>",
"     Other therapies may be preferred (eg, bivalirudin); long half-life and irreversibility of danaparoid make it a poor choice in these settings. Refer to product labeling for dosing recommendations.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Catheter patency:",
"     </b>",
"     Mix 750 units with 50 mL normal saline. Flush catheter with 5-10 mL of resulting solution as needed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Conversion to oral anticoagulant therapy (OAC):",
"     </b>",
"     Establish adequate antithrombotic effect with danaparoid prior to initiation of oral anticoagulant (OAC) therapy. PT/INR should be therapeutic before discontinuing use of danaparoid.",
"     <b>",
"      Note:",
"     </b>",
"     Laboratory values taken within 5 hours of danaparoid administration may be unreliable.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Conversion of SubQ danaparoid to OAC (based on current danaparoid dose):",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Danaparoid 750 units every 12 hours: Initiate OAC and maintain danaparoid therapy until PT/INR is therapeutic; may take up to 5 days.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Danaparoid 1250 units every 12 hours: Initiate OAC and decrease danaparoid to 750 units every 12 hours; maintain danaparoid therapy until PT/INR is therapeutic; may take up to 5 days.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Conversion of I.V. danaparoid to OAC:",
"     </i>",
"     Initiate OAC with concurrent danaparoid I.V. infusion (maximum 300 units/hour); discontinue I.V. infusion once INR is therapeutic (maximum INR: 3.0). If bleeding risk is present, I.V. infusion should be reduced to 75 units/hour and OAC initiation withheld for 24 hours",
"     <b>",
"      or",
"     </b>",
"     danaparoid I.V. infusion may be switched to subcutaneous route at a dose of 1250 units every 12 hours and the recommended conversion of SubQ danaparoid to OAC regimen followed (ie,  subsequent reduction to 750 units every 12 hours while OAC initiated).",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F156580\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Dosing recommendations per manufacturer labeling unless otherwise noted. Dose expressed as anti-Xa units.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Acute thrombosis:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Treatment: I.V.: Initial: 30 units/kg as a bolus; Maintenance: 1.2-4 units/kg/hour.",
"     <b>",
"      Note:",
"     </b>",
"     Anticipated plasma anti-Xa levels after bolus: 400-700 units/L; steady-state levels: 400-600 units/L (or 500-800 units/L for higher doses).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Prophylaxis: SubQ: 10 units/kg every 12 hours",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F156564\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F156565\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:0em;text-align:justify;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Danaparoid half-life is significantly prolonged in renal impairment; anti-Xa levels should be closely monitored. Dosage reduction, especially with maintenance doses, may be required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Mild or moderate impairment: There are no dosage adjustments provided in manufacturer's labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Severe impairment (serum creatinine &ge;220 micromol/L [&ge;2.5 mg/dL]): Following initial dose, dose reductions or temporary discontinuation of therapy may be necessary to prevent accumulation of plasma anti-Xa (indicated by consistent, steady state-plasma anti-Xa activity &gt;0.5 anti-Xa units).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Hemodialysis:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Children: I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     First two dialysis sessions:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;text-align:justify;\">",
"     &lt;10 years: 30 units/kg",
"     <i>",
"      plus",
"     </i>",
"     1000 units",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;text-align:justify;\">",
"     10-17 years: 30 units/kg",
"     <i>",
"      plus",
"     </i>",
"     1500 units",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     Third and subsequent sessions (based on predialysis anti-Xa levels):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;text-align:justify;\">",
"     &lt;300 units/L: Administer previous dialysis dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;text-align:justify;\">",
"     300-500 units/L: Reduce total dose by 250 units",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;text-align:justify;\">",
"     &gt;500 units/L: No dose required with next dialysis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Adults: I.V.: 1500-3750 units before dialysis session.",
"     <b>",
"      Note:",
"     </b>",
"     Dose depends on frequency of dialysis regimen (eg, daily dialysis vs every-other-day or less frequently) and weight of patient with the lower dose recommended for patients &lt;55 kg. Do not administer prior to dialysis if plasma antifactor Xa levels &gt;400 units/L and not receiving daily dialysis; however, if fibrin threads are present in bubble chamber may administer 1500 units.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Hemofiltration: Adults: I.V.: 55-90 kg: 2500 units as a bolus, followed by 600 units/hour for 4 hours, then 400 units/hour for 4 hours, then 200-600 units/hour to maintain adequate anti-Xa levels.",
"     <b>",
"      Note:",
"     </b>",
"     If patient is &lt;55 kg, reduce bolus dose to 2000 units, followed by 400 units/hour for 4 hours, then 150-400 units/hour to maintain adequate anti-Xa levels.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F13162275\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no dosage adjustments provided in manufacturer's labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foccan drugH1Div\" id=\"F5950034\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: Canada",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Injection, solution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Orgaran&reg;: 750 anti-Xa units/0.6 mL (0.6 mL)",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11218429\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not available in U.S.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F802622\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May administer intravenously as bolus or infusion, or by subcutaneous injection. When administered intravenously, do not mix with other drugs. For subcutaneous administration, rotate injection sites. Do",
"     <b>",
"      not",
"     </b>",
"     administer intramuscularly.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F13162104\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, NS, LR",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F156547\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prevention of postoperative deep vein thrombosis (DVT) following orthopedic or major abdominal and thoracic surgery; prevention of DVT in patients with confirmed diagnosis of non-hemorrhagic stroke; management of heparin-induced thrombocytopenia (HIT)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F6052981\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Orgaran&reg; may be confused with argatroban",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F156588\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     As with all anticoagulants, bleeding is the major adverse effect of danaparoid. Hemorrhage may occur at virtually any site. Risk is dependent on multiple variables.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Frequency not always defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Arterial pressure decreased, atrial fibrillation, cerebral infarction, DVT, hypotension, peripheral edema",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Pain (5%), fever (2% to 5%), confusion, fatigue, insomnia, loss of consciousness, restlessness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Rash (1%), bruising",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Nausea (3%), constipation (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Urinary retention (1%), urinary incontinence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Cerebral hemorrhage, hematoma, hemorrhage, spinal or epidural hematomas (may occur following neuraxial anesthesia or spinal puncture, resulting in paralysis), thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Alkaline phosphatase increased, ALT increased (transient), AST increased (transient)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Injection site hematoma (&le;5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Hemiparesis, involuntary muscle contractions, tremor",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Hematuria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Apnea, asthma",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Infection (2%), allergic reaction, sepsis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F156550\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to danaparoid, or any component of the formulation (including sulfites); history of thrombocytopenia while receiving danaparoid or when associated with a positive",
"     <i>",
"      in vitro",
"     </i>",
"     test for antiplatelet antibodies in the presence of danaparoid; hemorrhagic stroke (without systemic emboli); acute hemorrhagic stroke; patients with active major bleeding; severe hemorrhagic diathesis (hemophilia, idiopathic thrombocytopenic purpura); acute or subacute bacterial endocarditis; active gastric or duodenal ulcer; surgery of CNS, eyes, or ears; diabetic or hemorrhagic retinopathy; severe uncontrolled hypertension; other conditions or diseases that increase risk of hemorrhage; not for I.M. use",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F156533\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bleeding: Monitor patient closely for signs or symptoms of bleeding. Certain patients are at increased risk of bleeding (eg, severe hepatic disease, patients undergoing knee surgery or other invasive procedures, concomitant therapy with platelet inhibitors, elderly).  Discontinue if bleeding occurs.",
"     <b>",
"      Note:",
"     </b>",
"     Danaparoid is",
"     <b>",
"      not",
"     </b>",
"     effectively antagonized by protamine sulfate. No other antidote is available, so extreme caution is needed in monitoring dose given and resulting factor Xa inhibition effect.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperkalemia: Monitor for hyperkalemia. Heparin can cause hyperkalemia by affecting aldosterone; similar reactions could occur with danaparoid.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Peptic ulcer disease: Use with caution in patients with a history of peptic ulcer disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Prosthetic heart valves: Safety and efficacy have not been established for use as thromboprophylaxis in patients with prosthetic heart valves.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with severe renal impairment; primarily renally eliminated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Stroke: Hemorrhagic stroke should be ruled out by CT scan prior to initiating therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thrombocytopenia: Use caution in patients with or with a history of thrombocytopenia (heparin-induced, congenital) or platelet defects. The manufacturer labeling recommends that patients with a history of heparin-induced thrombocytopenia be tested for cross-reactivity with danaparoid prior to initiating therapy; if test is positive, alternative therapy should be employed unless otherwise not available. If danaparoid is administered, therapy must be discontinued immediately with clinical signs of positive cross-reactivity (eg, increased reduction in platelet counts, thrombosis, skin necrosis). May resume therapy (if needed) only after laboratory confirmed negative test for danaparoid activated antiplatelet antibodies. Cutaneous allergy tests may help detect the presence of cross-reactivity between heparins and danaparoid (Grassegger, 2001).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sodium sulfite: This product contains sodium sulfite which may cause allergic-type reactions, including anaphylactic symptoms and life-threatening asthmatic episodes in susceptible people; this is seen more frequently in asthmatics.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Conversion to other products: Not to be used interchangeably (unit for unit) with heparin or any other low molecular weight heparins.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neuraxial anesthesia:",
"     <b>",
"      Spinal or epidural hematomas, including subsequent paralysis, may occur with recent or anticipated neuraxial anesthesia (epidural or spinal anesthesia) or spinal puncture in patients anticoagulated with LMWH or heparinoids.",
"     </b>",
"     Consider risk versus benefit prior to spinal procedures; risk is increased by the use of concomitant agents which may alter hemostasis, the use of indwelling epidural catheters for analgesia, a history of spinal deformity or spinal surgery, as well as a history of traumatic or repeated epidural or spinal punctures. Spinal procedures should be avoided for 12 hours after the last danaparoid dose; allow at least 2 hours after procedure before resuming danaparoid therapy. Patient should be observed closely for bleeding and signs and symptoms of neurological impairment if therapy is administered during or immediately following diagnostic lumbar puncture, epidural anesthesia, or spinal anesthesia.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299123\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F156538\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticoagulants: May enhance the anticoagulant effect of other Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Apixaban: May enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Collagenase (Systemic): Anticoagulants may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: May enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Anticoagulants may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Drotrecogin Alfa (Activated): Danaparoid may enhance the adverse/toxic effect of Drotrecogin Alfa (Activated). Bleeding may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Anticoagulants. Bleeding may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ibritumomab: Anticoagulants may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to an increased risk of bleeding.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omacetaxine: Anticoagulants may enhance the adverse/toxic effect of Omacetaxine. Specifically, the risk for bleeding-related events may be increased.  Management: Avoid concurrent use of anticoagulants with omacetaxine in patients with a platelet count of less than 50,000/uL.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omega-3 Fatty Acids: May enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentosan Polysulfate Sodium: May enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the adverse/toxic effect of Anticoagulants. Specifically, the antiplatelet effects of these agents may lead to an increased risk of bleeding with the combination.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: Anticoagulants may enhance the anticoagulant effect of Rivaroxaban.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: May enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thrombolytic Agents: May enhance the anticoagulant effect of Anticoagulants. Management: See full drug monograph for guidelines for the use of alteplase for acute ischemic stroke during treatment with oral anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tipranavir: May enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tositumomab and Iodine I 131 Tositumomab: Anticoagulants may enhance the adverse/toxic effect of Tositumomab and Iodine I 131 Tositumomab. Specifically, the risk of bleeding-related adverse effects may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin E: May enhance the anticoagulant effect of Anticoagulants. Vitamin E may also increase the overall risk for bleeding.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F156557\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Herb/Nutraceutical: Avoid cat's claw, dong quai, evening primrose, feverfew, garlic, ginger, ginkgo, red clover, horse chestnut, green tea, and ginseng (all have additional antiplatelet activity).",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13161901\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects have not been observed in animal reproduction studies. The manufacturer labeling states that incidental observations in pregnant women during the last trimesters, gave no indication that use during pregnancy results in fetal abnormalities or exacerbation of bleeding in the mother or infant during delivery. Use in pregnant women however is generally not recommended unless deemed medically necessary and alternative therapy is unavailable. Danaparoid does not cross the placenta and is the preferred anticoagulant in pregnant women with HIT (Guyatt, 2012).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F156568\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F13161913\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Only low amounts of anit-Xa activity have been found breast milk following maternal use of danaparoid; however, because it is not absorbed when taken orally, it is unlikely to cause adverse events in a nursing infant. Use of danaparoid may be continued in breast-feeding. The manufacturer labeling recommends that women receiving danaparoid avoid breast-feeding.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F156542\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Platelets (baseline, every other day during week 1, twice weekly during weeks 2 and 3, and once weekly thereafter); occult blood or other signs of bleeding; anti-Xa activity (if available). See manufacturer&rsquo;s recommendations within labeling regarding anticipated anti-Xa levels.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F156552\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Orgaran (AT, AU, BE, CH, DE, FI, FR, GB, GR, IT, LU, NL, NO, NZ, SE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F156532\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits factor Xa and IIa (anti-Xa effects &gt;20 times anti-IIa effects). Prevents fibrin formation in the coagulation pathway via thrombin generation inhibition.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F156549\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Peak effect: SubQ: Maximum antifactor Xa activities occur in 4-5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: SubQ: ~100%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Anti-Xa activity: ~25 hours (renal impairment: 29-35 hours); Thrombin generation inhibition activity: ~7 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Primarily urine",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Grassegger A, Fritsch P, and Reider N, &ldquo;Delayed-Type Hypersensitivity and Cross-Reactivity to Heparins and Danaparoid: A Prospective Study,&rdquo; Dermatol Surg, 2001, 27(1):47-52.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/18/41254/abstract-text/11231243/pubmed\" id=\"11231243\" target=\"_blank\">",
"        11231243",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Guyatt GH, Akl EA, Crowther M, et al, &ldquo;Executive Summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 2012, 141(2 Suppl):7-47.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/18/41254/abstract-text/22315257/pubmed\" id=\"22315257\" target=\"_blank\">",
"        22315257",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Linkins L, Dans AL, Moores LK, et al, &ldquo;Treatment and Prevention of Heparin-Induced Thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 2012, 141(2 Suppl):e495-530.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/18/41254/abstract-text/22315270/pubmed\" id=\"22315270\" target=\"_blank\">",
"        22315270",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9320 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-201.77.166.39-AB2AAAC1E4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_18_41254=[""].join("\n");
var outline_f40_18_41254=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156561\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156590\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156563\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156580\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156564\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156565\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13162275\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5950034\">",
"      Dosage Forms: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11218429\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F802622\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13162104\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156547\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6052981\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156588\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156550\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156533\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299123\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156538\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156557\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13161901\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156568\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13161913\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156542\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156552\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156532\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156549\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9320\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9320|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?35/30/36324?source=related_link\">",
"      Danaparoid: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_18_41255="PML-RARa action";
var content_f40_18_41255=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F64089&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F64089&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 562px\">",
"   <div class=\"ttl\">",
"    PML-RARa action in acute promyelocytic leukemia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 542px; height: 624px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Acute promyelocytic leukemia is characterized by a translocation involving the retinoic acid receptor-alpha (RARa) locus on chromosome 17. In over 90 percent of cases, there is a balanced translocation t(15;17)(q24.1;q21.1) involving the ubiquitously expressed PML gene on chromosome 15, resulting in a PML-RARa fusion protein. As shown in the upper diagram, this PML-RARa fusion protein forms a homodimer that binds to RARa target genes and acts with corepressors to block transcription of these genes. This results in blocked differentiation and enhanced self-renewal of the promyelocytes. As shown in the lower diagram, the addition of all-trans retinoic acid (ATRA) and/or arsenic trioxide results in degradation of the PML-RARa fusion protein and release of the corepressors. This allows the normal RARa to bind to target genes and promote transcription leading to differentiation of the promyelocyte to a mature granulocyte.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_18_41255=[""].join("\n");
var outline_f40_18_41255=null;
var title_f40_18_41256="Placental development and physiology";
var content_f40_18_41256=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Placental development and physiology",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/18/41256/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/18/41256/contributors\">",
"     Victoria Roberts, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/18/41256/contributors\">",
"     Leslie Myatt, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/18/41256/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/18/41256/contributors\">",
"     Charles J Lockwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/18/41256/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/18/41256/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?40/18/41256/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 2, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Development of the placenta is a highly regulated process that is essential for normal fetal growth and development, and for maintenance of a healthy pregnancy. The placenta fulfills several critical roles as the interface between mother and fetus: it prevents rejection of the fetal allograft, enables respiratory gas exchange, transports nutrients, eliminates fetal waste products, and secretes peptide and steroid hormones.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EARLY DEVELOPMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12098174\">",
"    <span class=\"h2\">",
"     Implantation and invasion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Development of the placenta and fetus is a continuous process that begins at the time of fertilization. The first three days of development occur within the fallopian tube. Four days after fertilization, the morula (a solid mass of blastomere cells) enters the uterus. On the fifth day after fertilization, the morula becomes a blastocyst as fluid accumulates and polarization of the cells occurs. The blastocyst has an outer layer of cells (trophoblast) that will form the placenta and fetal membranes, an inner cell mass at one pole that will form the embryo, and a fluid filled cavity. The inner and outer cell masses multiply and the fluid cavity enlarges until the expanded blastocyst hatches out of the zona shell. Initially it is bathed in uterine secretions that provide oxygen and metabolic substrates; however, these secretions soon become inadequate for support of further development. Therefore, within 24 hours of hatching (about day 6 after fertilization), the blastocyst implants in the uterine lining, which provides access to substrates (glycogen filled stromal cells) necessary for continued growth. Implantation involves movement of the blastocyst to an optimal location (typically the mid to upper anterior or posterior wall of the uterus), adhesion, and invasion. As the trophoblast erodes deeper into the decidua, vacuoles form and become confluent to form lacunae by day 13 after fertilization. The lacunar space eventually becomes the intervillous space.",
"   </p>",
"   <p>",
"    The progenitor cytotrophoblast cell is the stem cell of the placenta. These cells proliferate throughout gestation, differentiating along two pathways to form either villous cytotrophoblast which ultimately can become syncytiotrophoblasts (outer cellular layer) or extravillous cytotrophoblasts (inner cellular layer) (",
"    <a class=\"graphic graphic_algorithm graphicRef57887 \" href=\"mobipreview.htm?31/37/32349\">",
"     algorithm 1",
"    </a>",
"    ). Syncytiotrophoblast is a specialized epithelium that has several functions, including transport of gases, nutrients, and waste products and synthesis of peptide and steroid hormones that regulate placental, fetal, and maternal systems. Extravillous trophoblast (EVT) has a proliferative component and an invasive component. There is also a migratory EVT, which is neither invasive nor proliferative. These cells populate the cell islands, septum, chorionic plate and chorion laeve.",
"   </p>",
"   <p>",
"    At four to five weeks of gestation (menstrual dates), EVT erupts in columns with proliferative trophoblast at the base and invasive trophoblast at the distal portion of the column. Invasive EVT that invades decidua is called interstitial EVT, whereas EVT that invades and remodels the spiral arteries is called endovascular EVT. Endovascular invasion (intramural or intra-arterial) involves replacement or displacement of vascular smooth muscle and endothelial cells and transforms the narrow spiral arteries into wide uteroplacental arteries (",
"    <a class=\"graphic graphic_algorithm graphicRef57887 \" href=\"mobipreview.htm?31/37/32349\">",
"     algorithm 1",
"    </a>",
"    ). Anastomoses between the dilated spiral arteries and endometrial veins form maternal sinusoids, which eventually distribute blood into the low resistance vascular network of the lacunar system, thus establishing the uteroplacental circulation.",
"   </p>",
"   <p>",
"    During invasion, EVT expresses specific proteins defining the stage and role in the differentiation and invasion process. These include integrin cell-extracellular matrix antigens, matrix metalloproteinases (MMPs), signal transduction proteins such as transforming growth factor-&szlig; (TGF-&szlig;), vascular endothelial growth factor (VEGF) and VEGF receptors, and insulin-like growth factor 2 (IGF2).",
"   </p>",
"   <p>",
"    To invade the decidua and myometrium, the EVT must degrade the extracellular matrix by employing several members of the MMP protease family. The activity of these MMPs is regulated by their tissue inhibitors (TIMPs). TIMP-1, an inhibitor of all MMPs, and TIMP-2 have been found in decidual cells and EVTs. Hepatocyte growth factor (HGF) stimulates trophoblast invasion via the met receptor and induction of MMP-9. The decidua prevents uninhibited EVT invasion by secreting locally acting factors (cytokines, protease inhibitors), which modulate trophoblast invasion.",
"   </p>",
"   <p>",
"    The trophoblast shell plugs the ends of uteroplacental vessels early in gestation, such that very early in gestation placental tissue develops in a low oxygen environment supported by histiotrophic nutrition [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/18/41256/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Histiotroph is an extracellular material that is produced by endometrial glands in the decidua and accumulates in the space between the maternal and fetal tissues. It is phagocytosed initially by the trophectoderm of the blastocyst, and later by the trophoblast of the placenta or the endoderm of the yolk sac. This environment is thought to protect the developing embryo from oxygen free radical mediated teratogenesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/18/41256/abstract/3\">",
"     3",
"    </a>",
"    ]. At 10 to 14 weeks of gestation, the trophoblastic plugs are displaced and blood flows into the intervillous space to facilitate gas and nutrient exchange (ie, hemotrophic nutrition: the exchange of blood-borne materials between the maternal and fetal circulations). The increased blood flow at this time increases the intraplacental oxygen concentration three-fold and imposes oxidative stress, which is overwhelming in some pregnancies and leads to miscarriage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/18/41256/abstract/4-6\">",
"     4-6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Oxygen is also a major regulator of trophoblast invasion. Expression of the transcription factor hypoxia-inducible factor 1 and of TGF-&szlig;3, an inhibitor of invasion, parallels changes in oxygen tension. Thus, they are high in the first trimester when oxygen tension in the placental bed is low and trophoblast invasion occurs, and then fall at 10 to 12 weeks of gestation when blood flow to the intervillous space is established and oxygen tension rises. In vitro, low oxygen tension (hypoxia) promotes trophoblast differentiation down the EVT pathway [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/18/41256/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12098281\">",
"    <span class=\"h2\">",
"     Villous development",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the second week of placental development, a layer of syncytiotrophoblast with a core of cytotrophoblast evaginates into the lacunar space to form primary mesenchymal villi. With further development, they acquire an inner core of embryonic mesoderm and become secondary villi. By day 21, the embryonic mesoderm differentiates into blood vessels that subsequently connect to vessels developing in the umbilical cord and embryo, thus forming tertiary villi. Some villi are anchored to the maternal decidua, others float freely in the lacuna. The embryonic circulation is always separated from maternal decidua and blood by a layer of trophoblast.",
"   </p>",
"   <p>",
"    Villous cytotrophoblast cells form a continuous layer (the Langhans layer) around first trimester placental villi and donate daughter cells to the overlying continuous syncytium, the syncytiotrophoblast. In late gestation, few villous cytotrophoblast cells are found. At term, the surface area of the syncytiotrophoblast is 12 to 14 m",
"    <sup>",
"     2",
"    </sup>",
"    . Turnover of syncytiotrophoblast is controlled by the rates of fusion of villous cytotrophoblast and apoptosis. The human endogenous defective retrovirus HERV-W-derived protein syncytin is highly expressed in syncytiotrophoblast and is responsible for cytotrophoblast fusion and syncytialization of trophoblast [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/18/41256/abstract/8\">",
"     8",
"    </a>",
"    ]. Decreased syncytin expression is seen in preeclamptic pregnancies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/18/41256/abstract/9,10\">",
"     9,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In pregnancies at high altitude where there is a relative hypoxia or those complicated by maternal anemia, proliferation of cytotrophoblast cells and increased syncytiotrophoblast formation increase the amount of placental surface area for exchange.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H175804821\">",
"    <span class=\"h2\">",
"     Vascular development",
"    </span>",
"    &nbsp;&mdash;&nbsp;The proportion of the placenta occupied by blood vessels increases throughout gestation to facilitate nutrient transport. The three stages",
"    <sup>",
"    </sup>",
"    of human placental vascular development are an initial stage of",
"    <sup>",
"    </sup>",
"    vasculogenesis followed by branching and then nonbranching",
"    <sup>",
"    </sup>",
"    angiogenesis. The two umbilical arteries and the vein divide into networks of secondary vessels, and then further divide into tertiary vessels before entering the main stem villi. These vessels then divide two to five times to form rami chorii (intermediate villi) and further divide to form ramuli chorii, some of which terminate in the terminal villi, the functional units of exchange (",
"    <a class=\"graphic graphic_figure graphicRef59367 \" href=\"mobipreview.htm?39/48/40712\">",
"     figure 1",
"    </a>",
"    ). The terminal villi each contain 3 to 5 capillaries which form capillary loops and occasional sinusoids, perhaps to reduce resistance and slow blood flow in order to maximize time for gas and nutrient exchange. Oxygen also regulates villous vasculogenesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/18/41256/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H175804869\">",
"    <span class=\"h2\">",
"     Fetal-placental vascular reactivity",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the absence of autonomic innervation, vascular reactivity in the placenta and umbilical cord is by humoral and",
"    <span class=\"nowrap\">",
"     autocrine/paracrine",
"    </span>",
"    factors. Regional differences in response to various families of mediators are seen throughout the umbilical cord, chorionic plate vessels, and villous vessels. Important mediators include the renin-angiotensin system, endothelin, nitric oxide, carbon monoxide, histamine, serotonin, prostaglandins, natriuretic peptides, parathyroid hormone, adrenomedullin, urocortin, and corticotropin-releasing hormone. There is abundant evidence that production and response to many of these factors are altered in pregnancies complicated by diabetes and preeclampsia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H175804914\">",
"    <span class=\"h2\">",
"     Anticoagulant activity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thrombosis in the placental vasculature can result in pregnancy loss [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/18/41256/abstract/12\">",
"     12",
"    </a>",
"    ]. To prevent stasis and coagulation of blood in the low velocity intervillous space, the trophoblast actively secretes substances (ADPase, nitric oxide and carbon monoxide) that prevent platelet and leukocyte adhesion and aggregation to the trophoblast surface [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/18/41256/abstract/13\">",
"     13",
"    </a>",
"    ]. The trophoblast surface also has anticoagulant activity. Upon syncytialization, negatively charged phospholipids (PS) are expressed on the trophoblast surface and this may potentially activate the intrinsic pathway of coagulation. Annexin A5, a member of the",
"    <span class=\"nowrap\">",
"     Ca",
"     <sup>",
"      2+",
"     </sup>",
"     /phospholipid-dependent",
"    </span>",
"    protein family, has been proposed as a regulator of thrombosis and homeostasis on the villous trophoblast of the placenta by binding to negatively charged phospholipids, where it acts as an anti-coagulant that forms a protective barrier over the trophoblast surface [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/18/41256/abstract/14\">",
"     14",
"    </a>",
"    ]. By contrast, antiphospholipid antibodies are thought to oppose the actions of annexin A5 and lead to blood coagulation and thus disrupt normal trophoblast function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/18/41256/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H175804990\">",
"    <span class=\"h2\">",
"     Imprinted genes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Imprinting refers to the differential expression of genetic material depending on whether it was inherited from the male or female parent. To date, at least 80 imprinted genes have been described in humans. Imprinted genes may have a role in placental development and in the fetal demand for, and the placental supply of, maternal nutrients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/18/41256/abstract/16-19\">",
"     16-19",
"    </a>",
"    ]. Gene knockout studies in mice have shown that the function of paternally expressed imprinted genes is to enhance fetal growth, whereas maternally imprinted genes suppress fetal growth.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H175804788\">",
"    <span class=\"h1\">",
"     ABNORMAL DEVELOPMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H175804536\">",
"    <span class=\"h2\">",
"     Preeclampsia and fetal growth restriction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alterations in trophoblast differentiation occur in various pathophysiological situations and may underlie pregnancy disorders, such as preeclampsia and fetal growth restriction (IUGR).",
"   </p>",
"   <p>",
"    Preeclampsia and IUGR are associated with defects in endovascular EVT invasion, where some spiral arteries are not invaded at all and some are superficially invaded, leading to lack of the normal physiological adaptation of spiral arteries to pregnancy, reduced blood flow into the intervillous space, and relative",
"    <span class=\"nowrap\">",
"     hypoxia/ischemia.",
"    </span>",
"    Interstitial EVT density, however, is not different in preeclamptic pregnancy. Minimal EVT apoptosis is seen in normal pregnancy, but 15 to 50 percent of cells are apoptotic in preeclamptic pregnancy, a finding associated with macrophages around spiral arteries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/18/41256/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mechanism for defective invasion may involve defects in protein expression. For example, integrin expression and increased TGF-&szlig; expression appear to play a role in inhibiting trophoblast invasion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/18/41256/abstract/20\">",
"     20",
"    </a>",
"    ]. In addition, trophoblast from preeclamptic pregnancies produce less HGF, and anti-HGF antibody blocks HGF-induced invasion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/18/41256/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    During normal pregnancy, syncytiotrophoblast fragments are constantly shed into the maternal circulation (approximately 100,000",
"    <span class=\"nowrap\">",
"     fragments/day)",
"    </span>",
"    as a result of apoptosis or necrosis, without eliciting a maternal immune response. The rate of syncytiotrophoblast apoptosis is increased from 2 to 3 percent in normal pregnancy to 5 to 6 percent in pregnancies complicated by IUGR [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/18/41256/abstract/22\">",
"     22",
"    </a>",
"    ] or preeclampsia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/18/41256/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2361569\">",
"    <span class=\"h2\">",
"     Placenta creta",
"    </span>",
"    &nbsp;&mdash;&nbsp;Placenta creta is characterized by lack of intervening decidua which allows direct contact of anchoring villous tissue to underlying myometrium. This leads to excessive invasion, an adherent placenta, and bleeding. The scenario has parallels to tubal pregnancy where the absence of decidua in the fallopian tube is associated with deep invasion of trophoblast into adjacent vessels.",
"   </p>",
"   <p>",
"    Placental attachment disorders are classified according to the depth of myometrial penetration. In placenta accreta, villi embed on the myometrium in the absence of decidua; in placenta increta, villi embed deeper into myometrium, whereas in placenta percreta, the villi have penetrated through the uterine serosa. Whether the pathology results from lack of decidua or over-invasiveness of trophoblast is controversial.",
"   </p>",
"   <p>",
"    Studies of EVT invasion in placenta creta are lacking. Conflicting findings have been presented regarding the extent and depth of vascular remodeling by EVT in these pregnancies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/18/41256/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. Creta is associated with increased depth of invasion by both interstitial and endovascular trophoblast, but outer myometrial vessels are not remodeled, suggesting it is not simply the lack of decidua that allows deep myometrial invasion. The strong association of placenta creta with a history of prior cesarean delivery and endometrial curettage suggests a role for uterine scarring. The depth of uterine invasion may be dependent on the depth of the original scar [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/18/41256/abstract/24\">",
"     24",
"    </a>",
"    ] with increta and percreta perhaps more likely to arise from dehiscence of a scar giving cells of the trophoblast columns access to large outer myometrial vessels. However, this explanation would not explain placenta accreta in primigravidas with no history of trauma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/18/41256/abstract/25\">",
"     25",
"    </a>",
"    ]. In summary, the pathophysiology of creta is complex and may involve both defects in decidua, trophoblast invasiveness, and physical uterine factors, such as scarring. Whether the progression from accreta to percreta is governed by defects in mechanisms regulating trophoblast invasion or determined by physical factors is also in need of study.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12098190\">",
"    <span class=\"h2\">",
"     Gestational trophoblastic disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gestational trophoblastic disease arises from abnormal proliferation of trophoblast. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/31/13816?source=see_link&amp;anchor=H9#H9\">",
"     \"Gestational trophoblastic disease: Pathology\", section on 'Pathogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     METABOLIC AND ENDOCRINE FUNCTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The metabolic and endocrine functions of the placenta must be tightly controlled to ensure maintenance of a healthy pregnancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Metabolic functions",
"    </span>",
"    &nbsp;&mdash;&nbsp;The placenta is capable of synthesizing glycogen and cholesterol, which are sources of energy for the developing fetus. Additionally, cholesterol is an important precursor in hormone production.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Glycogen synthesis",
"      </strong>",
"      &mdash; The placenta is capable of synthesizing appreciable amounts of glycogen, which it stores as an energy reserve. The uptake of glucose from the maternal circulation is a rate limiting step in this process, which involves a series of enzymes and regulators. Of particular importance is the enzyme glycogenin, which is co-expressed with the high affinity GLUT-3 transporter in the endothelium, basal decidua, and invading extravillous trophoblast of the human placenta [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/18/41256/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Cholesterol synthesis",
"      </strong>",
"      &mdash; The demands for cholesterol in the fetus are high. In early pregnancy, maternal cholesterol contributes substantially to this requirement, while in late gestation, the fetus synthesizes cholesterol from placental stores of fatty acids established from maternal body fat accumulation in early pregnancy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/18/41256/abstract/27\">",
"       27",
"      </a>",
"      ]. Placental cholesterol is an important precursor for placental production of progesterone and estrogens.",
"     </li>",
"     <li>",
"      <strong>",
"       Protein metabolism",
"      </strong>",
"      &mdash; Protein metabolism in the placenta is largely governed by the demands of growth throughout gestation. At week 10, placental protein production is approximately 1.5 g per day, but by term this figure rises to 7.5 g daily [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/18/41256/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Lactate",
"      </strong>",
"      &mdash; Lactate, a waste product of metabolism, is produced in large quantities by the placenta and therefore needs to be efficiently removed. L-lactate transporters are active on the microvillous membrane of human placenta and are present on the basal membrane [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/18/41256/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Endocrine functions",
"    </span>",
"    &nbsp;&mdash;&nbsp;The placenta is not innervated, hence any communication between it, the mother, and the fetus must involve humoral agents. The signaling molecules secreted by the placenta can act locally through paracrine and autocrine regulation. The placenta also acts as an important endocrine organ and is responsible for the release of hormones into both the fetal and maternal circulation. The hormones produced by the placenta can be split into two categories: peptide hormones (human chorionic gonadotropin [hCG], human placental lactogen [hPL], cytokines, growth hormone [GH], insulin-like growth factors [IGF's], corticotropin releasing hormone [CRH], vascular endothelial growth factor [VEGF], placental growth factor [PIGF]) and steroid hormones (estrogens, progesterone and glucocorticoids).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Peptide hormones",
"    </span>",
"    &nbsp;&mdash;&nbsp;The main site of production of the placental hormones is the trophoblast of the chorionic villi.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Human chorionic gonadotropin",
"      </strong>",
"      &mdash; HCG is secreted by the syncytiotrophoblast into the maternal blood, where it maintains the endocrine activity of the corpus luteum (ie, synthesis of progesterone during the early stages of pregnancy). It can be detected in maternal serum as early as day 8 after conception. Levels of hCG rise throughout the early stages of pregnancy and reach their maximum level at week 8 of gestation. By week 13, the level drops dramatically and reaches a low steady state. By this time, the placenta itself produces enough progesterone to support pregnancy.",
"     </li>",
"     <li>",
"      <strong>",
"       Human placental lactogen",
"      </strong>",
"      &mdash; HPL is a single chain peptide hormone synthesized by the trophoblast and released into the maternal blood. The principal action of hPL is to increase the supply of glucose to the fetus by decreasing maternal stores of fatty acids. It does this by altering maternal secretion of insulin.",
"     </li>",
"     <li>",
"      <strong>",
"       Insulin-like growth factors",
"      </strong>",
"      &mdash; The IGF signaling system plays an important role in normal physiology and fetal growth regulation. There are three ligands, insulin, IGF-I and IGF-2, at least four receptors and six IGF binding proteins (IGFBPs). The IGF axis is a complex signaling pathway that is a major regulator of growth in the fetus and postnatally. IGF-2 is the predominant growth factor and acts by binding to the IGF-1 receptor and initiating a signaling cascade that induces cellular proliferation, survival, and growth [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/18/41256/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Corticotropin releasing hormone",
"      </strong>",
"      &mdash; CRH is a 162 amino acid peptide that is synthesized by syncytiotrophoblast. Glucocorticoids stimulate placental CRH expression (but inhibit hypothalmic CRH), whereas progesterone and estrogen inhibit CRH. CRH concentration in the maternal circulation increases exponentially throughout gestation, but it is bound to a CRH binding protein (CRHBP) secreted by liver, so there is no CRH effect on the maternal pituitary. Concentrations of CRHBP decrease prior to term, so that unbound CRH becomes available, and this is postulated to play a role in the onset of labor.",
"      <br/>",
"      <br/>",
"      In women with idiopathic preterm labor, a more rapid increase in maternal CRH concentration is seen, leading to the hypothesis that placental CRH determines the length of gestation (\"placental clock\"). CRH secreted into the fetal circulation may drive increased cortisol production, maturation of the fetal lung, and increased surfactant production. CRH and the related protein urocortin are also vasodilators of the fetal-placental circulation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/18/41256/abstract/31,32\">",
"       31,32",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/40/32393?source=see_link\">",
"       \"Pathogenesis of spontaneous preterm birth\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Vascular endothelial growth factor and placental growth factor",
"      </strong>",
"      &mdash; VEGF is synthesized in villous trophoblast and macrophages, where it is then secreted into the maternal circulation and acts via two receptors, VEGF-R1 (FLT) and VEGF-R2 (KDR), which are found in villous vascular endothelium [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/18/41256/abstract/33\">",
"       33",
"      </a>",
"      ]. The action of VEGF secreted into maternal plasma is negated by binding to a soluble binding protein sFLT-1. Hypoxia stimulates production of both VEGF and sFLT-1 with increased concentrations seen in preeclamptic pregnancy. In the placenta, VEGF acting via FLT-1 and KDR is thought to be involved in branching angiogenesis in early pregnancy. PIGF is produced in villous syncytiotrophoblast and the media of large villous vessels and also acts via VEGF-R1 and -R2. PIGF acts via FLT-1 in non-branching angiogenesis in the last trimester of pregnancy and expression is down-regulated by hypoxia, suggesting that oxygen tension may regulate the balance of VEGF and PIGF and thus, the effects seen [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/18/41256/abstract/34\">",
"       34",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/61/34777?source=see_link\">",
"       \"Pathogenesis of preeclampsia\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Steroid hormones",
"    </span>",
"    &nbsp;&mdash;&nbsp;The steroid hormones comprise a group of molecules all derived from a common precursor, cholesterol. Steroid hormones are lipophilic molecules, which are protein bound in the bloodstream and can readily cross the bi-lipid membrane of cells. When these hormones bind to their intracellular receptors, the specific complex formed has high affinity for nuclear binding sites. They alter the genetic activity of the cell and thus alter biochemical events.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Progesterone",
"      </strong>",
"      &mdash; Progesterone is necessary for the maintenance of a quiescent, non-contractile uterus. The hormone has anti-inflammatory and immunosuppressive functions which protect the conceptus from immunological rejection by the mother. Initially, progesterone is produced by the corpus luteum in order to prepare the endometrium for implantation of the conceptus. Around 35 to 47 days post ovulation, the placenta takes over progesterone production (luteo-placental shift) and the levels are sufficient to solely support the maintenance of pregnancy. Maternal cholesterol is the substrate for progesterone synthesis and the 3-hydroxysteroid dehydrogenase enzyme (3-HSD) is the rate limiting step. Progesterone concentrations are higher in pregnant women over 30 years and lower in multiparous women and smokers compared with younger women, nulliparas, and nonsmokers, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/18/41256/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Estrogens",
"      </strong>",
"      &mdash; Estrogens are secreted by the corpus luteum and the adrenal cortex, as well as the placenta. hCG stimulates the synthesis of estrogen in the placenta, where the syncytiotrophoblast produces it in large quantities. However, the placenta alone is not capable of estrogen production de novo as it cannot hydroxylate C21 steroids at the 17 position. The maternal, and primarily the fetal, bloodstreams that perfuse the placenta provide dehydroepiandrosterone sulfate (DHEAS), the substrate for estrone and estradiol, and 16-hydroxy-DHEAS, the substrate for estriol. Large amounts of DHEAs are secreted by the fetal adrenal glands and converted to estrogens in the placenta [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/18/41256/abstract/36\">",
"       36",
"      </a>",
"      ]. Hydrolysis by placental sulfatase yields DHEA and 16-hydroxy-DHEA, which are then acted on by 3-HSD and aromatase to yield estrogens. Aromatase is oxygen sensitive, which may account for the low concentration of estrogens in women with placental insufficiency. Placental production of estrogens is higher when the fetus is female and increases in a linear fashion to term [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/18/41256/abstract/35\">",
"       35",
"      </a>",
"      ]. Estrogen production is lower in women over 30 years and multiparous women compared with young women and nulliparas, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/18/41256/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Glucocorticoids",
"      </strong>",
"      &mdash; Glucocorticoids play a crucial role in regulation of organ development and maturation. However, fetal exposure to excessive maternal glucocorticoids may cause growth restriction and can lead to problems, such as hypertension, in later life. Although the placenta does not synthesize glucocorticoids de novo, it regulates exposure of the fetus to glucocorticoids by the 11&szlig;- hydroxy-steroid dehydrogenase enzymes, which catalyze reduction (11&szlig;-HSD1) or oxidation (11&szlig;-HSD2) of glucocorticoids. 11&szlig;-HSD2 is located throughout the syncytiotrophoblast layer where its expression increases with gestational age [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/18/41256/abstract/37\">",
"       37",
"      </a>",
"      ], and it serves to metabolize cortisol to inactive cortisone, thus protecting the fetus against excessive exposure to maternal cortisol. Additionally, a substantial increase in 11&szlig;-HSD2 is observed around 10 to 12 weeks of gestation when blood flow to the intervillous space is established [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/18/41256/abstract/38\">",
"       38",
"      </a>",
"      ]. An increase in the ratio of 11&szlig;-HSD2 to 11&szlig;-HSD1 in placental membranes near term is associated with a switch in placental glucocorticoid metabolism, which may be responsible for the maturation of the fetal hypothalamic-pituitary-adrenal axis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/18/41256/abstract/39\">",
"       39",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     PLACENTAL TRANSFER",
"    </span>",
"    &nbsp;&mdash;&nbsp;The syncytiotrophoblast layer of the placenta is the main site of exchange for nutrients and gases between the maternal bloodstream and the fetus. The efficient transfer of nutrients and solutes across the placenta is essential for normal fetal growth and development.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Mechanisms",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several mechanisms by which transfer occurs:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Solvent drag",
"    </span>",
"    &nbsp;&mdash;&nbsp;Solvent drag is the movement (bulk flow) of water in which solutes and nutrients are dissolved. Bulk flow has been demonstrated in the perfused human placental cotyledon in response to hydrostatic pressure changes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/18/41256/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Simple diffusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Simple diffusion is the passive transfer of solutes driven by concentration and electrical gradients. All solutes are transferred by diffusion, but the relative contribution is dependent on molecular properties. As an example, lipophilic molecules, such as respiratory gases, are readily exchanged by simple diffusion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/18/41256/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Transcellular transfer",
"    </span>",
"    &nbsp;&mdash;&nbsp;This type of transfer utilizes transport proteins in the microvilli or basal membrane of the syncytiotrophoblast. There are three types:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Channels",
"      </strong>",
"      &mdash; These proteins form water-filled pores in the plasma membrane through which ions diffuse down an electrochemical gradient. Charged hydrophilic substances, which are insoluble in lipids, can be transported this way. Aquaporins are an example of channels that function in the transport of water and small molecules; they are essential for fetal development [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/18/41256/abstract/42\">",
"       42",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Facilitated diffusion",
"      </strong>",
"      &mdash; These transporters are saturable carrier proteins, which are independent of metabolic energy. As an example, glucose is transported by the facilitated GLUT transporters.",
"     </li>",
"     <li>",
"      <strong>",
"       Carrier mediated active transport",
"      </strong>",
"      &mdash; Primary active transport utilizes ATP to move solutes against a gradient, Na",
"      <sup>",
"       +",
"      </sup>",
"      K",
"      <sup>",
"       +",
"      </sup>",
"      ATPase and Ca",
"      <sup>",
"       2+",
"      </sup>",
"      ATPase are two examples. Secondary active transport utilizes concentration gradients across the cell that are set by the primary system, Na",
"      <sup>",
"       +",
"      </sup>",
"      amino acid co-transport and the",
"      <span class=\"nowrap\">",
"       Ca",
"       <sup>",
"        2+",
"       </sup>",
"       /Na",
"       <sup>",
"        +",
"       </sup>",
"      </span>",
"      exchanger are examples. Transport ATPases are known to be present in human placenta. These include the Na",
"      <sup>",
"       +",
"      </sup>",
"      : K",
"      <sup>",
"       +",
"      </sup>",
"      pump (Na",
"      <sup>",
"       +",
"      </sup>",
"      K",
"      <sup>",
"       +",
"      </sup>",
"      ATPase), which is localized to the microvillous and basal membrane [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/18/41256/abstract/43\">",
"       43",
"      </a>",
"      ], and a high affinity Ca",
"      <sup>",
"       2+",
"      </sup>",
"      ATPase located on the basal membrane [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/18/41256/abstract/44\">",
"       44",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Endocytosis and exocytosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;During endocytosis, material is engulfed in a sample of extracellular fluid to form a fluid filled vesicle following invagination of the cell surface. Exocytosis is the reverse of this process, where vesicles fuse with the cell membrane to release their contents. This process can be receptor mediated: triggered by a specific interaction between the solute and a receptor on the cell membrane.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Transfer of specific substances",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Respiratory gas exchange",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both oxygen and carbon dioxide are lipophilic molecules which will cross the placenta by simple diffusion. The placental membranes are highly permeable to O",
"    <sub>",
"     2",
"    </sub>",
"    and CO",
"    <sub>",
"     2",
"    </sub>",
"    , thus blood flow is the rate limiting step for exchange of the respiratory gases across this tissue [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/18/41256/abstract/45\">",
"     45",
"    </a>",
"    ]. The partial pressure and the difference between maternal and fetal hemoglobin affinity for O",
"    <sub>",
"     2",
"    </sub>",
"    are two important factors that determine rate of exchange.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Glucose transport",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucose is the primary substrate for fetal oxidative metabolism, thus its efficient transfer across the placenta is essential for normal fetal growth and development. The placenta itself is not capable of producing appreciable amounts of glucose until late in gestation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/18/41256/abstract/46\">",
"     46",
"    </a>",
"    ]. Therefore, uptake of maternal glucose is essential for glycogen synthesis. Members of the glucose transporter (GLUT) family facilitate glucose transfer; GLUT 1 is the abundant subtype expressed in the human trophoblast [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/18/41256/abstract/47\">",
"     47",
"    </a>",
"    ]. Normal pregnancy is a state of insulin resistance so as to increase glucose availability for the fetus. Insulin resistance is exacerbated in pregnancies complicated by diabetes, where the mother may become hyperglycemic, leading to fetal hyperglycemia. As a result of fetal hyperglycemia, there is increased production of insulin, IGF-1, and leptin, resulting in stimulation of fetoplacental growth [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/18/41256/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Amino acid transport",
"    </span>",
"    &nbsp;&mdash;&nbsp;The fetus is dependent on placental transfer of amino acids for protein synthesis for fetal growth. Protein degradation and interconversion to intermediate substrates give rise to synthesis of either glucose or ketone bodies.",
"   </p>",
"   <p>",
"    The placenta plays a critical role in the delivery of amino acids to the fetus. Transfer involves three steps: uptake from the maternal circulation across the microvillous membrane, transport through the trophoblast cytoplasm, and transport across the basal membrane into the umbilical circulation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/18/41256/abstract/48\">",
"     48",
"    </a>",
"    ]. Transport systems within the trophoblast can be either sodium-dependent or sodium-independent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/18/41256/abstract/49,50\">",
"     49,50",
"    </a>",
"    ], and differ based on their ionic substrates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/18/41256/abstract/48\">",
"     48",
"    </a>",
"    ]. All amino acids are not transferred equally [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/18/41256/abstract/51\">",
"     51",
"    </a>",
"    ] and transfer can be impaired in pregnancies complicated by fetal growth restriction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/18/41256/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Fatty acid transport",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fatty acids are essential for fetal development, both as an energy source and also as a precursor for several important bioactive compounds, such as prostaglandins and thromboxane. The placenta has a considerable capacity for fat uptake and transport of fatty acids. Transport involves the breakdown of triglycerides (from maternal adipose tissue) to free fatty acids and glycerol and re-esterification with intracellularly generated glycerol phosphate on the fetal side. This conversion is mediated by lipase activity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Immunoglobulin G transfer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some proteins are transferred across the placenta. Maternal antibodies are readily transported across the placenta to confer immunity to the fetus. From early in the second trimester the concentration of Immunoglobulin G (IgG) in fetal blood increases with most antibodies being acquired in the third trimester. IgG is transported across the syncytiotrophoblast via the Fc receptor, FcRn [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/18/41256/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most drugs cross the placenta by simple diffusion; however, any of the mechanisms of placental transfer described above may be involved. Plasma membrane carriers, biotransforming enzymes, and export pumps also play a role [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/18/41256/abstract/54\">",
"     54",
"    </a>",
"    ]. Factors that affect transfer include molecular weight, degree of ionization, lipid solubility, protein binding, and fetal and placental blood flow. Nonionized, nonprotein bound, lipid soluble drugs with molecular weight below 600 Daltons freely cross the placenta [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/18/41256/abstract/55\">",
"     55",
"    </a>",
"    ]. High molecular weight drugs, such as insulin (6000 Daltons), are not transported in significant amounts.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2354901\">",
"    <span class=\"h3\">",
"     Calcium and vitamin D",
"    </span>",
"    &nbsp;&mdash;&nbsp;(See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/33/2584?source=see_link&amp;anchor=H14#H14\">",
"     \"Calcium physiology in pregnancy\", section on 'Placental transport'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The placenta is an organ for exchange of oxygen, nutrients, antibodies, hormones, and waste products between the mother and fetus. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The progenitor villous trophoblast cell proliferates throughout gestation, differentiating along two pathways to form either invasive extravillous trophoblast (EVT) or syncytiotrophoblast. Invasive EVT that invades decidua is the interstitial EVT, and EVT that invades and remodels the spiral arteries is the endovascular EVT. The syncytiotrophoblast is a specialized epithelium covering the villous tree and has several functions, such as transport of gases, nutrients, and waste products and synthesis of peptide and steroid hormones that regulate placental, fetal, and maternal systems. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Early development'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Placental vasculature is shown in the figure (",
"      <a class=\"graphic graphic_figure graphicRef59367 \" href=\"mobipreview.htm?39/48/40712\">",
"       figure 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H175804821\">",
"       'Vascular development'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The placenta is involved in metabolism of glycogen, cholesterol, and protein. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Metabolic functions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The placenta produces peptide (human chorionic gonadotropin, human placental lactogen, cytokines, growth hormone, insulin-like growth factors, corticotropin releasing hormone, VEGF, placental growth factor) and steroid hormones (estrogens, progesterone and glucocorticoids). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Endocrine functions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are several mechanisms by which placental transfer occurs (eg, solvent drag, simple diffusion, transcellular transfer,",
"      <span class=\"nowrap\">",
"       endocytosis/exocytosis).",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Placental transfer'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/18/41256/abstract/1\">",
"      Hustin J, Schaaps JP. Echographic [corrected] and anatomic studies of the maternotrophoblastic border during the first trimester of pregnancy. Am J Obstet Gynecol 1987; 157:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/18/41256/abstract/2\">",
"      Burton GJ, Hempstock J, Jauniaux E. Nutrition of the human fetus during the first trimester--a review. Placenta 2001; 22 Suppl A:S70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/18/41256/abstract/3\">",
"      Burton GJ, Hempstock J, Jauniaux E. Oxygen, early embryonic metabolism and free radical-mediated embryopathies. Reprod Biomed Online 2003; 6:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/18/41256/abstract/4\">",
"      Burton GJ, Jauniaux E. Placental oxidative stress: from miscarriage to preeclampsia. J Soc Gynecol Investig 2004; 11:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/18/41256/abstract/5\">",
"      Jauniaux E, Watson AL, Hempstock J, et al. Onset of maternal arterial blood flow and placental oxidative stress. A possible factor in human early pregnancy failure. Am J Pathol 2000; 157:2111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/18/41256/abstract/6\">",
"      Burton GJ, Jauniaux E. Oxidative stress. Best Pract Res Clin Obstet Gynaecol 2011; 25:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/18/41256/abstract/7\">",
"      Caniggia I, Winter J, Lye SJ, Post M. Oxygen and placental development during the first trimester: implications for the pathophysiology of pre-eclampsia. Placenta 2000; 21 Suppl A:S25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/18/41256/abstract/8\">",
"      Mi S, Lee X, Li X, et al. Syncytin is a captive retroviral envelope protein involved in human placental morphogenesis. Nature 2000; 403:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/18/41256/abstract/9\">",
"      Lee X, Keith JC Jr, Stumm N, et al. Downregulation of placental syncytin expression and abnormal protein localization in pre-eclampsia. Placenta 2001; 22:808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/18/41256/abstract/10\">",
"      Knerr I, Beinder E, Rascher W. Syncytin, a novel human endogenous retroviral gene in human placenta: evidence for its dysregulation in preeclampsia and HELLP syndrome. Am J Obstet Gynecol 2002; 186:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/18/41256/abstract/11\">",
"      Charnock-Jones DS, Burton GJ. Placental vascular morphogenesis. Baillieres Best Pract Res Clin Obstet Gynaecol 2000; 14:953.",
"     </a>",
"    </li>",
"    <li>",
"     Flint Porter, T, Silver, RM, Ware Branch, D. Pregnancy loss and antiphospholipid antibodies, in Hughes Syndrome Antiphospholipid Syndrome, Khamashta, MA (Ed), Springer-Verlag, London 2000. p.179.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/18/41256/abstract/13\">",
"      Myatt L. Role of placenta in preeclampsia. Endocrine 2002; 19:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/18/41256/abstract/14\">",
"      Krikun G, Lockwood CJ, Wu XX, et al. The expression of the placental anticoagulant protein, annexin V, by villous trophoblasts: immunolocalization and in vitro regulation. Placenta 1994; 15:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/18/41256/abstract/15\">",
"      Rand JH, Wu XX, Andree HA, et al. Pregnancy loss in the antiphospholipid-antibody syndrome--a possible thrombogenic mechanism. N Engl J Med 1997; 337:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/18/41256/abstract/16\">",
"      Reik W, Const&acirc;ncia M, Fowden A, et al. Regulation of supply and demand for maternal nutrients in mammals by imprinted genes. J Physiol 2003; 547:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/18/41256/abstract/17\">",
"      Koukoura O, Sifakis S, Zaravinos A, et al. Hypomethylation along with increased H19 expression in placentas from pregnancies complicated with fetal growth restriction. Placenta 2011; 32:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/18/41256/abstract/18\">",
"      Fowden AL, Coan PM, Angiolini E, et al. Imprinted genes and the epigenetic regulation of placental phenotype. Prog Biophys Mol Biol 2011; 106:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/18/41256/abstract/19\">",
"      Nelissen EC, van Montfoort AP, Dumoulin JC, Evers JL. Epigenetics and the placenta. Hum Reprod Update 2011; 17:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/18/41256/abstract/20\">",
"      Caniggia I, Grisaru-Gravnosky S, Kuliszewsky M, et al. Inhibition of TGF-beta 3 restores the invasive capability of extravillous trophoblasts in preeclamptic pregnancies. J Clin Invest 1999; 103:1641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/18/41256/abstract/21\">",
"      Dokras A, Gardner LM, Seftor EA, Hendrix MJ. Regulation of human cytotrophoblast morphogenesis by hepatocyte growth factor/scatter factor. Biol Reprod 2001; 65:1278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/18/41256/abstract/22\">",
"      Ishihara N, Matsuo H, Murakoshi H, et al. Increased apoptosis in the syncytiotrophoblast in human term placentas complicated by either preeclampsia or intrauterine growth retardation. Am J Obstet Gynecol 2002; 186:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/18/41256/abstract/23\">",
"      Leung DN, Smith SC, To KF, et al. Increased placental apoptosis in pregnancies complicated by preeclampsia. Am J Obstet Gynecol 2001; 184:1249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/18/41256/abstract/24\">",
"      Tantbirojn P, Crum CP, Parast MM. Pathophysiology of placenta creta: the role of decidua and extravillous trophoblast. Placenta 2008; 29:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/18/41256/abstract/25\">",
"      Khong TY. The pathology of placenta accreta, a worldwide epidemic. J Clin Pathol 2008; 61:1243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/18/41256/abstract/26\">",
"      Hahn D, Blaschitz A, Korgun ET, et al. From maternal glucose to fetal glycogen: expression of key regulators in the human placenta. Mol Hum Reprod 2001; 7:1173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/18/41256/abstract/27\">",
"      Herrera E, Amusquivar E, L&oacute;pez-Soldado I, Ortega H. Maternal lipid metabolism and placental lipid transfer. Horm Res 2006; 65 Suppl 3:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/18/41256/abstract/28\">",
"      Beaconsfield P, Birdwood G, Beaconsfield R. The placenta. Sci Am 1980; 243:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/18/41256/abstract/29\">",
"      Settle P, Mynett K, Speake P, et al. Polarized lactate transporter activity and expression in the syncytiotrophoblast of the term human placenta. Placenta 2004; 25:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/18/41256/abstract/30\">",
"      Randhawa R, Cohen P. The role of the insulin-like growth factor system in prenatal growth. Mol Genet Metab 2005; 86:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/18/41256/abstract/31\">",
"      Clifton VL, Read MA, Leitch IM, et al. Corticotropin-releasing hormone-induced vasodilatation in the human fetal placental circulation. J Clin Endocrinol Metab 1994; 79:666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/18/41256/abstract/32\">",
"      Clifton VL, Read MA, Leitch IM, et al. Corticotropin-releasing hormone-induced vasodilatation in the human fetal-placental circulation: involvement of the nitric oxide-cyclic guanosine 3',5'-monophosphate-mediated pathway. J Clin Endocrinol Metab 1995; 80:2888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/18/41256/abstract/33\">",
"      Charnock-Jones DS, Sharkey AM, Boocock CA, et al. Vascular endothelial growth factor receptor localization and activation in human trophoblast and choriocarcinoma cells. Biol Reprod 1994; 51:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/18/41256/abstract/34\">",
"      Shore VH, Wang TH, Wang CL, et al. Vascular endothelial growth factor, placenta growth factor and their receptors in isolated human trophoblast. Placenta 1997; 18:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/18/41256/abstract/35\">",
"      Toriola AT, V&auml;&auml;r&auml;sm&auml;ki M, Lehtinen M, et al. Determinants of maternal sex steroids during the first half of pregnancy. Obstet Gynecol 2011; 118:1029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/18/41256/abstract/36\">",
"      Siiteri, PK. The continuing saga of dehydroepiandrosterone (DHEA). J Clin Endocrinol Metab 2005; 90:3600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/18/41256/abstract/37\">",
"      Murphy VE, Clifton VL. Alterations in human placental 11beta-hydroxysteroid dehydrogenase type 1 and 2 with gestational age and labour. Placenta 2003; 24:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/18/41256/abstract/38\">",
"      Alfaidy N, Gupta S, DeMarco C, et al. Oxygen regulation of placental 11 beta-hydroxysteroid dehydrogenase 2: physiological and pathological implications. J Clin Endocrinol Metab 2002; 87:4797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/18/41256/abstract/39\">",
"      Pepe GJ, Burch MG, Albrecht ED. Localization and developmental regulation of 11beta-hydroxysteroid dehydrogenase-1 and -2 in the baboon syncytiotrophoblast. Endocrinology 2001; 142:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/18/41256/abstract/40\">",
"      Brownbill P, Mahendran D, Owen D, et al. Denudations as paracellular routes for alphafetoprotein and creatinine across the human syncytiotrophoblast. Am J Physiol Regul Integr Comp Physiol 2000; 278:R677.",
"     </a>",
"    </li>",
"    <li>",
"     Sibley, CP, Boyd, RDH. Mechanisms of transfer across the human placenta, in Fetal and Neonatal physiology, Fox, Pa (Ed), WB Saunders Company, Philadelphia 2004. p.111.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/18/41256/abstract/42\">",
"      Liu H, Wintour EM. Aquaporins in development -- a review. Reprod Biol Endocrinol 2005; 3:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/18/41256/abstract/43\">",
"      Johansson M, Jansson T, Powell TL. Na(+)-K(+)-ATPase is distributed to microvillous and basal membrane of the syncytiotrophoblast in human placenta. Am J Physiol Regul Integr Comp Physiol 2000; 279:R287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/18/41256/abstract/44\">",
"      Strid H, Powell TL. ATP-dependent Ca2+ transport is up-regulated during third trimester in human syncytiotrophoblast basal membranes. Pediatr Res 2000; 48:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/18/41256/abstract/45\">",
"      Carter AM. Factors affecting gas transfer across the placenta and the oxygen supply to the fetus. J Dev Physiol 1989; 12:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/18/41256/abstract/46\">",
"      Leonce J, Brockton N, Robinson S, et al. Glucose production in the human placenta. Placenta 2006; 27 Suppl A:S103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/18/41256/abstract/47\">",
"      Illsley NP. Glucose transporters in the human placenta. Placenta 2000; 21:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/18/41256/abstract/48\">",
"      Regnault TR, de Vrijer B, Battaglia FC. Transport and metabolism of amino acids in placenta. Endocrine 2002; 19:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/18/41256/abstract/49\">",
"      Jansson T, Powell TL. Placental nutrient transfer and fetal growth. Nutrition 2000; 16:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/18/41256/abstract/50\">",
"      Regnault TR, Marconi AM, Smith CH, et al. Placental amino acid transport systems and fetal growth restriction--a workshop report. Placenta 2005; 26 Suppl A:S76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/18/41256/abstract/51\">",
"      Galan HL, Marconi AM, Paolini CL, et al. The transplacental transport of essential amino acids in uncomplicated human pregnancies. Am J Obstet Gynecol 2009; 200:91.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/18/41256/abstract/52\">",
"      Ronzoni S, Marconi AM, Paolini CL, et al. The effect of a maternal infusion of amino acids on umbilical uptake in pregnancies complicated by intrauterine growth restriction. Am J Obstet Gynecol 2002; 187:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/18/41256/abstract/53\">",
"      Simister NE. Placental transport of immunoglobulin G. Vaccine 2003; 21:3365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/18/41256/abstract/54\">",
"      Marin JJ, Briz O, Serrano MA. A review on the molecular mechanisms involved in the placental barrier for drugs. Curr Drug Deliv 2004; 1:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/18/41256/abstract/55\">",
"      Syme MR, Paxton JW, Keelan JA. Drug transfer and metabolism by the human placenta. Clin Pharmacokinet 2004; 43:487.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2284 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-122.72.76.133-33CB703E27-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_18_41256=[""].join("\n");
var outline_f40_18_41256=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H28\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EARLY DEVELOPMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12098174\">",
"      Implantation and invasion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12098281\">",
"      Villous development",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H175804821\">",
"      Vascular development",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H175804869\">",
"      Fetal-placental vascular reactivity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H175804914\">",
"      Anticoagulant activity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H175804990\">",
"      Imprinted genes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H175804788\">",
"      ABNORMAL DEVELOPMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H175804536\">",
"      Preeclampsia and fetal growth restriction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2361569\">",
"      Placenta creta",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12098190\">",
"      Gestational trophoblastic disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      METABOLIC AND ENDOCRINE FUNCTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Metabolic functions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Endocrine functions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Peptide hormones",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Steroid hormones",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      PLACENTAL TRANSFER",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Mechanisms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Solvent drag",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Simple diffusion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Transcellular transfer",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Endocytosis and exocytosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Transfer of specific substances",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Respiratory gas exchange",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Glucose transport",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Amino acid transport",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Fatty acid transport",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Immunoglobulin G transfer",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Drugs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2354901\">",
"      - Calcium and vitamin D",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/2284\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/2284|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?31/37/32349\" title=\"algorithm 1\">",
"      Formation of extravillous trophoblast",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/2284|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?39/48/40712\" title=\"figure 1\">",
"      Placental vasculature",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/33/2584?source=related_link\">",
"      Calcium physiology in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/31/13816?source=related_link\">",
"      Gestational trophoblastic disease: Pathology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/61/34777?source=related_link\">",
"      Pathogenesis of preeclampsia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/40/32393?source=related_link\">",
"      Pathogenesis of spontaneous preterm birth",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_18_41257="Anemia of chronic kidney disease: Target hemoglobin/hematocrit for patients treated with erythropoietic agents";
var content_f40_18_41257=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Anemia of chronic kidney disease: Target hemoglobin/hematocrit for patients treated with erythropoietic agents",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/18/41257/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/18/41257/contributors\">",
"     Jeffrey S Berns, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/18/41257/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/18/41257/contributors\">",
"     Steve J Schwab, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/18/41257/contributors\">",
"     Gary C Curhan, MD, ScD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/18/41257/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/18/41257/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?40/18/41257/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 4, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anemia has been defined by the World Health Organization (WHO) as a hemoglobin (Hgb) concentration below 13.0",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    for adult males and post-menopausal women, and an Hgb below 12.0",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    for premenopausal women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/18/41257/abstract/1\">",
"     1",
"    </a>",
"    ]. Based upon these criteria, nearly 90 percent of patients with a glomerular filtration rate (GFR) less than 25 to 30",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    have anemia, many with Hgb levels below 10",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/18/41257/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ever since the approval of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/48/2825?source=see_link\">",
"     recombinant human erythropoietin",
"    </a>",
"    (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/48/2825?source=see_link\">",
"     epoetin alfa",
"    </a>",
"    , EPO) by the United States Food and Drug Administration (FDA), this and other erythropoietin stimulating agents (ESAs), have become the standard of care for the treatment of the anemia that occurs in most patients with advanced chronic kidney disease (CKD) and end-stage renal disease (ESRD). As a result, mean Hgb and hematocrit (Hct) levels in patients with CKD, particularly those on dialysis, rose steadily through 2005 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/18/41257/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. By 2006, 90 percent of patients maintained on chronic dialysis in the United States received ESAs, with a mean Hgb level among dialysis patients of 12.0",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/18/41257/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]; two-thirds of all patients had Hgb levels between 11 and 13",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/18/41257/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Anemia has also been implicated as a contributing factor in many of the symptoms associated with reduced kidney function. These include fatigue, depression, reduced exercise tolerance, dyspnea, and cardiovascular consequences, such as left ventricular hypertrophy (LVH) and left ventricular systolic dysfunction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/18/41257/abstract/6\">",
"     6",
"    </a>",
"    ]. It is also associated with an increased risk of morbidity and mortality principally due to cardiac disease and stroke [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/18/41257/abstract/7-10\">",
"     7-10",
"    </a>",
"    ], and with an increased risk of hospitalization, hospital length of stay, and mortality in patients with predialysis CKD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/18/41257/abstract/11-14\">",
"     11-14",
"    </a>",
"    ]. Associations, however, do not prove causality; thus these associations may reflect underlying comorbid conditions and severity of illness that contribute to both the severity of anemia, reduced responsiveness to ESAs, and poorer outcomes.",
"   </p>",
"   <p>",
"    A review of the data relating to target Hgb or Hct levels for patients with anemia due to renal disease treated with erythropoietic stimulating agents is presented here. Issues relating to erythropoietin, darbepoetin, and iron administration are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/45/33496?source=see_link\">",
"     \"Erythropoietin for the anemia of chronic kidney disease among predialysis and peritoneal dialysis patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/31/5626?source=see_link\">",
"     \"Erythropoietin for the anemia of chronic kidney disease in hemodialysis patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/21/23896?source=see_link\">",
"     \"Darbepoetin alfa for the management of anemia in chronic kidney disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/55/37752?source=see_link\">",
"     \"Iron balance in non-dialysis, peritoneal dialysis, and home hemodialysis patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/39/38521?source=see_link\">",
"     \"Use of iron preparations in hemodialysis patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H792388815\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;An overview of treatment options for anemia among dialysis and non-dialysis CKD patients, including the relative indications for treatment with ESAs versus transfusion is presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/31/5626?source=see_link&amp;anchor=H9#H9\">",
"     \"Erythropoietin for the anemia of chronic kidney disease in hemodialysis patients\", section on 'Indications'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/45/33496?source=see_link&amp;anchor=H8#H8\">",
"     \"Erythropoietin for the anemia of chronic kidney disease among predialysis and peritoneal dialysis patients\", section on 'Whom to treat and target hemoglobin level'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TARGET LEVELS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ideally, the target Hgb or Hct in patients with CKD, including end-stage renal disease (ESRD), treated with any erythropoietic agent would be defined as that value that is clinically optimal for each patient, based upon their special circumstances, such as general level of function and employment, and comorbidities, such as ischemic coronary disease and heart failure.",
"   </p>",
"   <p>",
"    There is increasing evidence that there is little benefit, and even potential risk, with increased morbidity and mortality, associated with targeting and maintaining Hgb levels greater than 13",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    in predialysis patients. In cancer patients with anemia as well, there is a similar relationship between high target hemoglobin levels and an increased incidence of thrombotic and vascular events and death when erythropoietin-stimulating agents are used. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/15/38138?source=see_link\">",
"     \"Role of erythropoiesis-stimulating agents in the treatment of anemia in patients with cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We acknowledge that the bulk of evidence pertains primarily to CKD patients who are older than 60 years of age and have substantial comorbidities such as diabetes and cardiovascular disease; thus may not apply to younger healthier patients. Results from trials in CKD patients have been also extrapolated to patients on hemodialysis and peritoneal dialysis.",
"   </p>",
"   <p>",
"    The most recent boxed warning on ESAs recommends that physicians and patients with CKD weigh the benefits of ESAs to decrease the need for transfusions against the increased risks for serious adverse cardiovascular events. The insert states that for each patient, one should individualize dosing and use the lowest dose of ESA sufficient to reduce the need for transfusion. Although a target hemoglobin range is not provided, the insert states that for patients with CKD who are not on dialysis&nbsp;one should consider starting ESA treatment only when the hemoglobin level is less than 10",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    and reduce or stop the ESA dose if the hemoglobin level exceeds 10",
"    <span class=\"nowrap\">",
"     g/dL.",
"    </span>",
"    For patients on dialysis, one should initiate ESA treatment when the hemoglobin level is less than 10",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    and reduce or interrupt the ESA dose if the hemoglobin level approaches or exceeds 11",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/18/41257/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For most dialysis patients we initiate ESAs when Hgb levels are below 10",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    whether or not there are symptoms directly attributable to anemia, in order to reduce the need for transfusion. However we do not treat all dialysis patients with ESAs: for some dialysis patients, we start ESAs at lower Hgb levels if at all, whereas we start ESAs at higher Hgb levels for other dialysis patients, such as those who have definite symptoms of anemia or functional or other of quality of life limitations related to anemia. In most dialysis patients who are treated with ESAs, we maintain levels between 10 and 11.5",
"    <span class=\"nowrap\">",
"     g/dL.",
"    </span>",
"    We do not target Hgb concentration &gt;13",
"    <span class=\"nowrap\">",
"     gm/dL.",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/15/38138?source=see_link\">",
"     \"Role of erythropoiesis-stimulating agents in the treatment of anemia in patients with cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For most non-dialysis patients with CKD we consider and initiate ESAs when Hgb levels are less than 10",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    and try to maintain goal Hgb levels between 10 and 11.5",
"    <span class=\"nowrap\">",
"     g/dL.",
"    </span>",
"    However, the goals of ESA treatment are patient-specific. In particular, we are attentive to possible symptoms of anemia in younger patients who have CKD with few co-morbidities who were not represented in the studies that informed the FDA-driven package insert. Among such patients (ie, younger with few comorbidities) whose symptoms of anemia do not respond to Hb levels of 10 to 11.5",
"    <span class=\"nowrap\">",
"     g/dl,",
"    </span>",
"    we maintain Hgb levels above 11.5",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    after discussing potential risks and benefits with each patient, but do not maintain Hgb levels above 13",
"    <span class=\"nowrap\">",
"     g/dL.",
"    </span>",
"   </p>",
"   <p>",
"    The rationale to limit the upper Hgb target to 11.5",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    rather than 11.0",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    among dialysis and non-dialysis CKD patients is that in the major randomized trials, the control group Hgb was usually &le; 11.5",
"    <span class=\"nowrap\">",
"     gm/",
"    </span>",
"    dL [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/18/41257/abstract/16-21\">",
"     16-21",
"    </a>",
"    ]. There are no data on the benefits of Hgb concentrations between 11.5 and 13",
"    <span class=\"nowrap\">",
"     gm/dL.",
"    </span>",
"    As noted above, Hgb targets &gt;13",
"    <span class=\"nowrap\">",
"     gm/dL",
"    </span>",
"    are associated with adverse outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/18/41257/abstract/16-21\">",
"     16-21",
"    </a>",
"    ]. These data are discussed below. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Randomized trials and systematic reviews'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL PRACTICE GUIDELINES",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is now general agreement that partial correction of severe anemia in patients with ESRD and CKD improves physiologic and clinical parameters and quality of life compared to the very low Hgb levels that were common prior to the availability of ESAs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/18/41257/abstract/15,22-26\">",
"     15,22-26",
"    </a>",
"    ]. However, the benefits and risks of maintaining various target Hgb levels are less well defined. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Randomized trials and systematic reviews'",
"    </a>",
"    below.):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The National Kidney Foundation (NKF) Dialysis Outcomes Quality Initiative (DOQI) guidelines for the anemia of chronic kidney disease were initially published in 1997, with revisions in 2001 and 2006 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/18/41257/abstract/22-24\">",
"       22-24",
"      </a>",
"      ]. The 2007 update for the hemoglobin target recommended that the selected Hgb target should generally be in the range of 11 to 12",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      in all patients with CKD [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/18/41257/abstract/25\">",
"       25",
"      </a>",
"      ]. They also recommended that the Hgb target should not exceed 13",
"      <span class=\"nowrap\">",
"       g/dL.",
"      </span>",
"      However these guidelines were issued prior to FDA dosing modification published in 2011 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/18/41257/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The 2012 KDIGO guidelines suggested that ESAs not be started among adult non-dialysis CKD patients with Hgb concentrations &ge;10",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/18/41257/abstract/26\">",
"       26",
"      </a>",
"      ]. For non-dialysis CKD patient with Hgb &lt;10",
"      <span class=\"nowrap\">",
"       g/dL,",
"      </span>",
"      the decision to start ESAs should be individualized based upon the rate of fall in Hgb concentration, prior response to iron therapy, risk of needing a transfusion, the risks related to ESA therapy and the presence of symptoms. Among dialysis patients, KDIGO suggests initiating ESAs when the Hgb concentration is below 10",
"      <span class=\"nowrap\">",
"       g/dL.",
"      </span>",
"     </li>",
"     <li>",
"      The KDIGO 2012 guidelines suggest that ESAs should generally not be used to maintain Hgb concentrations above 11.5",
"      <span class=\"nowrap\">",
"       g/dL,",
"      </span>",
"      but that individualization of therapy will be necessary as some patients may have improvements in quality of life at Hgb &ge;11.5",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      and will be prepared to accept the risks [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/18/41257/abstract/26\">",
"       26",
"      </a>",
"      ]. The KDIGO guidelines recommended that ESAs not be used to maintain Hgb &ge;13",
"      <span class=\"nowrap\">",
"       g/dL.",
"      </span>",
"     </li>",
"     <li>",
"      The 2012 KDIGO guidelines recommended that ESAs be used with great caution if at all in CKD patients with active malignancy, especially if cure is anticipated , or with a history of stroke or a history of malignancy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Current practice and recommendations for target Hgb or Hct ranges in patients with CKD and ESRD reflect both regulatory and fiscal policies as well as results of clinical studies. In clinical practice, it is difficult to maintain individual patient Hgb values within any narrow range [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/18/41257/abstract/25,27-29\">",
"     25,27-29",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Population studies'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H6\">",
"     'Randomized trials and systematic reviews'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     POPULATION STUDIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many retrospective population-based of hemodialysis patients have suggested better outcomes associated with Hgb values between 11 and 13",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    (ie, Hct between 33 and 39 percent) compared to values below this range [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/18/41257/abstract/11-13,30-40\">",
"     11-13,30-40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This conclusion is largely based upon data derived from the United States Renal Data Systems (USRDS) or HCFA database, which examined the association between anemia and hospitalization and mortality among United States Medicare hemodialysis patients, although similar findings have been reported in other studies.",
"   </p>",
"   <p>",
"    However such associations do not prove causality and may reflect in part underlying co-morbid conditions and severity of illness that contributes to both severity of anemia and poorer outcomes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     RANDOMIZED TRIALS AND SYSTEMATIC REVIEWS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical benefits and adverse effects associated with attaining normal or near-normal Hgb values, compared with lower levels, have been evaluated in multiple randomized trials, meta-analyses, and systematic reviews [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/18/41257/abstract/16-21\">",
"     16-21",
"    </a>",
"    ]. Evaluated outcomes have included overall mortality, cardiovascular mortality, and morbidity due to cardiovascular and cerebrovascular disease, blood pressure control, quality of life and functional status, and access thrombosis.",
"   </p>",
"   <p>",
"    Increasing evidence from multiple trials, particularly the Normal Hematocrit trial in hemodialysis patients and the CHOIR, CREATE and TREAT trials in predialysis patients with CKD, suggest that Hgb levels approaching the normal range compared to levels of moderate anemia do not result in significant clinical benefit and are associated with increased risk of adverse outcomes. These findings are consistent with results in patients with malignancy in whom attaining excessively high hemoglobin target levels with erythropoietic agents are associated with adverse effects, including increased mortality. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/15/38138?source=see_link\">",
"     \"Role of erythropoiesis-stimulating agents in the treatment of anemia in patients with cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Based upon currently available evidence, we feel that the maintenance of hemoglobin levels above 13",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    may be associated with increased morbidity and mortality in dialysis and predialysis patients with CKD. We prefer having Hgb levels in the 10 to 11.5",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    range for most patients. We acknowledge however, that the bulk of evidence pertains primarily to CKD patients with diabetes",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    substantial burdens of cardiovascular disease and other comorbid conditions. It is not clear whether it is safe to maintain lower Hgb levels in some patients or whether higher Hgb levels should be maintained in younger and healthier patients than were included in recent clinical trials.",
"   </p>",
"   <p>",
"    While we try to maintain Hgb levels between 10 to 11.5",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    in most patients, Hgb levels above 11.5",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    will occur transiently in many patients due to a variety of factors and should prompt appropriate gradual dose reductions in the ESA being used. Such transient elevations of Hgb above 11.5",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    are not likely to be associated with important clinical consequences, although some (but not all) studies have reported an association between greater degrees of Hgb variability and adverse clinical outcomes. Among dialysis and predialysis patients with CKD who are treated with erythropoietic agents, we recommend",
"    <strong>",
"     NOT",
"    </strong>",
"    targeting Hgb levels above 13",
"    <span class=\"nowrap\">",
"     g/dL.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Systematic reviews",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of meta-analyses and systematic reviews have been performed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/18/41257/abstract/16,17,20,25,41,42\">",
"     16,17,20,25,41,42",
"    </a>",
"    ]. In the most recent meta-analysis (27 trials, 10,452 patients), compared with lower targets or placebo, higher Hgb targets were associated with an increased risk for stroke (relative risk [RR] 1.51, 95% CI 1.03 to 2.21), hypertension (RR 1.67, 95 % CI 1.31 to 2.12), and vascular thrombosis (RR 1.33, 95% CI 1.16 to 1.53) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/18/41257/abstract/41\">",
"     41",
"    </a>",
"    ]. Trends that favored lower Hgb targets or placebo that were not statistically different were observed for mortality (RR 1.09, 95% CI 0.99 to 1.20), serious cardiovascular events (RR 1.15, 95% CI 0.98 to 1.33), and ESRD (RR 1.08, 95% CI 0.97 to 1.20). Treatment effects were consistent across all stages of CKD. The interpretation of this meta-analysis is limited by the heterogeneity of patients and interventions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Normal Hematocrit trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The issue of whether a normal hematocrit value should be the target level in dialysis patients based upon improved cardiovascular morbidity and mortality was best addressed in the United States Normal Hematocrit trial of hemodialysis patients with heart failure or coronary artery disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/18/41257/abstract/19\">",
"     19",
"    </a>",
"    ]. In this study, 1233 hemodialysis patients with cardiac disease, defined as heart failure or ischemic heart disease, and baseline Hct values of 27 to 33 percent on EPO, were randomly assigned to achieve and maintain a Hct of 42 or 30 percent. The mean age of these patients was about 65 years, and the primary end point was time to death or first nonfatal myocardial infarction.",
"   </p>",
"   <p>",
"    At an interim analysis by the data monitoring committee, the study was terminated after 29 months for two reasons:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      It was extremely unlikely (as determined statistically) that benefits would eventually be realized with higher target values if the study were to continue since the group targeted to normal values had a higher mortality that was approaching, but had not yet attained, statistical significance (futility); the one-year and two-year mortality rates were 7 percent higher in the normal Hct group than in the low Hct group.",
"     </li>",
"     <li>",
"      The rate of adverse vascular access event due to thrombosis of grafts and fistulae in the group targeted to the normal Hb concentrations had become significantly higher than in the lower hematocrit group. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Adverse effects'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    No differences were initially reported between the groups for all-cause hospitalization or other endpoints such as nonfatal myocardial infarction (MI) or stroke [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/18/41257/abstract/19\">",
"     19",
"    </a>",
"    ]. However, according to the trial report submitted to the United States FDA, the higher hematocrit group had a higher rate of hospitalization, although the difference was of marginal statistical significance (RR 1.14, 95% CI 0.99-1.30) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/18/41257/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Trials in CKD patients not yet on dialysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The issue of whether a normal or near-normal hemoglobin value should be the target level in predialysis patients with CKD was best addressed in the CHOIR, CREATE, and TREAT studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/18/41257/abstract/21,44,45\">",
"     21,44,45",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      CHOIR trial &mdash; In the CHOIR trial, 1432 patients with CKD (estimated GFR between 15 to 50",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m2) and a Hgb level less than 11",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      were randomly assigned to achieve a target hemoglobin level of either 13.5 or 11.3",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/18/41257/abstract/45\">",
"       45",
"      </a>",
"      ]. The primary endpoint was the composite of death, myocardial infarction, stroke, and hospitalization for heart failure (without renal replacement therapy). The patients assigned to the higher target only achieved a mean Hgb level of 12.6",
"      <span class=\"nowrap\">",
"       g/dL,",
"      </span>",
"      while a mean level of 11.3",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      was observed in the lower Hgb group.",
"      <br/>",
"      <br/>",
"      The CHOIR trial was terminated early (at a median duration of 16 months) because there was less than a 5 percent chance of demonstrating a relative cardiovascular benefit in the high hemoglobin group. In addition, there were a significantly higher number of events in the high hemoglobin arm (125 versus 97 events, hazard ratio [HR] 1.34, 95% CI 1.03-1.74). This difference was primarily due to nonsignificant trends in the high hemoglobin group for an increased risk of death (52 versus 36 deaths, HR of 1.48, 0.97-2.27) and hospitalization for heart failure (64 versus 47 events, HR of 1.41, 0.97-2.05). Both arms showed similar improvement in quality of life measures. (See sections below for further details of the outcomes of this study).",
"      <br/>",
"      <br/>",
"      However, the following limitations in the CHOIR study require further evaluation to better understand the implications of the study findings:",
"     </li>",
"     <li>",
"      Despite randomization, the group assigned to the high Hgb arm had more underlying comorbid conditions associated with a poor prognosis and adverse outcomes than the low Hgb arm. There was a significantly higher number of patients in the high Hgb arm with hypertension (95 versus 92 percent), a history of CABG (17 versus 14 percent), and greater severity of heart failure (NHANES CHF score &ge;3, 26.6 versus 21.1 percent). In addition, a subsequent report published by the study's sponsor found that the association between randomization group and composite outcome events was no longer statistically significant after multivariate analysis and adjustment for heart failure, atrial",
"      <span class=\"nowrap\">",
"       fibrillation/flutter,",
"      </span>",
"      lower serum albumin, higher percent reticulocyte count, and older age (HR 1.2, 95% CI 0.95-1.6) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/18/41257/abstract/46\">",
"       46",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Further support for this observation is that patients in the high Hgb arm were unable to reach the target Hgb level, despite the administration of a median dose of erythropoietin that was almost three times higher than any other study performed in kidney patients. This suggests that patients in this arm may have been \"erythropoietin-resistant,\" a condition commonly associated with a significant number of comorbid disorders. These factors may have also contributed to the trend toward an increased risk for hospitalization due to heart failure despite a difference in achieved hemoglobin level between the two arms of only 1.3",
"      <span class=\"nowrap\">",
"       g/dL.",
"      </span>",
"     </li>",
"     <li>",
"      Prior to study termination, a significant fraction of enrolled patients withdrew for various unreported reasons (21 percent) or due to the need for renal replacement therapy (17 percent). The study was not blinded and indications for renal replacement therapy were at the discretion of the investigators caring for the patients. Although the proportion requiring renal replacement therapy was similar in the two arms, the impact of such a large fraction of patients who terminated the study early and whose subsequent morbidity and mortality data were censored may have influenced the study outcome. In addition, there was no baseline information",
"      <strong>",
"       presented",
"      </strong>",
"      concerning the approximately 800 patients who actually completed the trial.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      CREATE trial &mdash; In the CREATE trial, 603 patients with GFRs between 15 and 35",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m2 and anemia were randomly assigned to a normal (13 to 15",
"      <span class=\"nowrap\">",
"       g/dL)",
"      </span>",
"      or subnormal (10.5 to 11.5",
"      <span class=\"nowrap\">",
"       g/dL)",
"      </span>",
"      Hgb level [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/18/41257/abstract/44\">",
"       44",
"      </a>",
"      ]. The primary endpoint was a composite of eight cardiovascular events, including sudden death, myocardial infarction, acute heart failure, stroke, transient ischemic attack, hospitalization for angina pectoris or arrhythmia, or complications of peripheral vascular disease. The achieved Hgb levels in the normal and subnormal groups were 13.5 and 11.5",
"      <span class=\"nowrap\">",
"       g/dL,",
"      </span>",
"      respectively.",
"      <br/>",
"      <br/>",
"      At three years, a similar risk of experiencing the primary endpoint was observed in both groups (HR of 0.78, 95% CI 0.53-1.14). Both arms also had similar changes in left ventricular mass and rates of progression of CKD. Increased general health, as well as enhanced quality of life, was observed in the high hemoglobin group. (See sections below for further details of this study).",
"     </li>",
"     <li>",
"      TREAT trial &mdash; In the TREAT trial, 4038 patients with type 2 diabetes and CKD (estimated GFR between 20 to 60",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m2) were randomly assigned to receive",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/49/33560?source=see_link\">",
"       darbepoetin alfa",
"      </a>",
"      to achieve a target hemoglobin level of 13",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      or to placebo, with darbepoetin administered if the Hgb level was less than 9",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/18/41257/abstract/21\">",
"       21",
"      </a>",
"      ]. The primary endpoint was the composite of death or a cardiovascular event (nonfatal myocardial infarction, heart failure, stroke, and hospitalization for myocardial ischemia) and of death or end-stage renal disease. The mean achieved Hgb level was 12.5",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      and 10.6",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      in the darbepoetin and placebo groups, respectively.",
"      <br/>",
"      <br/>",
"      At a median followup of 29 months, both arms had similar risks of death or a cardiovascular event (HR of 1.05, 95% CI 0.94-1.17) or of death or end-stage renal disease (HR of 1.06, 95% CI 0.95-1.19). However, there was an increased risk of fatal or nonfatal stroke with darbepoetin alfa (101 versus 53 patients with placebo, HR of 1.92, 95% CI 1.38-2.68), while red cell transfusions were significantly more common in the placebo group (496 versus 297 patients). Fatigue was only modestly less common with darbepoetin. There was also an increased risk of death due to malignancy in the darbepoetin group, primarily in patients with a past history of malignancy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Effect upon LVH",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effect upon LVH with the attainment of normal or near-normal hemoglobin concentrations has been examined in dialysis patients. This is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/21/6486?source=see_link\">",
"     \"Anemia and left ventricular hypertrophy in chronic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Quality of life",
"    </span>",
"    &nbsp;&mdash;&nbsp;An improved quality of life and functional status is associated with the attainment of a near-normal or normal Hgb concentration in some but not all studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/18/41257/abstract/21,44,45,47-56\">",
"     21,44,45,47-56",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Two 2010 systematic reviews found that the administration of erythropoietic agents to increase Hgb levels improved exercise tolerance, energy, and physical function among patients with CKD [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/18/41257/abstract/55,56\">",
"       55,56",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Benefits with a normal Hgb concentration in terms of quality of life were shown in the CREATE study [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/18/41257/abstract/44\">",
"       44",
"      </a>",
"      ]. Compared with those in the 10.5 to 11.5",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      group, patients assigned to the 13 to 15",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      Hgb level had, at end of year one, significantly better quality of life, general and mental health, physical function and role, social function, and vitality [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/18/41257/abstract/44\">",
"       44",
"      </a>",
"      ]. Benefits in general health and vitality were maintained over the second year of the study.",
"     </li>",
"     <li>",
"      Improvements in quality of life, neurocognitive function, and exercise performance have been noted in additional Hgb near-normal or normalization studies [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/18/41257/abstract/47,48,50-53\">",
"       47,48,50-53",
"      </a>",
"      ]. A similar benefit has also been observed in patients with malignancy who have received erythropoietic agents. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/15/38138?source=see_link\">",
"       \"Role of erythropoiesis-stimulating agents in the treatment of anemia in patients with cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In the TREAT study, fatigue, energy and physical functioning were assessed at 25 weeks using the Functional Assessment of Cancer Therapy-fatigue (FACT-fatigue) and the Short Form-36 (SF-36) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/18/41257/abstract/21\">",
"       21",
"      </a>",
"      ]. A modest improvement in fatigue was noted in those assigned to darbepoetin, but there was no change in energy or physical function. The improvement in fatigue was also noted at 97 weeks among a subset of 2295 patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/18/41257/abstract/57\">",
"       57",
"      </a>",
"      ]. In this subset, overall quality of life as assessed by the self-administered assessment measure, EuroQol (EQ-5D), was also modestly improved in the darbepoetin group.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    No quality of life benefits were observed in the CHOIR study, although this may have been due to the large dropout rate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/18/41257/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;As previously mentioned, the US Normal Hematocrit trial was terminated prematurely because the group targeted to normal values had a higher mortality that was approaching statistical significance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/18/41257/abstract/19\">",
"     19",
"    </a>",
"    ]. Similar findings were noted in the CHOIR study of predialysis patients with CKD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/18/41257/abstract/45\">",
"     45",
"    </a>",
"    ]. Increased mortality has also been observed in patients with malignancy who have received erythropoietic agents. A detailed discussion of the Normal hematocrit and CHOIR trials can be found elsewhere in this topic. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Randomized trials and systematic reviews'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/15/38138?source=see_link\">",
"     \"Role of erythropoiesis-stimulating agents in the treatment of anemia in patients with cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Additional possible major adverse consequences with normal or near-normal Hgb levels include cerebrovascular events, arteriovenous access thrombosis, and hypertension:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the TREAT trial, there was an increased risk of fatal or nonfatal stroke with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/49/33560?source=see_link\">",
"       darbepoetin alfa",
"      </a>",
"      (101 versus 53 patients with placebo, HR of 1.92, 95% CI 1.38-2.68) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/18/41257/abstract/21\">",
"       21",
"      </a>",
"      ]. In another study, an increased risk of cerebrovascular events was also seen among incident hemodialysis patients randomly assigned to Hgb levels of 13.5 to 14.5",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      versus 9.5 to 11.5",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/18/41257/abstract/47\">",
"       47",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The incidence of access thrombosis was higher with normal Hgb levels in the United States Normal Hematocrit study [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/18/41257/abstract/19,58\">",
"       19,58",
"      </a>",
"      ]; this finding was not observed in other smaller studies [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/18/41257/abstract/49,59\">",
"       49,59",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?16/21/16727?source=see_link\">",
"       \"Overview of the treatment of stenosis and thrombotic complications of hemodialysis arteriovenous grafts and fistulas\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      An increase in thrombotic events has also been noted in patients with malignancy who have received erythropoietic agents. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/15/38138?source=see_link\">",
"       \"Role of erythropoiesis-stimulating agents in the treatment of anemia in patients with cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A significant number of patients who receive ESAs will develop an elevation in diastolic pressure of 10 mmHg or more [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/18/41257/abstract/16,60\">",
"       16,60",
"      </a>",
"      ]. However, no difference in blood pressure was observed in the two arms of the US Normal Hematocrit and CREATE studies, suggesting that attaining normal Hgb levels does not confer an added risk for hypertension [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/18/41257/abstract/19,44,61\">",
"       19,44,61",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?8/15/8436?source=see_link\">",
"       \"Hypertension following erythropoietin in chronic kidney disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A post hoc analysis of the CHOIR trial cited above, showed that a higher hemoglobin target was associated with a greater risk of progression of CKD in this study [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/18/41257/abstract/62\">",
"       62",
"      </a>",
"      ]. The limitations of the CHOIR trial are discussed above. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Trials in CKD patients not yet on dialysis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Overall, any adverse effects may result directly from the higher Hgb level, perhaps mediated by hemodynamic or rheologic effects. There may also be indirect effects due to higher ESA doses, additional intravenous iron that is required to support the higher Hgb levels (although unproven), or alterations of dialysis adequacy.",
"   </p>",
"   <p>",
"    An increased economic cost of maintaining higher Hgb levels is also significant. One report concluded that maintaining a target Hgb of 11 to 12",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    with epoetin in hemodialysis patients was associated with an incremental cost per quality-adjusted life year (QALY) gain of $50,000 to $60,000, versus that associated with a Hgb target level of 9.5 to 10.5",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/18/41257/abstract/63\">",
"     63",
"    </a>",
"    ]. The incremental cost per QALY gained for the maintenance of a target Hgb of 14",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    compared to the 12 to 12.5",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    range was estimated to be over $800,000.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     ESA doses, target Hgb levels, and response to ESA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Factors underlying the increased mortality with higher target Hgb levels may include the inability to achieve target levels, the lack of initial response, the exact target Hgb level, toxic effects of higher doses of ESAs, presence of comorbid conditions,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    other characteristics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/18/41257/abstract/19,31,64-70\">",
"     19,31,64-70",
"    </a>",
"    ]. The relative importance of these factors was evaluated in a secondary analyses of the CHOIR and TREAT trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/18/41257/abstract/68,70\">",
"     68,70",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In an unadjusted analysis of the CHOIR trial, an increased risk of the primary composite endpoint (death, myocardial infarction, heart failure, or stroke) at four months was associated with both an inability to achieve target levels and higher doses of epoetin (greater than 20,000 units per week). However, analysis using an adjusted model found that ONLY high dose epoetin therapy resulted in an independent increased risk of the primary composite endpoint (HR 1.57, 95% CI 1.04-2.36). This increased risk was observed in both high and low target Hgb groups, particularly among those unable to reach target Hgb levels. There were no significant interactions among achieved hemoglobin level, high dose therapy, and assigned treatment arm. Similar results were noted in an analysis at nine months.",
"      <br/>",
"      <br/>",
"      Although this is a secondary analysis of the CHOIR trial, these results suggest that an increased mortality may be due to higher ESA doses rather than the higher target hemoglobin level [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/18/41257/abstract/71\">",
"       71",
"      </a>",
"      ]. Therefore, we suggest that the dose of epoetin alpha generally not exceed 20,000 units per week in patients with CKD who are not on dialysis, at least until further study clarifies this issue.",
"      <br/>",
"      <br/>",
"      It is not clear if these findings extend to dialysis patients. In one observational study of elderly hemodialysis patients, for example, doses of epoetin alpha that exceeded 30,000 units per week were not associated with harm or benefit [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/18/41257/abstract/72\">",
"       72",
"      </a>",
"      ]. Thus, dosing of epoetin alpha for dialysis patients can exceed 20,000 units per week, if necessary. In patients who are unable to achieve",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      maintain target hemoglobin levels despite EPO doses as high as 20,000 units per week, a specific cause for ESA-hyporesponsiveness should be sought. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?5/31/5626?source=see_link&amp;anchor=H18#H18\">",
"       \"Erythropoietin for the anemia of chronic kidney disease in hemodialysis patients\", section on 'Hyporesponsiveness to ESAs'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The relationship between the initial Hgb response to two doses of darbepoetin and outcomes was evaluated among 1872 patients with CKD and type 2 diabetes in a secondary analysis of the TREAT trial [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/18/41257/abstract/70\">",
"       70",
"      </a>",
"      ]. A poor initial response was defined as the lowest quartile of percent change in Hgb level (less than 2 percent). Compared with those who had a better hemoglobin response (defined as a change in Hgb level ranging from 2 to 15 percent or more), patients with a poor response had significantly higher rates of the composite cardiovascular end point (adjusted hazard ratio 1.31, 95% CI 1.09-1.59) or death (1.41, 95% CI 1.12-1.78). Those with a poor initial response also received higher doses of darbepoetin (232 versus 176 mcg) and had a lower Hgb level at 12 weeks. Although the exact mechanism is unclear, these findings suggest that the increased mortality observed in Hgb target studies is related to relative unresponsiveness to the ESA. This, in turn, may indicate that, in target Hgb studies, the requirement to use increasingly higher ESA doses identifies a population of &ldquo;sicker&rdquo; patients, namely the poor responders.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Anemia has been implicated as a contributing factor in many of the symptoms associated with reduced kidney function. The partial correction of anemia in CKD patients with ESRD and CKD improves physiologic and clinical parameters and quality of life compared to the severely low Hgb levels that were common prior to the availability of ESAs. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical practice guidelines'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The treatment of anemia among dialysis patients should be individualized. We suggest targeting Hgb levels in the range of 10 to 11.5",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      in most dialysis (hemodialysis and peritoneal) patients who are treated with ESAs (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). In such patients with Hgb levels above 11.5",
"      <span class=\"nowrap\">",
"       g/dL,",
"      </span>",
"      appropriate measures should be instituted, such as decreasing the dose of the ESA or increasing the dosing interval, to maintain Hgb levels in the range of 10 to 11.5",
"      <span class=\"nowrap\">",
"       g/dL.",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Target levels'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Randomized trials and systematic reviews'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14\">",
"       'Adverse effects'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Among dialysis patients with CKD who are treated with ESAs, we recommend",
"      <strong>",
"       NOT",
"      </strong>",
"      targeting Hgb levels above 13",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Hgb targets &gt;13",
"      <span class=\"nowrap\">",
"       gm/dL",
"      </span>",
"      are associated with adverse outcomes. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Target levels'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Randomized trials and systematic reviews'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14\">",
"       'Adverse effects'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The treatment of anemia among non-dialysis patients with CKD should be individualized. For most non-dialysis patients with CKD who have symptoms attributable to anemia we suggest initiating ESAs when the Hgb level is &lt;10",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). However we are attentive to possible symptoms of anemia in younger patients who have CKD with few co-morbidities whose symptoms of anemia occur at higher Hgb levels; for such patients we may initiate ESAs at Hgb levels of 10",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      or even higher after discussing potential risks and benefits with each patient (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Target levels'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For most patients with CKD who are not on dialysis and are on ESAs, we suggest maintaining Hgb levels between 10 and 11.5",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Some clinicians would allow a Hb level greater than 11.5",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      for younger patients with CKD who have few comorbidities and who have persistent, severe symptoms of anemia. There are no data on the benefits of Hgb concentrations between 11.5 and 13",
"      <span class=\"nowrap\">",
"       gm/dL.",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Target levels'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'Trials in CKD patients not yet on dialysis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <br/>",
"      Among predialysis patients with CKD who are treated with erythropoietic agents, we recommend",
"      <strong>",
"       NOT",
"      </strong>",
"      targeting Hgb levels above 13",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Hgb targets &gt;13",
"      <span class=\"nowrap\">",
"       gm/dL",
"      </span>",
"      are associated with adverse outcomes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/18/41257/abstract/16-21\">",
"       16-21",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Target levels'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Randomized trials and systematic reviews'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14\">",
"       'Adverse effects'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     World Health Organization. Nutritional Anaemias: Report of a WHO Scientific Group. Geneva, Switzerland: World Health Organization, 1968.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/18/41257/abstract/2\">",
"      Kazmi WH, Kausz AT, Khan S, et al. Anemia: an early complication of chronic renal insufficiency. Am J Kidney Dis 2001; 38:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/18/41257/abstract/3\">",
"      Obrador GT, Roberts T, St Peter WL, et al. Trends in anemia at initiation of dialysis in the United States. Kidney Int 2001; 60:1875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/18/41257/abstract/4\">",
"      Hariharan S, Yang H. Introduction. Am J Kidney Dis. 2006; 47:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/18/41257/abstract/5\">",
"      2005 Annual Report. ESRD clinical performance measures project. Am J Kidney Dis 2006; 48:S33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/18/41257/abstract/6\">",
"      Levin A, Thompson CR, Ethier J, et al. Left ventricular mass index increase in early renal disease: impact of decline in hemoglobin. Am J Kidney Dis 1999; 34:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/18/41257/abstract/7\">",
"      Jurkovitz CT, Abramson JL, Vaccarino LV, et al. Association of high serum creatinine and anemia increases the risk of coronary events: results from the prospective community-based atherosclerosis risk in communities (ARIC) study. J Am Soc Nephrol 2003; 14:2919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/18/41257/abstract/8\">",
"      Abramson JL, Jurkovitz CT, Vaccarino V, et al. Chronic kidney disease, anemia, and incident stroke in a middle-aged, community-based population: the ARIC Study. Kidney Int 2003; 64:610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/18/41257/abstract/9\">",
"      Sarnak MJ, Tighiouart H, Manjunath G, et al. Anemia as a risk factor for cardiovascular disease in The Atherosclerosis Risk in Communities (ARIC) study. J Am Coll Cardiol 2002; 40:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/18/41257/abstract/10\">",
"      McClellan WM, Flanders WD, Langston RD, et al. Anemia and renal insufficiency are independent risk factors for death among patients with congestive heart failure admitted to community hospitals: a population-based study. J Am Soc Nephrol 2002; 13:1928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/18/41257/abstract/11\">",
"      Ma JZ, Ebben J, Xia H, Collins AJ. Hematocrit level and associated mortality in hemodialysis patients. J Am Soc Nephrol 1999; 10:610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/18/41257/abstract/12\">",
"      Xia H, Ebben J, Ma JZ, Collins AJ. Hematocrit levels and hospitalization risks in hemodialysis patients. J Am Soc Nephrol 1999; 10:1309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/18/41257/abstract/13\">",
"      Collins AJ, Li S, St Peter W, et al. Death, hospitalization, and economic associations among incident hemodialysis patients with hematocrit values of 36 to 39%. J Am Soc Nephrol 2001; 12:2465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/18/41257/abstract/14\">",
"      Collins AJ, Ma JZ, Ebben J. Impact of hematocrit on morbidity and mortality. Semin Nephrol 2000; 20:345.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.fda.gov/Drugs/DrugSafety/ucm259639.htm (Accessed on July 28, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/18/41257/abstract/16\">",
"      Strippoli GF, Craig JC, Manno C, Schena FP. Hemoglobin targets for the anemia of chronic kidney disease: a meta-analysis of randomized, controlled trials. J Am Soc Nephrol 2004; 15:3154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/18/41257/abstract/17\">",
"      Volkova N, Arab L. Evidence-based systematic literature review of hemoglobin/hematocrit and all-cause mortality in dialysis patients. Am J Kidney Dis 2006; 47:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/18/41257/abstract/18\">",
"      Parfrey PS. Target hemoglobin level for EPO therapy in CKD. Am J Kidney Dis 2006; 47:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/18/41257/abstract/19\">",
"      Besarab A, Bolton WK, Browne JK, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998; 339:584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/18/41257/abstract/20\">",
"      Phrommintikul A, Haas SJ, Elsik M, Krum H. Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis. Lancet 2007; 369:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/18/41257/abstract/21\">",
"      Pfeffer MA, Burdmann EA, Chen CY, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009; 361:2019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/18/41257/abstract/22\">",
"      NKF-DOQI clinical practice guidelines for the treatment of anemia of chronic renal failure. National Kidney Foundation-Dialysis Outcomes Quality Initiative. Am J Kidney Dis 1997; 30:S192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/18/41257/abstract/23\">",
"      IV. NKF-K/DOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease: update 2000. Am J Kidney Dis 2001; 37:S182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/18/41257/abstract/24\">",
"      NKF-K/DOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease. Am J Kidney Dis 2006; 47(Suppl 4):S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/18/41257/abstract/25\">",
"      NKF-K/DOQI Clinical Practice Guidelines and Clinical practice recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. Am J Kidney Dis 2007; 50:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/18/41257/abstract/26\">",
"      KDIGO clinical practice guidelines for anemia in chronic kidney disease. Kidney Int Suppl 2012; 2:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/18/41257/abstract/27\">",
"      Berns JS, Elzein H, Lynn RI, et al. Hemoglobin variability in epoetin-treated hemodialysis patients. Kidney Int 2003; 64:1514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/18/41257/abstract/28\">",
"      Lacson E Jr, Ofsthun N, Lazarus JM. Effect of variability in anemia management on hemoglobin outcomes in ESRD. Am J Kidney Dis 2003; 41:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/18/41257/abstract/29\">",
"      Fishbane S, Berns JS. Hemoglobin cycling in hemodialysis patients treated with recombinant human erythropoietin. Kidney Int 2005; 68:1337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/18/41257/abstract/30\">",
"      Li S, Collins AJ. Association of hematocrit value with cardiovascular morbidity and mortality in incident hemodialysis patients. Kidney Int 2004; 65:626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/18/41257/abstract/31\">",
"      Ofsthun N, Labrecque J, Lacson E, et al. The effects of higher hemoglobin levels on mortality and hospitalization in hemodialysis patients. Kidney Int 2003; 63:1908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/18/41257/abstract/32\">",
"      Pisoni RL, Bragg-Gresham JL, Young EW, et al. Anemia management and outcomes from 12 countries in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2004; 44:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/18/41257/abstract/33\">",
"      Li S, Foley RN, Collins AJ. Anemia, hospitalization, and mortality in patients receiving peritoneal dialysis in the United States. Kidney Int 2004; 65:1864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/18/41257/abstract/34\">",
"      Robinson BM, Joffe MM, Berns JS, et al. Anemia and mortality in hemodialysis patients: accounting for morbidity and treatment variables updated over time. Kidney Int 2005; 68:2323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/18/41257/abstract/35\">",
"      Messana JM, Chuang CC, Turenne M, et al. Association of quarterly average achieved hematocrit with mortality in dialysis patients: a time-dependent comorbidity-adjusted model. Am J Kidney Dis 2009; 53:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/18/41257/abstract/36\">",
"      Wolfe RA, Hulbert-Shearon TE, Ashby VB, et al. Improvements in dialysis patient mortality are associated with improvements in urea reduction ratio and hematocrit, 1999 to 2002. Am J Kidney Dis 2005; 45:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/18/41257/abstract/37\">",
"      Regidor DL, Kopple JD, Kovesdy CP, et al. Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients. J Am Soc Nephrol 2006; 17:1181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/18/41257/abstract/38\">",
"      Locatelli F, Pisoni RL, Combe C, et al. Anaemia in haemodialysis patients of five European countries: association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 2004; 19:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/18/41257/abstract/39\">",
"      Lu WX, Jones-Burton C, Zhan M, et al. Survival benefit of recombinant human erythropoietin administration prior to onset of end-stage renal disease: variations across surrogates for quality of care and time. Nephron Clin Pract 2005; 101:c79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/18/41257/abstract/40\">",
"      Gilbertson DT, Ebben JP, Foley RN, et al. Hemoglobin level variability: associations with mortality. Clin J Am Soc Nephrol 2008; 3:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/18/41257/abstract/41\">",
"      Palmer SC, Navaneethan SD, Craig JC, et al. Meta-analysis: erythropoiesis-stimulating agents in patients with chronic kidney disease. Ann Intern Med 2010; 153:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/18/41257/abstract/42\">",
"      Clement FM, Klarenbach S, Tonelli M, et al. The impact of selecting a high hemoglobin target level on health-related quality of life for patients with chronic kidney disease: a systematic review and meta-analysis. Arch Intern Med 2009; 169:1104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/18/41257/abstract/43\">",
"      Coyne DW. The health-related quality of life was not improved by targeting higher hemoglobin in the Normal Hematocrit Trial. Kidney Int 2012; 82:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/18/41257/abstract/44\">",
"      Dr&uuml;eke TB, Locatelli F, Clyne N, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006; 355:2071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/18/41257/abstract/45\">",
"      Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006; 355:2085.",
"     </a>",
"    </li>",
"    <li>",
"     www.clinicaltrials.gov (Accessed on April 27, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/18/41257/abstract/47\">",
"      Parfrey PS, Foley RN, Wittreich BH, et al. Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease. J Am Soc Nephrol 2005; 16:2180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/18/41257/abstract/48\">",
"      Ritz E, Laville M, Bilous RW, et al. Target level for hemoglobin correction in patients with diabetes and CKD: primary results of the Anemia Correction in Diabetes (ACORD) Study. Am J Kidney Dis 2007; 49:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/18/41257/abstract/49\">",
"      Moreno F, Sanz-Guajardo D, L&oacute;pez-G&oacute;mez JM, et al. Increasing the hematocrit has a beneficial effect on quality of life and is safe in selected hemodialysis patients. Spanish Cooperative Renal Patients Quality of Life Study Group of the Spanish Society of Nephrology. J Am Soc Nephrol 2000; 11:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/18/41257/abstract/50\">",
"      McMahon LP, Mason K, Skinner SL, et al. Effects of haemoglobin normalization on quality of life and cardiovascular parameters in end-stage renal failure. Nephrol Dial Transplant 2000; 15:1425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/18/41257/abstract/51\">",
"      Double-blind, placebo-controlled study of the therapeutic use of recombinant human erythropoietin for anemia associated with chronic renal failure in predialysis patients. The US Recombinant Human Erythropoietin Predialysis Study Group. Am J Kidney Dis 1991; 18:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/18/41257/abstract/52\">",
"      Pickett JL, Theberge DC, Brown WS, et al. Normalizing hematocrit in dialysis patients improves brain function. Am J Kidney Dis 1999; 33:1122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/18/41257/abstract/53\">",
"      McMahon LP, McKenna MJ, Sangkabutra T, et al. Physical performance and associated electrolyte changes after haemoglobin normalization: a comparative study in haemodialysis patients. Nephrol Dial Transplant 1999; 14:1182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/18/41257/abstract/54\">",
"      Foley RN, Curtis BM, Parfrey PS. Erythropoietin therapy, hemoglobin targets, and quality of life in healthy hemodialysis patients: a randomized trial. Clin J Am Soc Nephrol 2009; 4:726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/18/41257/abstract/55\">",
"      Gandra SR, Finkelstein FO, Bennett AV, et al. Impact of erythropoiesis-stimulating agents on energy and physical function in nondialysis CKD patients with anemia: a systematic review. Am J Kidney Dis 2010; 55:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/18/41257/abstract/56\">",
"      Johansen KL, Finkelstein FO, Revicki DA, et al. Systematic review and meta-analysis of exercise tolerance and physical functioning in dialysis patients treated with erythropoiesis-stimulating agents. Am J Kidney Dis 2010; 55:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/18/41257/abstract/57\">",
"      Lewis EF, Pfeffer MA, Feng A, et al. Darbepoetin alfa impact on health status in diabetes patients with kidney disease: a randomized trial. Clin J Am Soc Nephrol 2011; 6:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/18/41257/abstract/58\">",
"      Churchill DN, Muirhead N, Goldstein M, et al. Probability of thrombosis of vascular access among hemodialysis patients treated with recombinant human erythropoietin. J Am Soc Nephrol 1994; 4:1809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/18/41257/abstract/59\">",
"      Furuland H, Linde T, Ahlm&eacute;n J, et al. A randomized controlled trial of haemoglobin normalization with epoetin alfa in pre-dialysis and dialysis patients. Nephrol Dial Transplant 2003; 18:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/18/41257/abstract/60\">",
"      Vaziri ND. Mechanism of erythropoietin-induced hypertension. Am J Kidney Dis 1999; 33:821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/18/41257/abstract/61\">",
"      Berns JS, Rudnick MR, Cohen RM, et al. Effects of normal hematocrit on ambulatory blood pressure in epoetin-treated hemodialysis patients with cardiac disease. Kidney Int 1999; 56:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/18/41257/abstract/62\">",
"      Inrig JK, Barnhart HX, Reddan D, et al. Effect of hemoglobin target on progression of kidney disease: a secondary analysis of the CHOIR (Correction of Hemoglobin and Outcomes in Renal Insufficiency) trial. Am J Kidney Dis 2012; 60:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/18/41257/abstract/63\">",
"      Tonelli M, Winkelmayer WC, Jindal KK, et al. The cost-effectiveness of maintaining higher hemoglobin targets with erythropoietin in hemodialysis patients. Kidney Int 2003; 64:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/18/41257/abstract/64\">",
"      Roberts TL, Foley RN, Weinhandl ED, et al. Anaemia and mortality in haemodialysis patients: interaction of propensity score for predicted anaemia and actual haemoglobin levels. Nephrol Dial Transplant 2006; 21:1652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/18/41257/abstract/65\">",
"      Kilpatrick RD, Critchlow CW, Fishbane S, et al. Greater epoetin alfa responsiveness is associated with improved survival in hemodialysis patients. Clin J Am Soc Nephrol 2008; 3:1077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/18/41257/abstract/66\">",
"      Bradbury BD, Wang O, Critchlow CW, et al. Exploring relative mortality and epoetin alfa dose among hemodialysis patients. Am J Kidney Dis 2008; 51:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/18/41257/abstract/67\">",
"      Fishbane S, Besarab A. Mechanism of increased mortality risk with erythropoietin treatment to higher hemoglobin targets. Clin J Am Soc Nephrol 2007; 2:1274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/18/41257/abstract/68\">",
"      Szczech LA, Barnhart HX, Inrig JK, et al. Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes. Kidney Int 2008; 74:791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/18/41257/abstract/69\">",
"      Singh AK. Resolved: Targeting a higher hemoglobin is associated with greater risk in patients with CKD anemia: pro. J Am Soc Nephrol 2009; 20:1436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/18/41257/abstract/70\">",
"      Solomon SD, Uno H, Lewis EF, et al. Erythropoietic response and outcomes in kidney disease and type 2 diabetes. N Engl J Med 2010; 363:1146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/18/41257/abstract/71\">",
"      Rosner MH, Bolton WK. The mortality risk associated with higher hemoglobin: is the therapy to blame? Kidney Int 2008; 74:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/18/41257/abstract/72\">",
"      Zhang Y, Thamer M, Cotter D, et al. Estimated effect of epoetin dosage on survival among elderly hemodialysis patients in the United States. Clin J Am Soc Nephrol 2009; 4:638.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1926 Version 16.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-89.32.226.102-D86B8ADF8C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_18_41257=[""].join("\n");
var outline_f40_18_41257=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H792388815\">",
"      INDICATIONS FOR TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TARGET LEVELS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL PRACTICE GUIDELINES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      POPULATION STUDIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      RANDOMIZED TRIALS AND SYSTEMATIC REVIEWS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Systematic reviews",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Normal Hematocrit trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Trials in CKD patients not yet on dialysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Effect upon LVH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Quality of life",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      ESA doses, target Hgb levels, and response to ESA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/21/6486?source=related_link\">",
"      Anemia and left ventricular hypertrophy in chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/21/23896?source=related_link\">",
"      Darbepoetin alfa for the management of anemia in chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/45/33496?source=related_link\">",
"      Erythropoietin for the anemia of chronic kidney disease among predialysis and peritoneal dialysis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/31/5626?source=related_link\">",
"      Erythropoietin for the anemia of chronic kidney disease in hemodialysis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/15/8436?source=related_link\">",
"      Hypertension following erythropoietin in chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/55/37752?source=related_link\">",
"      Iron balance in non-dialysis, peritoneal dialysis, and home hemodialysis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/21/16727?source=related_link\">",
"      Overview of the treatment of stenosis and thrombotic complications of hemodialysis arteriovenous grafts and fistulas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/15/38138?source=related_link\">",
"      Role of erythropoiesis-stimulating agents in the treatment of anemia in patients with cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/39/38521?source=related_link\">",
"      Use of iron preparations in hemodialysis patients",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_18_41258="Dyshidrotic eczema hand";
var content_f40_18_41258=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F55722%7EPC%2F75738%7EDERM%2F82781%7EDERM%2F82783&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F55722%7EPC%2F75738%7EDERM%2F82781%7EDERM%2F82783&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Dyshidrotic eczema",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 279px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Small vesicles are visible on the lateral fingers.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Goodheart HP. Goodheart's photoguide to common skin disorders, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright &copy; 2003 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Dyshidrotic eczema",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 430px; height: 321px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Dyshidrotic eczema can present with vesicles on feet, and should be distinguished from acute tinea pedis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Goodheart, HP. Goodheart's Photoguide of Common Skin Disorders, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright &copy; 2003 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Dyshidrotic eczema of the hands",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAF6AfgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwC1oyqkebO3Yqo+Z27/AJ9a2YonYBpLjHspx+FRxuW++wAA79KkEu8k5HPGSOBXO02euoqJLZRoGJjj+brkjJrShjIk8wLvP3unA+tUrQFWLgqD0U9jV3zEz+7XMZPTJ4qoxREm7ilVdV8yTB5JVRjB7USSiGLMecEdVPQ/1FV7yZ4nYNHg8ct0Qe/asTVNTRZXjsXeQjgOBgA9zVaIlq5b1XU0toz5jgTMcjaex7CuYDTXzMZPlj/ugn8z6mnJb8K0pYndkknrV2JMOiIV3Hpj09TU7glYktLQwbABlnPToR+FSPI3nKUGWLYSMc78d/pUFzfJBlIPvsMZPOwepPqaq287yqAq7Tnlv4j9aeiFZ9TVmlbzy0zeZIT8wHTPpUiwyytvkyqKevQflUen2mCWdgcH5s9B7k1NPqRg+RWA44IHOPbP86dtNTO7voSTi3tIy74VuuW64+lc3PM1zd+aM7Fb5FOBtPUHHpUGq3/nsyRbiD/ExycelQW0bu4LLuHTGetTo9DeMXY1WuXlZpJmEjkksAMAn14qrEjSys0mfmOcLzxVhYpUUlsLgEgDtVWELHguzBB096ENR0JZ4S8TtjCgZPOcew96S3jwxLoQT91e5+vpSXd1u6KgRfuqvTHvUCXpYBFYD1J/zzTY03sace4N8q5kXk8ZNWoEySZSSegRACfz6Csr7QUHys0nHJJ2r/jTVlGT5jbgOiRnAoCxtSXRVdoKxgDBVeWNRBxKMxLgd2kNZJmBbKKFVeijk1OkjKCrhieoB6ii4uU0VjjzuYhy3QHgdankuTj93iNAORwB/wDXFYbrJJMrn93H3XdyRVhgvmMyK5THAY5NCkkHs77suSSE/NnORzngf98jtSxXKj5C8rAjlFPlj8cVSmDuq7m2gjjsB71atdJuEhEzIwiyAJJflH4Z5P4VHO7l8llqSswIJUhR2C8nH1qJlXg8j61bW2ijkQvKzg8EIMfqamZFBIjQIo7sdxqiGrGcqMGBxhT0ZuKnaISD0OckjpUskW9yv+sOcF6fJblQA524IPHOPwpK6ZXIisbYO3yNx3PY1OLdBksQSegpwjKsSrsR+X6VMEZwNwC/WnoU1Yrm1BXg4+h61NbxSKoZ14qZICHGMGppUlHBbp6UkuoWvpcRVZ8n7vPWleHBGWyo647+9OiSQu25W2etTBB93cB71SdyXDUzp48ucHAB64qGVSqOGGQR+NbawYRuc85xjio7qFipyox3460ralpIwLeQEEHcFPTmrYQbeDz2NVZ4DCgxwQ3Sr8a52AnHseppLsaSXVEqwIy4YtuHoOpqVbFNoJaQD0GKsW4ZkKCKMnHXp+NSm0f5Vlh2vjJ2uMH8aZkzHe2A3sRnJ7nmo4rceUSF47ZGa3JoFjUAkhs9FcMKrLEPMcFnIHOCKkLaGNLADg889Paqk1plM7ScH1rpjap5RbkenIpJbWPAAdB8ucqMGqMmjh7zThIu5UAb2Fc/qOiCVcNCDz6V6RLCgJQfNnknFUpLUN2GOg74p8xDpo82trH7BIfMtFmVfvZ4P4EV1Gj6voxYRys1k+B8sy8H/gQ4rSudM8yNtynjnj0rGvdHyv7tQd3rzWsaz2Zzzo9UdxZWsUyCSCSKaPGf3bBvx4qV5YITjO8j0ryuTQ5YX8yAvDKO8TFT+lTf2vr1irRvcpPz0mQE/mK6IVoPc4qmFqPZ3PQri+Izlto9KwdS1q3tkdi4+pNcRqWv6rMpCRIh9VbiuJ1KTUrh2M4kx6LVvERWxnHCOXxHZ6z44jRmWFi7Zxwa4zVPEt7es+JNi+gNZLxuPvBh9RURXPXB+lYyrykdNPDwh0B3aRgWY59c1EeDUm05prKfTmstzddkNPp3/SinheDSMCWpDsRn/ZPHejnBPegjtuz9KVgCM9fagBO5AOO+KKUDb9B60UBZn08JtxUlfoCcitLTZfKZm8lpXX7w7Y/pXKvfXsiLGFSLadylVwf1p0FrcTbvOllwxJOWOCfWsvQ73qjobzWbONysZV+MHysnB7gk/wBKoz6rkbLdZnJHLucKfoOv51UjtUVcoOD2B/lUnlgApnHp70XYiPdPcYErMVznGeCalihVcbgM9gajKSbCsQIqZYzGjLL8xAzwaExOLGXz7I0Ab5w2SQOn0qok3HAYRDmRjwzD0FOv3/1YTJx1GOPzqjdT4xGjEoCGJz95v/rUxKNhDKJpmKLkt93P8P8A+oVtWUSosb3GdmOgI3H6Vj2UW758gEdSePyrRMgPyRBpPfpSuU43Ls+opsEI6DJxzx/jWVcTPOc52qByenAq4LcwsBwXIwcfNipf7PLwHAwSOc0XuL2aiYcNp5rb2J2564q/pskYufJEPmY45rXjtFRFVgd7DCgHoKmYJblxbQruBDFnAUHHY+tHK76FXVrFS4GB5ar6gMegrHunyh807nPyr7etaN9NGVV2cyZAG3GMk8nA9BWC++5uHwNuTkJ2FPqSkQMweM5wO3FFtYl5d6ljtHTtWhBZjcVcZ44rUsrV3hMZwB6A9frQ1cd+XUxVgZuQOD+tWYLFmw+O30rooLFVIEgAIPU9qnMSJncNvPyrj7/0FHK3uHOuhhwWjgsEUluvHb61IYgpyrrvJwcHk1oXAd1VWIjVTjy14b8v8apx2EnnI8smyI/w9zWc5WKWuo2KwneUMxjEajDEnoavR2saKRGw5/jYYH4CrCxRfKzA8DnirMJTgrGMHAJYdD9KpLuJsowQrGWdYgxI/wBa652/QVYPnXj8+bLJ0Uk5x/hVieRQGD7nIIIOcKPwoMzMw8sDB6belUK7epQlidXw33h1HWnoxZeBnnr0AqysDZYySYb+6gycfXtUsKbWIhjBJxjd8xH9KLDZAiu3zBAsY4ODgfnSITMdsKoAOMoOp+pqa6gkZz5pJY+p4H4VPbWkkUal5CsX3WZsZ/8Ar1N3celir5DBt0jAe3U0LAzHoQCa0cIg2xruHZm4zTgmASQc9uOKqwiqI8qBgnHPtipFiJw3IHY1pRQgrgA7cZwfSnQQ9VfACnkEcCkCK8KcZ2jA9aGjTfySQeenSr4iAcZyAem1ePwoe23E5bH6/hVINjOKE/LbsVbj71WJLWQRZfa/QMVGAKuxxmIHyy+T2xk/UVat4XI2jaRjofukHsT7/wA6B81jlr+zbazMmGBzVqHTwViZsZPUjkL/AI1q3cCCMx91GAD/AHfT6g060EZt7dgVMgGThcbPY+tK2paloQxWcaBiCp2nBDVJ5EESb5IYDz/ePIqZJUmD+WWyWzgL2qKYKQ21mjTpkgfyo0IcdSvcrHLcqVW3RAu4BTkYquBH5j4CEeu3k1IJXEnyt82cliBj6VLKkjbyzqTuySpCgfpUjehTk2iIMFXb7LTsK67Ruye2BU3lqFchmIBO1QO/uahbe0u3ft6BjnJFO5nYpNAqlcYBHHI4/KkEBJ3blUDg8d/pVuGDAlLM7AsQpx1qZYNgy6k8/MDwRSSHJWRlGzMmcN26mqz6cV/1uCO3NbsqLEeDux68VUkuY8nDZH0oM2m9jFn01SvpjpxWXcaIkjM2w+vWuuyG2qTwQSQRVWTBOAFyRyBQJQODm8PBi3BH4VRuPDPHAyTXoojQNtZdrnsTnNJJAjnyyo4Gc0ajcO55gvhHzMtLjHsKzr/wXCqswUD1GM8V6xLboOM4PZapT2oLEE4OOB60czJ9keOz+EYFJ2tIpqhL4SmGCjnPuK9lltIm7K3ruHSqlxZxr95QPQU+dgqPY8ePhS8wdu0/hUUnhTUACdqH8a9WkgUkgcegHeqcqsXMaEgAc855qrl/V2eWN4fvFYhgBUUuh3StxtOffHNeprpvnAjJPckipP7GVc716DPNHMyfYHkbaXdDOIGPrt5or2CLTwpG1Rjp05NFF2HsWjRF3KDwqh2GdwGTU0MzMAskpIxg571mIXVgCWXPpwTU8QLYDDIGeM9Klmy1NqGSNRjhufzp7SRAZIBI7jmsqCFk5OdgPcVbANvh2z5Z/u4Oam4NdSxHcIy4VDxzx3puTLncGVAOSBxVQTRgkxrkn3p6TGQFdpUCgbVzO1GUhmwM45z/AI1DBtZtzjK7SPoamvoGdd4wSemDUdkg+XcOc802zRRujRghyQo5GOfpWmkK7CFUKue3bjvUFvErlsDgDrV+JCsjEEMQO9IVhIYQj/u1yV5z68VcnkjhsZBGX3EDJwMmnwwtsJXcPqOMVTv1Cwtliefmz0xVLQnRsZLcSpGqIQryrk46gVTIxkMwZV5bvj2+tE5aVt6pgHjI9PahImRxE5we+RnaPX607i5UV7hfOZcfMB0A7D0osrJYzluRgg47VcMaKvIfjkcYzT4ULMRuVAOSSaS3uTZtaEn2dI9pJyvbHpViGLgnISPOeR1qsZkQgopkB4GePwxSieRnJlBbcBtPTp2xTurg46WZfa7jgBEalpSPvP2HtWY8shfMshVD1Hc1NOGZ24EKkDgck1BJa/aD8pfAHr1qZPsOEUgkuPLcCEYYHOepzTojJ5ik8s3ryKe1sAAzkLg4wPStGKzRgu9ivufSpsy5cqQyPn7ozn2zVswuqszsEyc/Px+Qp6xONxtv3UQHJYct24qylogjDAyOSMFiMDH171ovMhtFVYQxDFPMjDYG/wCUH3qQokriMSGRscKo2qD71I0JUgSB3PQBj0FSSRMFxkKnXGMZP0piuiKRFRcFQzhsMqH5R6c96kWORgC5WJTwFQcn8KeF2giJAMDdvbk/hToyfLyqli3O4/41LYrMTyWRsxpgEdXNRvkhwxGQM7iOlX0QyAKQrnHCqM0jw/MpUAr3Kjge1Fxx0M6NfNI28uOjHoK0Le0jEbbsyHGfl7fjTIseYAiFgfuk8n8qtfKM+Yyu/cD/AApFt9iCNjGu0YB7cZzTiDIRIEbI6lzxVh2UojKgDD17n6VEdzIR5iqDgnine4JkkauQ2FDt244H51atmj5D7FOOh6VXjjy5B3Og6FnIDURuu9Qi7VJ5UAY+mad7BJc2haIIZpDnA+YsP4fSlEjFW2ggtjcM8H0/A/pUYbAy6yE56sfue59RSNvjmEUkOAw+RlOQR32+oNO4kmMmVgpeTKhmzn+JT0yB+hH41VtZfJE6cn5twUHgn1zVxs7cMACMkENuL/T39R6VmqW8udEVflbcGA/lQ9DWKurGrCDJOwSTG8B1QcnODSToAVRMZGFJJ4JHUc/zrJ0qVZpj59xtkxhTg44PetP7QT8qpt3H5go6Y7ipTuhSi0yJIBA+C4Y/TO4f40/a7ZMZyx+UdAP/ANdPlKFwWBBzjg8ioVVXUgAswPzZ659qVkiHrqQFSo8ojBB6sev1psMG987QeM4HakkU4zuO0cD5cfnTFklRyED7gMD2FF0gUbsRY1jg3HGM8AnJPPSnNKhUMoAPf2+lZ8MpdmDbuCenFWFlU9uTz9KLjlCzEnczZzkk9zVUpgdM9j7VPwCTu5PfNJ0b5sgd896nQLNCNkopLHPQ46YqGTDHIwq9eD1qTohAIxnioiGVsjk4oEkBUA4P3iOcHNRuduFX5hnqRU0ZXDMw6CqpVm59uM0yuUjmbnhefaoJiqD+LzCO/anyfKwxz9aqTl3fJ5PoTigahcYSTzsDE+9VLz5gymLn2NXYopCCcHJ6AU54t5GMY6ZI6/Wg0UUmc88O0EsuOMCmx2bABmXBb9a3r6xhZokXcOeT6mpZYQjfLzgcUalu3Qx4YcFQFz9RUzwg9RyKvbF3YUc9STUnk7zyOoxx3qrXIsZ0cIKfdyM4zRWstqeMDg9RRRZhY4pHxjk4+8BVjz8uOQApzx2qvKuAAPujkUsalW3hePT1qTKMS6kwzhiM9c7jx+NRXAaSUA/KvbrTUTcFGFKgnPH6VcjiAYfPlxzx6f8A6qZXLcbawKDwXAxxn1q0IivXOBwaWJW37iTtHSr8MAYKC272HpUlcpTlgaRAQAew7VRMDJMpAOM5+tdMkI3BOvOMGnSWqsxV1J9cdR/9alZgpdDNslJjYknPXFa6xnY3ygAcg45rLWEx3TKGJBP6VsRcRgSHPUAdzVRFNdhCCGwWJ2nBAyO9R3aAW7ngsw2gHvmrcjDzCoyTnHpjioWh8yOR3weOfyqtzOxlRARhS2WAyAB2PrSSIVUooGTyxA5P41YAxGnd/wBFFIFJJVWPU5Yjt71IMiUh1CqoZs9+lV5WUyFSS/GcAcVckT5AF+5/OohEd21Bz256UCRHEOrnC44UZ6GnLHIcSLlQTjdU0cA3YK729COB9alkiaRQTliOcDpRYLjYtgX5SWOefTNTosjqzHCL3JOBSRR+XjgFv0+vvUs0ZOGfLH07CmCV2Rhgp+RN/uR/KrttIu9R94t/FjJPsKS2g2ktLkcD9e9W4oYbW7kkOePu59+9GoNIt2ykMxUI23jc3Tkf4VKCfLO5sMPly/HT0FQQ3JVFESBcHBf1ND4Zg4JYg8n+tUmZct9xzMquHTqRgs3X8BSKu192856H+ImlA3MFJXaT0X/GkJGwoOf90f1pMOUURmOTyyASORuOcUSAAKrEu3cDtSDqpYgDOCoHX6052w+YkKemcMRUNlqJPCpVSSAAOxHFPmdZFG0M7ADBJwBUUaO7FseY2OCTUjRsF3N8zDgc5/SgLEZHmb9zgMMfKo4x7mpo8+UgiXODkDFJzGGZIyTjJVuKYjMpAL8P6Hn6UtS7Dn3x+ZllBbpu5/8A1VahjRgcZwy85G3P0NQrIiyDbHl/bkn61aBkkiLARgL0A5+vFWkBG0UeAMHIHAzg0zy1Qsdi5PvnP4VP5ijJ8xTnooGT+VJsBBIEnB4BAUU3YS3IFjlnZWEgi292bGPpVV1KyhW3OQc/IenuvvWhNCTyBCCOmTk5+tQsgzvWROBn5V7+/wDiKk0iTKDLH5burSD5g2cB/f2NUoFP9oXFupz5qblJ6qRT5fMdd5kw/r0IPvURZ4pElYbWj+bk9RVNjirCIxiiMaKMxt/rFAJ+oqRJWK/LtUgg8jOPXFPlRlO9QoYgqQDx6imQyYPmYZZEPy7hijY13QpZxuO/GDuwo4+oprzORuY4yOuOSferrFJgGTdsVSWz2Gev/wBaqFwyY+SXP93/AGhUshK7Iy8m9SWPpg84/wDrUrELlnYoyjIx3pgAK71cjuaV90RI25+XOSeAPWlcfKZ0AXDnJyWJz6U3O59wztPaqrFllki+ULuxkHIPvT/MOwRhcZON/t6YqL9DRw6kynLAIufrUnlMx3MvfAFNiLEA96nMhwTzj/apmUk+hXdgr44x9KPMSUlQcnoBTJYpOMEHPaksrUZeZ96so4A7k9/pRfWyGorcfIuzCbcnILc8e1QyD9+2TlB1K9BV9kCxuzfjTBCqIGxjvzVq5MrIy5l3EAEYHQ0+O0Mm5iMYGSTVt4QJMqMqRk/WlYCGJSCdrsencCqQtSLyEW0Y5IkdgiKO3ck1Hb2zSyIA2MZ+ZewHepLh3e5SLnagzjHQmtfSJILe4hNwCyoXUqnc9RVLVjk2lpuYeqhEu0iQ7vLBYsRjk1HOn/Hvkj5geKnum/tG/mnWPYrygKnoKdqcbR3iqQBsQDA7UmC3sVI7fc+0rzVu2sC/GeQCcCn2K7p0DDI3YI9eK1LQFITuXnZ2HTJpocmVRZKqNtUc7cH0zRWjOxdWkB+XccKo7gYooYkeQRoCVzzjHJ6fSp0TcdoHU9PSpRAG5zx6D9Ksx24IHXOOuP1rICERYBCHKj0HT/PWpEyJe2N2M47VbhVFJIXkd88H0qVYsICVBPGW70ajQ6Ft5JZSj5ByV4P4VYyvUDHbPTFJbRhc/eAC9Sc094ySGAJDcDcKBximx8cpLYOCQPpVsAtF3yOPp7VStlDAA8Ec4PSr+NqE4KkHnHSgJKxm3UTBN4GGz1B5FSxSruILDCfKcdqsSLzvOQOvI6+9Ys++K7LMOD39feh6FJXRv27bwCzHDY49alZzFDI4Iyq44HfpWVbznsTtP51feRGtNqsCzMBj2FNMynCzKSEnjHzMcH/GnyqDHhei9T0zT1QY3Yy2cdOg9ak2hhkjEeee2aBPVlJlZ2woIUdaFTJ2x9OuferTKXIAG1B0ApUTa2UPGRwB0NIT2CJlQgkfe6VMFDqSF2qeAKaY89Bt/oamjyDuJyy+3SmQkAT5V2jGO56n2q3HGhiAkGCR9SfrUabGc4+bg8U55AgHy8nhR/WmtEMZdyrHFGUB3gHdjuKig/0tPMjHyZ2nPUkd6Rxt28E8HPpSo6xptVsgcgAcCpbZWiWhdtCIdw4kA4Kntmp2kZgd3UdRVS1DN82cewq4D8w3KEQngLyfxqkrbGTI2iKsf4iec5wMUkZUyc8Ar0B4z9atzr+7IO0sgyN3+NVGz5auygnOMmkyoq6Hb1JxGowRnA7HvzS4BC5Yn6DpUBPIGQcMSO1W4HH3dnJ9e1TuVaxYti6xYDY55J6ihiGbdnc2cYY80DmMkjG3gk9PrSAgt8pLn8lzTJS1FBJU8ZHTnt+NQkoqlVZm5z8n9afKny4lYn/ZXp+VRzTOEBjURoPlBHFBaRMq4BLeVAOxHLUscsbNgbpDjBHWqYKsw3sxY9TjJqRZAqsNgGe2aY3E1IXO0hAkY/X8T2qGQKzDcWbOepPWqomUKeVXPTOMH8qRpmYH5CwA9P60XEoMsB4gNwiO7gZ3Yz+fWq8kwGMbMAYK8/yojXzWKlh2+QDr7c/0pJVBkBUbWLZAx8y/Slcu1mPimB4foOARzge3r9KLja6Fd4CnuOhqBotq5X51znOO/uKQcuM/e9/6etJspRLFlLLNbPFhJHiHHHOPWmyq6qhJUg87f4l/KoQfKkiaOQxyEFcqOv1FWY5WM0ayrsmUYyOO9UncvZ3Q1t7uW5CgZBI/nUNxHKkZZlR1fg7eM/4GrQI80vIBy21sjgfhUrsVBHlsARxu6kf1oE5WehjLIFdt6uoxxx1pGdnGAqhD369PSrFwy4Cqu8ehPX8ao7AXAQqnPJ7f5FZ7GiSepm30himVlPyvkHIx+NTRTMuz584Hp0o1G3k+zkuoYkjDiqdtIzL1VutTsy9GtDWglDHlup6+lTH924BYEn15rNSQBeAB25p4lLYyCQO/WqTMZQbZoSMuVAUEY/I5pGYhQQfmzgg9KoeYV2H5vcmpjcBoyMA7xxx1qr6EKLRcV43UhsrlguO1OcMI3ZcklcjB6VSjP7srvypYcevHWrUfMLZOHwOvemhySRWlPyA5JOMnHaoWkBkjj8zI2hsHoue1Wbk4EfyqGOO/WnT2QllfyQAyD7tBaSsVmRvM80ZwTjr19KmupXaJvKTbIT5h+mOalRCsA3Lgg9SKguomMSOrYcnGD6d6uJOhR0WUleSRzn1Oc1dvHM+r3JJz8uOFxwBWdYyC0mmRtrbScccZosJt91MwzvZiDk9am+yLcNWzXQiOXeW44ckDpxU4l/d7VYsDtJGKoM6mI4BGIgCc8jJp6MVcqrFicJgHrVJkJdzThB3kMNgY4IH60VCswEbvuAYZ/nRTcrAlc4CMNHnjvnB7g1YhJ5HLAdsYz/ntSRMzEqcFu2PTvU6BgdygAemOg9axMwRTu+UDdnHsaeMMCuSGYjG32pBGwIG4/T0H+NTMjBVY4Ixk8UbmisWYSREQ+SueeRz1/wAKEZ3O3PyE8UlqQcFcgDr3PQ1altx5YKqT3wOxq7CTsyFFbhccj07VY6vtc/zpsHy5DE7W4z3BqdVeRgGPI6EenanYchw+V1bGV6lazNUgDpkAlv5VpjG3YScj16g0ycIVwc+YB1A60mhR0Mi0x5S4Pb05zV4xSJIrR8jbk59arR/LdbO7EYBrT3HfJgZIO0Y9qUQnoVRMMqrkDtwfyqwU837/AAvrUNxbLI23A34yDTo1eEhZckA8EH86ZFlZEoj2478Hp3FNK7fuk4Pp/OrSKqqDjjAz/SmSAqPkwBnFIViJihwDx2NIgkbcAfmYAEA44prgqflQ7s4yP5GpBwMljg9VX+tMmSsOR2Hyp25FNdsIrO2W9B60wghsR+vWlQbmLMMZ64oEtRCTMdrfl2qWGP7qgZx3pQmM7BznirywqhEgJAI5GeAaLgx0Sqig7ct3xUis8jZbgr95iOlNw8B3AgHHIb3piByP3hOz+8emKdybFneChjVcvnI9B+NRJC9xuEjNuALAE4GRTPN+XES9R34zUqs0hDTE89celSyooZFEgZSxG4nJUVMCFfgA8cmkVRsAH3gfuj0pGOADjCf3RwT9alDJhEXYFjuJHTt7UmGPDHA7bQcEipA4Gc4CNxgDmmNNtXJOwdM45P4VQhfMC4CrtY/xZqk5Dk5O/IJ9s5p8sjKA6KcZxk1C2XC7ySB1welTZmsVbUVZiu4DGBzj19qlEi/eZyuR8pJI21UkKxHhlCe+M0zcW/u7QPlycYp3sacl9S+GBBKAtjjLn/61MIUKDhceoxmmwkHCqS568scVLJE+ASxIxkg5Ap7iVkHnDaVTPB9M4Hap3cbF8tg64+91Vfw6ioEkjjQq7JHg5+VTn86XzFdFKLnjaJCP5mgGrljcMgnj0APP4Hp+dRvGQQPx6f071HFmM43DaTkkcg/41MkxC7cLt6c9B/UVNidipcI3l9CQB+A+lMa6adUScAuBgtnqex+tX3j8shlYEfxJms65ktUuVfLeWTyucEe9OxpGSZNbXEq2/wAwx833tufzqVpZGGHO/uBjOPpVaLUbczFTISn8LsP54pLm/t0RzC4291HQ+/tTE7t6k2GZiq7cN2/rTpLZnI3Y49e5/wAaLC6tViO4qZG5z2INW21CNGYqyMuMHIz9D9aOUzlVadkZjxbJY1YkqMlgDyfxrDmi+z3jqeFJyCffmuhuLxGX5VVWHzZHSsS+ljnvlWWQ527dxHTvUuOhcJtlfzAD8vJz0PelEy87hg5xxTvvLtkAcgZ461EyBmIQcDsaVrDcrl5NjR+3WowqjJViATgLjrUMbFdo4I/lSi5YSk4GccZ/lVJGd2noWpDtVVPyjOcirSToIxwSWOAT61QM49iPUU24mG0BcYHJx1p7DtctNIjTKrklAcn1FTQssjkBiTk4JrMifdndgHGc1ctmUOuTz1z60F2sjUTKrtJ7EYPfjNQCL7VDINyq64OOtMlk2kfNhT2xUBkkSEmMLx696pMmxjxZ+1zGVV+UHjoB70WOF3MCOTnPakdz9o/eAEOp6+tNtWKI0YX5WGfoc1EtGbJ3RqW3+tXHIIClSenNWWYopZCGCtvJx8y1lrIQWJxnI571N5zuS6McqMe9NSJcSxJKpjZc/MT/AD70Vn3E/wAoJyMkA4HWihy1GomPCQ+NrbVxjcehJ749PariFxn5SCMDcf8APX2qtEgTPTPTp1P+NSRvluTkdSf5/wD66kw3JS7R/KQfQjrg/X1q3GybQOSxJwCKgjUyHauG46D+n+NOVfKTO4+xNF2h2RMGKMGQDP8AFnpVyB2nTKg7+MqP89KpIPlAB49KnhdoXQpxzg56Yppg0WETG37xHOR6EH+VLvwx2BTnBIPY+1LnYfmYESDIwf1o+aNlf5Qp6j+oq7iV27MkjUtzJle3rg0sq/ujuAfA6r1HpUkcq4VgAY+SD03Urx7lDqwKc445H1qSk9TnrvdGyujK2DkHoQfer1uzqVHJLc4FJLEs0kjcLx0qSxOeHIygxn2pI0m7osRgjBBOT3/nViVfOiZNuAejCkjxtQgsSTk+xqxCmBkKcjuT0qjB6alO1LwMI5uOMDPcVNL8642gj+dPkhZsnbuOOe3T0qJJNrlXPzdPrQkS9dSC7Z2YMGHmEY49qdGmYunzHnOevtTZ9okfAJJ559aInIUE9RT2E1dEgRWVRnA/nRtGNuDknkCoizSyBEPzHvjpV5UAGGILdiB096HaxPw7kcMLMxflVHtVzzN2Qu0s3UgcZqu0pwY0PHU+59ajilcgKmF/2sdfrSDVlwum453M/T2zUA+Y8nkDIFQybkXg4cHBA7Cq7ahHE6iMsWzxu7UFxg2aMYB6854B9qnkcEr8wAHTb6VRSYysrghcLyoGKtJgqQSoX1FJobViaThQcqOzbOo96jDkOfL24J+ppxYYzkLH0JPYVFE33tg3cYZjwKWwrCqx2srDA65JyaikcAj5eQPrx60pI3hicnuQcUwyqxUAlyvy/Lii5UUCMdp3dG4zjmnZZVJcmMgepzmmksygNhcHGDUDqG+Yscnqcnika6CTSiQ/uxn3Y9KgYPkMWD+p3ZqwYgeQRjHY4pjIxXlsqOTg0ilJJDobpgmFVUbrkVOrA/fLOzHI2ucD8Ky7gskvlqpz/E47VctJAsbMT2+Y4/Wmn0FNdUXWdbQEys8W4ZC8H8SD2qKW5nlIOFXjqq7Qfyqsv745yxGQBu5/pU0Vu0bFR8ynrjPFProTayE850bIkG7GCTyKjF3Nu5bdnuRg1M0GVJA356n0qkY24JwQOw/nSaZpHUmad9oxx6n/AOtWfdxzS/NvxjrxVgjrhgRjj61UlnKfJg7j154NS33HbsY9x9ohZV85iDkgjpWfdRXRQObpgzc4Xn9K3zE7hWyGxnIx2rOmAbCIQWHTHaqjYibfQyDdasqcXChCeDzz+FRPret28YlAt7kbtnlqxDfka6KO2jaFVlWPcRkNyAPY1W/si2kaRJYJxcL+84f70WOQD6itY01J2OGrXnHU56fxvexoy3VnIpHBwQ2KpL46iyGdnTdyVYc1yvxE1a2XUGstImbylH7xg3QEfc+vrXEGRsjLE9uSaqVNJmMcZJrVH0JZeJra82tFMpfHJU81rrqKyqACrLjqK+ZYZpIm3xO0bj+JWINdHpPjLULQ7Zj58XA5OGxUOBpDFJ6M96S8KZLYPoBSySB8lWUg85NeYWHjq0lKh5mjfPAkHT8a3LfxFFLjbIrKO4PBFCi7WNPapu6Z14mdAC4JB5z7U+SZWK7D1GRj+tc9HrCqOvHTrkU6O8MzkRruYc8HtScWaKomdCk6leoPt3q1FcABSefSuYj1EEBSSG6cirtvd/JgkZx0pcrNOdHQtdnDAscDvmkNwc7SeMg5Fc+bongn6U5r3jhuQKlXKbuWbq7LTiMFWjQnB7kelSQjjDkjI+8DwawYLsG6YZzzxmtSOdHK/MeBge9J73KTNEY4APHIpN23POM1V84qRjrnimyMSvLZ5pXNFqSyPhWViMA5H1oqnISerHA6c0U73KQ0M7YIyBjHHcVajjZju+bPUnr+f+FPS0JYAnavT1P4CtO3twI0Djgdu498Cqt3OO5nxjGdynJ6Dp+v9KmRs9sn69avGIZb5MKRjnkD39zVOZSJDjOT0U9T9aGrFJ3FDAEd+2akzujDA8A8j3qFCygFiSelWIm65FIbHx/IeCWH54z6U91ZmXfnI7561JDgr0okxklSSD2PamjPmswQmNgWGcjkGpXLRJlSGLDAIP8AOocKH3KTx3P9aWPAkbAyEGetFzRO+4BFCdg3v39qrhTDcI7Rnb3+lXYAVIb5WjI+6fWmXMe+MhuR2PoPSgrmsxYWJWPGeDmtDcH24AVT97I5+lZlmDwjEMeqnNaBfYu3POAKpETXYsGPH3PmXHY9Kp3UQlQ4bDg8YHWplkyg2ghh1FKFJJA7Dp6UGSvuZoLCXDrsb371JGPmBcBkB5HrVi5hV1LNjIrPEmxhHJ97PDUmVbmNOGNVBkCFFPIJ9KSVj5eRwMY+tRK5wFyTnsOeKsICQoOMDpniqWxm9ymI3Y45UGn4ZG/dkAnvinBiXYZ+X1PelZGL7QQD+tIpeZFMSw8tQORkknGPxrnr+Es3OXjcYcIdp69c10kkflKVU/nyM1X+zgqWGGL424pSV9EbU58pFZpKnlnOV6Fj0/GtR5goyihUYfe2cGqEQMTtGinLDDEN8tWEllaXcMEg/KM8e9PpYUtXcsRoOHkDEn7mOp/CkllIPIwBjCKfQ55p0jhQWXOT94kY+v0qDK7cLufJ6Yxj6mlYlDW3SKGmIVew6Cp4PLVDuyoPooNUL+XylI3hpGwM44UVDDM21S5JYHhO31NTdJ2ZpZtGqCZSHIwg4FMYGVyuMknC47VYguE+y8R9zgFuefpVVD+9IDbs9wKbViItjo02nHOOgycZpbg7Yx82H6dOP/r1EJc52nC9BURLO+98gY+Y+1SNaO5UdCCAmSpO0Ed6nj+YYyOB0z6fTrTljNxcAuuIx91D29KuxWyllUoAo5IJ4GPYdKaVzRzCziMZyyEdCWI5HpWh5ZaAMVK9yAoyf1piICi7hu79BjHpzVqaICLa2CO/I59OgrRKxk5XZnrvJ2lyozyCDUMsQ2YKDI6mrDfu1IQKCf4skVUaQyBueQfXNJlpX1RUkiAOB0qnPDj5hzWqwBySM/Sqk3zA846dqhml2Y80pjwFIBJ496piMzzlwNrD8OauXsRYccepptumMtgED7wz1oS1Il3IWklVdjlQScZPFcp4u8VHQdPkXaJLhyY4EY48v1Y+1dFr95HDYSybflVgvPUZ/pXjvxFtZ1vY7yeV5A6+Uc9FI6Y9jW8E1qebiZq1mchJIXdnZtzsSzHHUnrUQABPb2p7Z7VHVWOQdx3PFHuRj8aaMnp+tIT1p2EOJ5qSKV4zmN2Q+xxUXv6UHp75osFzatPEF9brtaQSL6PV+38VSIymSIqQcgqc4rmBR2PFKxam0d3D4siLhldo2I+YdjW3ZeJ4X5LYPXCnivKd2KVSc8cN2I7UuXsaxrtbntiatHKAxf5iO5p5vI2wS3H1rxuDUruHlZT6c1fg8RXURw4Lgf3TilymixB6JPdi3ugVJKOOoNaVlqWcbn+X+Veax67HMoEhKE8gsO9aWn62pB/eKM/L61Dgaxro9MTUQV9SehprXZY5LdK46DUxtU7wR0HNWk1D0Ofelym8ayOoN0QfvUVzn9obiPm4FFJxNFWR6lDD0784yRVgb1O0Miq3H1/LmqyNuUY78dKniYgrn7w4/wA4qjNR1uTIpO5WLscenJ/Co5oOSACuOGGf6/0qyhGGyQm7kc4Bx14HJNIVXCqCVIGQTgEg/wAv50OzKvYptAwHC9OeB/P2qNlJYEtk4wPSr8qbELDgMcYB5Y/4e9V22noAMdR6Vm0FyON3Vg2cKeCKmRy2c4wO1Md1OFyM+lNYNkAIAMc+poJaRYKLtJxgcZqKUpvWMAnnJ9qcsvlgs2CuKSMBgznhs5we4oGtCSMnPZT3x6VaeIOgIPy+mOvtVJW+YgkDPbFWFl+XapYeo700U0yo5aF9ygZz+VXYZVZN4bk8Z6896rtEHGSQB3PpVWPNvNsJHlnuO1Mb1NUsVBCg5+vanRyqgA3YOPXmoN6iIDcSzDk+1RMvJb+Ht60EpdC0ZMqSB9TTHtVl+ZxirEVueSDu4GSeAKexx8pGfSgV7bGcqtbyAOSVx1qeQ5GFbtnOadOyuOhFZMkjxSZQgqTnB60rgo8xpRbmHBwf0NSlwnIIyePXmqcUyuhJOG7ihJAoU7Sw4A+tAONy4zZACqB6npTAjsf3YKp0LEYzTFKucc4HNWHJIAUqB2wf0phsQqojbGQoBz9KeoCruzgkkfXNPWLJyBxj9aljTPLLgjpjtTsF7kcUZOM9PSjHlEpEGAPXIp0zA8xjOTnHfNMluPs0X7w5Zui+n1ovYLN7FC8jUsWP+s6bc9aZb25Rtx4VifqRSW8q3E+5gCeuRVwkBSzg+Yf5VnpLU020GCTyYjsGFJwPm6/SglxalmOG5QAY4/GkcZTeRyAdoA+77/WlcnDRgYJHzZ/h/Kqeo0kIHCkImGjGB+NNncF1iUBtnLY7mkiHkxMzcYGVOO/aizQFt0vcgkk0hNLcsW5YEqfvE7iP/rVcDNuaNO/J4zUcPzEsRx94gDGR6VYCo7j5RuY/Oc/07elUSWYXwmwt85Ocnt+FTLIqKyLJlsZwCRuqkPmBLLjcfl55NEkTtESQOvKgZIPQVV+xPKrkl3GPJBibr1w3APsKz4MkjeQeeCc81fCvsfOcgYGaetuFVEHBPGSfzpMvmS0KrRjYoAX+9gVnXEQVc9D0HvW269drHGcjOM8VUuIyV3be+celKxKm1oYF3H3CnNZuoyLbRh2OBjp2P1rYvRty1c7rjCezMf8AETil1CTMS+uorm9COxMfBCD17Z9awfH1gl3os0kSsJIvnI9fX9K6zT7CAzK7Rp5gx83XNHiW2EmnzBMYKHBHXGORVxb6nDXSaPntowV9sZpvljIz6U+V9rFR2OKhzu5x2xW5xAVGeOtGMnqfejB69T6U+JS1NIluxEysFPemk81qQxbuCODUN3YtEdyjIqnBpEqavYpA84xRmnEDPFNA9azNQXAJwPzpRgZHODznvSY5+lL9KBh1PelJ5IPekHUUg5JzTAdn0NGfzpKB1pDLcV/cR4Cye/K1bj1y4QDeoYjryRWUCzMAo3EkAD1NbWq6RZaTrkGn6hqLMqgfbpIYi32djyVUfx4BFDSGm0Ttrk8DBJYJY5MAkOCCAeQcH19aKqeKba6staeG+uzev5cbR3JJPmxFQUIz22447UUrIrnZ9OwAA7i/OegxUyOGbIBVCcEk/wCPSqMG9gDyW7YyatxKEJyBjPIzg/pWVz1UXQD5e8t7bgNuB/vHp+FKiKoDcZPQ4IB99x6/hTEbDBgqgY4Prz75/lVyMOy/dOTg7s7S/wBCen4ChITdipNzgBWUEggHr9B3xUMkbAcKAOOD1xV14NpDBDtI67sA/ieTUMyvtUBTg5PAwP8A9VTJCUtSgfkyygljxTmdjgg8mpQuM4yT0NN249CO1SU9SuuSMsMLnrinBiN2Oc9R6fSpgo3A8gZIqGb+PHHcE0C6hEQ24d88H0qYEgZOd2OMd6jteSck8jI4qwY2K5Xg00XfoTDBRRg7j1x0qtcw7gU53A5yQOlTQsUDByPzoPzMWJyVGORTEipaSYfa+eOAT0q3HId2WHyjk4qC5ti7BwenNRGQhAC3sB3o2DSWxvWMisDvIx3A7n0qSZomxnAxxn1/+tXP28kit8pw3AAxkn61f84E7S2SPQ96FO5m6buSTqJMhc8deahWLDAhOTxUsKMUbeSfmxwMYqcQlsEDA70rGi0VjNuoFJB+43TI6Gs8yzW8v75cx5+8vpXQG2+UEZPJyMZzUcluhzlMjpnrS5RxlyleF1YBo8AejdakkYgnbyBxiqk1vJC2YSQevtTTclEPmAhicHNWTa7ujQt5w6EhuR1HpVk5K4Q7t38OazIJC0oUg7OuQaufaBHkt19xQtSJKzLW1IkMjMCR+h9KzpYvOZncYDdB3FSEtOQSTgdF7AVE1wBLyxA6DB7Urq2o0n0JI4BDbHHIY8+9MiXJw2SQPlqYuQik/dXgAf1otyuGabiMDJx1PtTsugJvqCphNxUFmGVB/ipI08td2QzNkDPf/wCtSbmuHZnwiY69AB6VFczOV82MMoJ2IOlMabuQXM2793wFTg8daS2lSSUL1HYevtUN0hWxZj97OM9zWXoyXJv2aTIiU1hKdpI3UU0dYmSWVcqBz7cVLBl1O84LH7udvFNtAQuVHX/OKsxYVzvjLnbxxkZrUgnCKluxTPJ4C4A/PvU1qhNuxwx8whuByMdASahcl1AwSRgcjkCrKswClV2heh681SZmxZEVQM9c9iDmomUyEtyxH3QDjBpjyckhsN9xeP1pBIQu7Ckjg47elDdybWGP8o27snoarXD5jOSRjGferbhS6kjgD86zruVV3Hg7QQR6VIXMTVJAhwpOPX0rmXYz3mDuEI6EdCfer2qXrXExiiHA+8cioI4tgAOdp9ulSn1HJaFiCOIY29veotTRRbNv+Ycj6VbVRsARVJ9fWoLxsQyIy569e1WjCotD5v1dQmp3iAYVZnA/Oq6KTzitvxFCP7evsAY80jAqnHbknoa6oxujy5zS0Koj5zj8qsw25bHHNXbe1OckcCr0Nr8/uO2K1jBnPKoVre3K4Per6WqyJtcZBq5DZE9QMGrsVkVH+z1reMLHO6nmcNqmnNbSbgvynk4rNPXGPrXqE2lJdQshXJPf1rhNZ0uSwnIIYIehrGtRcfeWx0UMQqnu31Mhjzx0pwx17ilxg4FHr14rnOwO+49aZ1JA70/IIPtSZx2FACMefoKAPQgdOQKOO5GaOvT/AOtQMU8fMDtxzkHp716V/ZtxrSxajqvgi8nvZUUtLDdiFLjjAdkPIJxzjrXmaPtdW4GGBG7p17+1d54nsrLV9auNQi8XaUn2gK7RSSSfuztAKjA+6COOlJgc74vfUH8Q3DavaraXQVALdfuxRhfkUe2MUVQ1W3S0vnhjvYL9FUH7RCSyNkdBnnjpRTA+pQVB4AOOg5PFW7Vt+dwbBGMDAx9Kz7NgZBtGc4HNXiY1OAqtKfl3KOFrnR6zTLsKiOUeWApxjg4yP51aLiPLMACe44J/maoWxIYjnJ5yQT+lWlfLAqdpx6hRj6DmrJY6MlH8wo6uemRz9AO31pJW5yyn/dz6+pH8qHzGAQ+ARjIG3j6nk01VLBhg7T/cBIqZAlqQNh/unB9uhqJk43DIUcVO0eyRQ3zdhk1IEwdxJx1we9RYvYpHO0AkdetVrhiWVRwQeuKuyxkkhRVZRvL7uo/SkVEZG+GCseetaUbbkDDkk4B9KopGQQyncoHJNW4yAAenqPWmiZCSuCTnG4HP1xTLZlZmbuTk57CluR8vAGemD2+lLAmwgHIOPXBphfQuFty71IJI+YmsW+QpKJAAc1vxqphBYZB6g9azrpN2RjvjPpTadiKbtIq7lEe4dDjnvTvKdiNuB8wB9BVaHIkaNjhSfzrTgI2jC5Hc1na5ve1zQgQ4IBOwjkHvip23bcbc+4/lVRXIGRwM45q2ZVWPk5Pp61otjB3uRZAcqc57j0pOMHGd1MZt0g2nAz29KVCytgck5H4UIvoRlTtYsc9iKgaENneFJP6VblYjd36YHSmqCVU7RyeCB1p2EtjMkimjYNFynXbSCdZcAgKM8mtCctjjOT17Y+tZ09t5u4nhv73SlbsNO+5aXiI4xg/3euKaIEYDIBP16VHaCSBgrqdvduwqwxG1vLbGSaTV9w1uOUgBUUEEdT704xPIQuOAe/r6moYod7YweOTzV25XESxhh5jcsVOcD0oQaIpqGkkEcSkpnn0Y+v0psnzzER/MqDhe3uamjj8teThgDk4pQpVGK8KMEduff2pgmV7lPNxGBwvH49zVeHdEm2MBiOT/AI1bmBijAPUd6x31FYbpYyS8jngD09TWcmkzWG2h0WnSN5XTbx1bvmtC0XdOSeFHRi3BPfpWZAWZS5IVyMhTxWlabURVY4J5Yr6fXtVK5MvItwxxiR0fOWG7GKZcY81gjcnjnmka4TG9ZVG7ICjnAFRm9CxuZFDSOMIBzgf41ZmlJ6joI1Uhmbcq5ADt2/CmNwdzHAJLEbe3aoyRIMogCrwATyfWmzzyqo3MCSeKQNFS6uNn3OAeCBWFqMstwCkJHXknnFaN4m+bkjcTzxUSxBFIAz71Dux6JGJDpaSKoZirKc5HerMluEQDBPp71omP5gF7CldcDcAOnfnFJRQOTtqU47VWtgW47n+lY2qoyIxGMgYB966RUzGOABjHArJ1KJZYmVgNwz3xitLHPJ6M8Gvbc3XiLUcKcCU5+tWYrHHG3mtS+tfsvi64jRBiVd5wep71t2+nFsER9f0r1aFPmhc+dxdb2dRowLbT8pyOKsx2ZVxwfrW69oyMDyfXinpbbmAJ4rpVNWPPeJKEcOR93OBUohDAKBx9a0Ps+xiqAHPHIq1bWSoNzgZzjHpWiSRhzTkypZRCHAYZz1qDX9Civ7N2jTkD7orYCxq+GAJ7Yq2pwpKgYxyDSlZqzNKd4S5lueAarp8ljctFIhxk7TVDpnP0r2HxboC3tu0saHcMnjsa8ovrd7ad4pQd444FeZWpOm/I9zDVlWjd7lTnnHPtTeOv4VNjI4wOKYT1zzzWJ0pDQvqQCfxpVXIwcUNjb7U4gjPtQMv6Jqw0lpmOn2F+ZQABdx7wmPT0rW/4TBP+hb8Pjtj7Mf8AGuXYcnt7U1hjJIGaAsXdXvl1C/e4W1trTcFHk2y7YxgYyB79aKfqVrYQIjafqJvGIXcDAYwMjJwcnODx2ooA+m4yzEBRtjHBHQmpk+U8AADpk9agiBcZ/rVqEnIBbaB2GRXLc9llyDBjUAAc5yMAkf1q4q4KjJI9B/8AWqnG5X5geQcg5PI9KubixAATHUnHT8TVXMnuPUiJQdyhhxk4B/xptxI5YBVbk5z0yPzpwPzbNy7MeoFOSEDaRgD1Cn+ZoGmQxZRjjaozyhGQaldPlBKsFbjPr9PanlmChVkLADdgH+tLbZVztkI45wc5/DpQJ9yjKrbTjn3qqmVzwePwzWrPghiVXOeDnFUmQNIFB4649DStYuMtCOPb14HPenSxAHcjE+oPSkkjKvyuCKGfYAck59PWgOpEwD4VzjJ9KsNuCgMQdv8AFTXXKDcB60132Rlck8d/5UDeo6CUumFLVHM+04O5u+RUkSrHAN3p1pscqM20lTt5xSltYSKrRtJGXC/TirNm+xFBB4HIboatiPJBUnjoBVaePyJyeQp7HihKyKvctRyh+HwGzgA1MdqJjAx2PaqqNlAOAPX1NOMhXqx44yP6H1pkW7CSyGN9zZJx1HX8adDMBx1BHBPakdQykN0Izz3qHIhbhd2PTtSvYqya1NIMm1TLyx/OkZc4cnG47QAOn0rKed/NEYxy2MseK1kk8kGPGXA2k9h+NUpJkuLiRMm4bT35Z+5qKYKU45HbNSOAqhlYHHUk9KqpP5r7Fb5z3FDdgUbhtU8Mx9OarmKVZMngccjpWhDB5QOdxLHHXrUhRVjz/CfQ0ik7bCWsipheCT+Qp5VUfOQV65FVvKYybkwqr2z1oEjLvLjK5xmmS1d3HyAPl2I2L82c9R6UjMGjLYAD+/b0pseJCpHAzwKfcCNEwoxxn8aBXtoUppFEhUsTxwMVJZWGCJGVS8g6cfdqjHEbi/AztQ9c9wK24ykRlK7SqjCsR1OMVEfeepo3y6IqSswDSEMxb5fw9quhyHCplkOCSO474qOONQgZgCqjjmptPjEjlcHcwIzgcDvVFp3Q+8uN0QUhAXOBxyB/IUQRCQDaCqKNo96jQ7rlpMF40O1QWqR2aOQBCgAOOe57mhsGtNCVQ6grH26EjmoJlwuD07n3qysuUwyMrk44PFVpzk4xlQfzNDMiqIfmJ79aUREYB6NRKx8xlAwevFSxszJlh6celSmDuV3i25wfkHQYpu0nHy8Y6VbeHgfNn3p8cIIJP096qxm2Z5GxNo5yec9qyb4KI5AwODx0610DqEbAOfc96xtRII5Hyk80zJs8Y8aBtO8S2l5n93IvlEdMEc8fnXaabcR3FlE6kHgZArH+IFgL22jQACRJVZCBzycEVoabZPZ2SRuGDkDgivTwTbi0fO5okpp9TTeJCp29arJZMJSc+mKmjjkRS2efQ1Z58jOMHHWu4823ciWAx+496bIkmPl5+lSp5gQZ5zyTU6HcAW70XApwWrM2Wx61bzsCDaMDqPWp+EPQHPP0oliEoz2xSuNRIJUSRAAOO/Fee+PPC7Ov2m2TGOcgV6Ii7OD075qSVY7iAwyDcrZByKmcVNWZpCbhLmifNUiMrFSNuDg57VCV6/Wu98deHGtLh7iFfqAOtcQVI6jFebUg4yse5Sqxqx5kQbTjFBJB5PJpzA496azZPTiszUVMM6hm2KSAW/uj1r0u90yHQZtX1C20eEiAQ2OlRSoZVupGGTLg/fJHpXmnllmVVAJcgAH1rudW06w03S7pTc6pPe6Hc26STfaNqLv5dYV/hwOAT3oBswvHVpDY+I5ooIUg3RxSSwJ92GVkBdB6YJPHaiq3ivTo9N1uaKGWSa3lRLmKSX75SRdw3erc80UBc+j0kLKuMn3GOKnDsWAxnHtUKoFGVByD+dTwp13Y7HmuXlZ7aaLlu5PUrgnuOlaETbQGXKk4xkmqlvGjqwjIyT34IqyInRgGIYAY4NVYh2LLMUKhWII/2jz+lPVzvEmMsOMks2Krj5D8yjG3Oc9as28ihd0shAA4B5z+tNGbFUDGcEP3IXGfzpGdcBiw3dBz0/KlLYKjYSMZYqKgkJkAYOgDcFS/T64odyVq9RlxMflG3JHfrmqST7WKPwemSOKuWdnIG5c5Y55PFLLHhtkkagKeSFxmpd2bJxWhXLyAfKOnXvmoGJJwB9QO9Xj9nD4EmMdcj+XrTZII3HyXERJ5APymhp2GpIjgIaIhzjAJAbtVJd0kzxyoQq859ferSrJEGGNzDpgZFCSLgBRyDyT60t7DGJGcAow59e3+fWo7PTf9JaRw23OducE/Q+vtWqAjQuWXbjHy09QrJhW54OMdRRKCb1JU3sRSNtVSACF98AfSoLxPPi2vnHb0HvUrKQMEHk5P/wBcVLDEdzMQZB7dh9api21M213pmKQggdBnmrvk+auFLBR19cVDdW+9yVGHB4yf85qSB5DFjge/WkD11Q9YiqevYkc0wxYXAwatRgyIcfKfeoJZVRdz9B0oYotsrNalsMBkZGQTVwvvORyTz7rUUDmb58qF7Hv/APXombJLRkLj1HUf40JLdFPXcSZgzDcR6e1Mt1iEu5EBOeo71TkEkxJT5WHJBPUVaijKDBYBh8wHtUvVlJaFy6lZED9jxjuBVexuGuJmQNtRecHpmpGIlGCSVJznvVmytFACkCPnJJ7DNVZtkuyRbhjMiBQBkDLFugqpeBGO2IfKOpP8Xv8ASpsq8eWYiHoi93PvVVmO7rk5z7GmyYrUqPGyHdG+MDpVVp3YnzQST6CtB0O4Hn8aQQZALc/WpsaFa22h2kHPyn5WOKkVzs55Gf1pssOFYDI47Cq1usyyqXLGP3FGxNr6mmFwc8Zz3HWprX92zkjnBx2wKqrKrAheCMHFWIHc9Tt9wetPcFdFqzh3HDN8gbBz+Z/GpltlTJlQsjDgYxtPqaS2wm3LEY5GD+daEKiYtHkNxxyWLd6pJPczdSzKS2byyEq3z4yFUHkdO9VjGSpLKQAcfjXQPAhUMWjUEfMMcjFVTEYkDzIW3DCEcE574o5LE+0Mi6hMLnIB3AEYojgKrvPfrWktu3ykKXPQcZGPT61HeD7OVM6eUzDIz3FJxBzKBVvvfKVFRPKeflPSpLi5jVQN6so5Cjqaz57kP95jjPakNO5HK0rkhAQM8k9qq3kW2Isenqaka7UEjBX3qpc3DuODuU/rTv3FOLehyPiAbGhkZgdkqtgD3rrdQ03zl3gYbriue1fZLEyyocEYOOK3fCeom+sXt52H2uzwGJOd8eeG+vY134OpZOJ4uZUW7T7GM6yRS7JFOPX1qRgSOhx0rotQ043UbMiYZefrWHGCpZGGNpwTXoXPEcbEcbA/Kehpsq+W+Oi9qnWIK5zTZEBOG/I0XBoIsufarcCIBg4Pv6VT3DgKckcU6KQ7j1HoKTAfJDuc5pAhQgHoKf5rb8kA/wBadJKHIBXgDtTQGbqtil/btE6gt2NeL+LNBl0y4d8HyyeRjp9K9ykyxAUYPWqWsaNHqtoyOAXxxms6tNVFZm1Gs6UtNj50fgkjrSbeeeB61u+JdDk0i9dJEby8/KT0rCZSMfrXmyi4uzPbhNTV0MbPQMcE4z6V6pFb6/LZyR6p4Tsb65uvKaSVr1Y/tBQfIzKG5OPTrXlh7EruAIJX19q7HW7TTfEGrSarbeJrGzgl2HyblmSW1wANqqOCBjjFIpmd4y07Xxdy6pr9mIzM4jLRMrJGQMKnyk7cAcA0VrazrWm3Nl4kuLe8ZzqHkWsMDKQ8hj25uH7DOD780UAeyqHwuWz69qlXG3AOPc0sRUKQTyasRRqFGefWuVI9fnsRo0qKP3nH97PWpVkmdsiVtykdBinnywNrAHHamyDZjBUqTyO9Fh81yeCe5RuJNq8g5GRU32u7AIZ1K54OOg9qjh2O2SMHHQd6V8Hrng8Z4p7E8yZNFd3W4KXPJ64qQ/vSFLozH+8mMVWQHqxOT3zU4wDlz83QEDmi42iVI2iI+ZgOxB4qQOTuXzGPrg5zVXJ5O7fu/vDpTW3KQTuIHbPSlcLXLbkDA4YgDtzSMkboDw7Adx0qMO7JuXac++agZ5InHyqwzniqGkK0SxOGQlWP901FK0wBJ2spPHGCKmMpflid360pHHzHGe/tSKWgkN6UTMsblc/MR/Wr8c8GFMbpuBz/APrrPddq7QwyRnvgikSJWGWAyO3tRcnR7m1EA8bSNlo85JxkfSmtITuTp29z7Z9KzNjxqoV2RT2DZA96eJrmKUuzLKejbj1p3IaLoXngEHBwOhNVbiNoyJYug4IHSka/lUFnjJDnjZzj/Co0uFBVw5UjrGw7elIqK6mlAzOgKc564NNvLVZk2vJkkAZA6Uy1mTaxiwVB+ZO9WXlGFyV2noKGk9xbO4xLaK3t1ihQDbwT13fhUUcXmN5blvl4wO9WBKqxDnc7cjHYev8A9alSbYo3KWfPCYwMepppWE2yo9v5jMy/K3QMBxTGgdn5JBHVSM5q01wpZX3crycD5RUshicgncgxncBz7U9BczRHFAFhZmO1V7HtRPKSq7hsiH3UHJb61Ii4jXzE3BTnaOg7nP41WlcHJLYLc4H9KGOM0ywW80b5T14Az2HtVV/lyxBBA4z3p0Vyqoyx7T9R938ajMgnkG59qgDlu/0pNaGkNyWzcXOdqkgDlj/QVaCckAEowwox1qtBIElMasBnpng//Wq4koDLzwDkeppLYU3roVzb7WYc4xwT3pPIBdQAAw5x2qR5Nm5NpG0kkk9u1RvOm4Atg9flGaZNmxssKFQ0qGInPPqKi+zPH80TBlPcnNW3uPkCooJz1bpj6VXlwXIZirnoE4H1osg1HW9xIjbHGMenYVr2MkEsWC+HbA3njH0rBVSj7RucA9xV1ZEWNY1l8vcT80h4UfSrRnJcxtXMkdvBhp98UjYVTyW+vf8AKs2W+8qVmBk85F2qm3euO3PaqWoXs3kCO28rkbTKCenfGarWlw0S7VhDMTjczHmm2TGHUuPf3MoA/wBVH1KRfLz6k1SknQE+ZuZ/zp6qwTlQzHrUCQDdnG09zUFJLqKGR0JH3ie4prohOM5HcEVZjhGfu/rStGApHUeh6ikHoZk0Ib+HA6HFUL2ybA2Hjrz2roBFnGMkVXlTkkAjHXIpWKOTubcldrrnjqaw7a5m0LVob1ATGjYkXsyH7wPrxz+FdxNb7yWwMfSsXUbVZUZSB6HiqhJxaZjXipxakjv7N0li3xlXjdcgg9QeRWHrFh85mhUbe/vWT4F1L7MX0mduY8tbk9SvdfwrqZLhFUq5yrc5r2YS51zI+Yq03CTizlxGrKCvPrgYpzWvmRkj72M02/P2eUugzGecCpraYSAGPkemelaHP6masJikJc9PwqO44wUGP51r3MSyISfvVjTK3ngKTgGmmS9Ca2fzAM4445qfcobnBPqarRxSFs5/Srf2YEZdsGmMZJLGGwo64HSpIshslsDPTFRvGANyjkGpogHUZ4pMDB8c+H49W053QAyAZ6V4NqNnJZ3TwzAqynqe4r6ltkyduDg9QRnNeZ/FXwtuT7XaIMjk4Fc9anzq63R24at7OVm9GeNqqllD5VCQGPoM816nqF/PYP4htLDRtPA0xIJrONrQOZoCQGbOMtnOcjpXlrofNEfQk7cN0GfWuzvZ9F8N60LabU/ET6lYIIPtEDooGRnaoPO3nivPPVbMj4hxv/wlUzuoTzYIZRCFC+SGQHZgf3emaKy9bu7a71Se4s5byWKTDGS8YNKzY+bcRx16UUxI+jwfmBHTFWAd0ff8DgVSDZAIXp61ajbKdAB7VyXPY5bEqxEuCfmP+92qyImkBATGD0picMCoFW43DEjaMf72KpIltkaBoiB6jGcdKikY7snhvU9PpVxow65UAfQ1Snt2JIHysOfm6UMcRIxv5A+XrwK0FQCPc5O31xVSO1KoTvyOvFWkZhwc4Pr0NSmW1cCpH+734FPQDJXkevanGNXBK/KeO1OaMgEEdOgo3JEXAADfgR1NNYF2bAxz0NPUDKhsH2qdgPKxHzxznrTTAgjtlGGPB7HtSsBjIXJB/OnEhgA33R2JqGZcHgkjrwe9MNSdgpTIUqT196jC7GL4GeOD0NQxSMzgc8davLGrqDt4J60XE9NGQylpcscKCeg7U1gCNrjOOvPWpWGxsEdR3FK0WdrOelAysVIxwMg+vSnwouDuBOT6cipTGCwwrMR0xUoVcnPBHYHmgluxWltVjwyrtJ43Cq88EyMCrv8ALjgnJ/8A1VseX8h8zhSMnOay5XdSYyMIQBk9TTYQk2VmjkZlkimcY59fzodbreW8zLN7cVdiTacKQF6AU4kAnI+lI1cmUQ0/XIb1Uj5amWWcEshB54B/hFSqCVYgH8KdtHy56UEOV0LHczqxOUBwAD2aqF40ju2WX1Kgfyq+6bQcdD0HfNU5Yw4AUEY9eppkR3KyXMqKIVxgnnPf61bsy8TBymSD1HWqMloqziQswA6AdK1bV12Djg80o3e5pKVloIt26NJsjUs3AJXlfpT7S9kVTvQ5z1AokZAw6gk9hSjaDyzKaYuZW2GS6j5k5LKSDhcheoqSTUIU3FAQF+7xzTFBZjsGF6E/4VHI0MbYcB27gdTU6o0TXYtSX8bxZwck8sBniq5uCVwsJBxhWBx+dRxSM2AVwB0UelWXbDbQMY7Gi7CVlsimPtLsC8mE6Hb/AI1NHHGjKWXd33E5qR2zGQRg5zx0qKJsOemewPQCncyd2Wo2y3zgbfep1A8zdtBUdeec1GQGAGenvVlQCmSAGzkelO9yHEhbJxwPekXcSBsyM9qnCszhiuE9KtoiFQy59+elMVrFR14JViD0x1pkkb43DB9c+3tV51CE7/m/iHWmbGX7oBBGMDg0nuNbFSLg4GSepx6fSm3CnbyckfeFXI4CiAnqRnmmTQl1yy4GeT0qiWzCnYr8vPuDVC5h+U8KO/WtuSJWbLbcE5GTnFULhcAjavNSDXNscTq6SwOlxbttnhPmIcdCK7LTbpNRsobjI2SqH68A9x+eaw9Rt924FRgnGTUPhKb7PeyabKQFkJlhz0P95f6iuzCVLPlfU8nMKF4+0XQ6OW2RsjjFVntja/ND0rUiVMgEZp9x5atsI+U+1ekeNymTsWZCQcHv9aoLDtlOfu1pXUQgbIzjvinEJNEduMikS4kFvIpbaB8oolUFvlP4VXjXyrghjipZXAOQeTTEhERi+GqcALgY6Uy2O/A/iB5qS5zHnI+oPpQBZt35yKraqEuoZIZsFWFRQzAnqce/SkuSZFyD81BV7ng/jrQv7P1F5NjfZ3YbtvUA8cVveI21uDUPJ0/wpa3WnxxotrNLYtM7R7RjcxOc9eD0rvtc0Wy1mxmS/uTaFVBVvL3k/lXmN/a2FncNFN461FHHbyZeB+dcGIhaV0enha3NDle6OO8QtdPqsz39jHp9ztUNbRw+UqjHB29s9feik14xf2pJ5Goy6nFtXF1IpVnOOmDzx0orA60fSCDHJxg1YjiLAheQaqBxjn271dt89E5965bansEqQkqN/UVPGNp+U8AYBPepotrJjg0GFW3lRg9uOKpgnfcVZFyPlBxVqJFkVgoU49ahjjXbjAParG1UjXpgnHNFyXHsV5Iiq5Xp0wKZkEqWB4q6Dk4IKoR17VDKMAGM4JPcVPKUhA/7vEeMHI4PWpQGKDIG7GCT2qOIqsfOQeRnFWBGxUggqR3YU7A3YrRxs8iBQAw646Gp5QVG4YVh1BqWOIZctle+QaSV8jgB16DNKwcy3KjZY5Bb3XH9aiY5O1zj2PIxSy4TALAE8kGqk95EgYMw47ii1jRe9sXI4VR935YrQA3KQOvU57cViRajGV+8uegJNLJqJSXDNgjtnrTukZzg2zbREOwksSflz6GiWIrhSf4iD3P5VlRaqiYDMAD83Xoe1Wv7ZjxkSeYzKSABkgfWhNC5ZIsiIrIqnduOOePmqYIYw25QoPUf0rLGoRpxbmVmK/vA4wPwprai7jAjIQD5Vz0NO6Bps03+b7y/LjKgnpVe5KPlXIycc+lRJdTCP5VUFl29zj1quDMhUqInA/vDOaG1YSjZkih4nCckHkNT3R2HTJHAGe1MM0xUoyRgn07UiyTO2HYKwx04zRzI0sywI8LyyrgZGetJG0Z5ySenAqF1ywLFsg98c0+NDxlsH0pNktaFmQlkYA429OOTUKQksWAXpySakbAXCnBxz/jT4n+QrgAdqafcztpoQeSFOGXn9Kcsaqh6ZJzwf0oaUDByMVUuLpY0Y55PAFFx2b2J5nTd8vUdj0NVLi7jiQ7m+b0xzVCWeSRiq5APHvTTbkgBwW/GpcjWMddRpvJZPlj3Rofenx/u2BjH1Jp627c5wKkWMZ+bj3qdSm+xNDKwwSAaRpnG4jgtzRsbHABPrSBdxIzk8cUtSULueQhST+FWYuGzIPTgelRJAAflLAe1TAFSTkk9Tg96Nepej2LkJ4JJKp6/0p082wADHP41CmSMlCq8fTNTxxIx5Gf8atGbik7slaUrGOeoqWxmBBxn1YnpUcluY4BuU72Hyrg81La248v5ScD/AGSP1p6jSViwJFfcEOAcYyf8KfGMldpO7OMj0qm4JJUD5umQeKvWYVVUnlV7ZLfypkSSEuA8QTaAUJ65x/KqpZ2/hwT90jv+JrRY5wQAPYAAH8OtVmjDLiNfm6gev4darUz06mPOCT13Erj6is+dCxznHpW5PG2SwAUdP8+grLmhzk5OQeKg0T0Mq5iDKQ4BH8q5fWrV8iWAlZI+Y3XqrDoa7C4X7x28Y5rFvIsq+QeR2qk30MJQTumavhzVv7W0xZZAFu422TL6N6j2IrVEW8fNxnoa4C3nk0TUFu40YxHCzxjuvr9RXeJcJKI2VtyMAysPQ9DXrUKnPHU+dxVD2M2ujFFpk7ZM4PSsq5ha2u+MiMjqa13chwc5/GopwJxt4zjvWxyNdjJkVJDkE56CmHgssowQOM01ke2ugW+5njNW5wlxGNvLdeKZnYjt+GJUYxS3TbwQefUDtUMRMbYbIPqac0uQxAHHpQO+hBESPl2/nUsZwwB+YHimWxBcF88DpSyMGl2oRx2oAupZPebxBGGKjDZIH86818e/D3VLxjcWdqC3X/WoM+3Jr0IDzBtyMk4q7eabo/lXkM9vNKLfart5mM56kVnUV1ys2pe6+ZHylqum3elXz2l/EIrhACyBg2MjI5HFFdj8U9Ah0fxHMbGDyrRkRkG4nIIzuyfWivOkuV2Z7MJKSuj1i2G5xkck9M1rRAoAWHtjPasexcAg5Oe/FbyOGBPtjrXKl1PZloS2wyB0A9KvRk4+6MdhtqhCSXx1B68Vow7VKgspU8jJppXYPQWMCOQM0Zwx6Ek/yqxsVnIHGeduMAfnSRyxswE2SOOETrUq4hiLCObjLAFB/WqVhNldwiD5yQAcD0qUw/Kp3pkkEDg5FVb+5VRgsHOfuqQaprdqkagQMzHPtkfSloUotmoyMAGCqR1CsAaijn2Bt6nI6DFZkdxJt3+Thc8Gq8wmdsrJjJ6CpcrDUb7myl3yxUZye5xiqN1dmNjgxrhsVmCCQbxvYse1MS2zzIM4PrS5ilCKJJ712gBXBI6nFZ2JJZWebewxwijArTNtvPIPT1qJUKycD5RxkdRUvUtOxBHHAFGbc5x3PercUSMu11Ix0zzUyxAqRgEe5p8K7FwmCB2NAnK42Kzif723g5AzU0VoirlTznGc1ZtVV/lBwxUkAnH61Yht85YZwDycjim7EXZWW3IUgEZPYnk1KsIZeBhh0NXltmMakEE/nSiPkArtBODimQ3YoRDK5Py7eORn8acFIA6Ywe1XzFsk2lcr944P6UPb5BwAUPTB/OmibmcVILB+h54pJQpYYU4Aq6YMk5A54U5qNosMRwQBz9KLD50VFOzAY/Lng4zVnBReFyuR+FSIEUEZzx0z1pUiPOz5kI6HtSsNO5CzllwMc9xUiHJGQRnsT1qXy8tsCAjjAz0zTriRLa3aOJPMnbjcPuimPczL+fYwP3pDn5cdqzIkkeXzJSSB0GOlbAt/3T+YS0rc7j3I61CW2jkYB5qWVtoirHGF65JJzkVYjiAAJUfjTVO1gVU4zzgc1cttu4uSTihIlkHloc/MFwOlRTpgYyMA81fuChiboCSPwqjJESGb8cVT7DjYj35BBwAT0qykSso+YAe1QrEyAHjPpirUCNuGegqCpJboasZVtpJLe5zT1XHTHvU5QLu3HB68dKQp067vpTRF2TRgOozgDPQ1OYgPLdcBwflUc5qGNAFJPzNjgD19KOQcbSzN3B6VVxFncQR5oIIPJOTj6VPvQjggH0GMVQ5wMblGBw3c1YjWXYhbCr2BOKaYco5AqSneSMjkqwx+Q6VYjlCYx16ZJA4pqnkNzgfKcc5/SpAi+VnGxsZHTH51V7kt3LMbp/rCyxKRwVGB7n1qCSYYKp8qZySBy3vn0qMq5O3loz07frUUq7pSUOE659fc0XsS4izMGGFI2HoAKoXMQZjxxV9RsQd8k9e3uajkBaNWIBxyFz+ppbkvRmHPGOoGO31qjcQgMMjjvxWzIpY7upzjpVa4jV1JXIxSA5nWLYNF+7jAA/WjwheDZJp0jYeHMkWe6nqB9KvXY4JIznpjtXKaykltPFdW5xPC4dGB6kdq3oVeSV2cmKw/tIWO789lIJGfpxUquCP9nPpWTY3iahZxXMWF3j5gOqt3FaKuGiGe3evVT6nz0k1oyO/iM0fqR0rNs2aB8S5wD+VafnhMcUkkcUqHtnmqM2iZPJuUAIG7+dZ97D9mY5+6ai3taygHlQeKfLM11FtY5+lArhbhGHOM+/eq92w83CDgelWra2GwjnmmT2rRyZABzQIWBC+056DpWndNNDqUaXLWrNLGqTBx8uO2/HesseYuGjDFQRkgZx9a1LtLe7mE88F/HK3LpHFkE+oPaokaQehyfxC0J9UWf7UifaEUABOm3HGPbFFb2pNLc3RJiaJdoQRt1CgYFFJwi7XKVSUdIswbV1UY24960Yp8qMgk9KwRcKDknGDnGaniuWZgF3D1J6V4h9qkjpYZAu0nI49aeL1yxEYJHv0xWVaZLB5HB74JrQViUwpIFCZL0Lq306bXilAfqMDpU0k1zeIWmuZCBxjOKpIo2nBOaniQg7fUdB2p3YrDYYVjLFRzng9zUqwEspGc+3Jq2kOQu7Cge9OkUJuKnHHIPemkDnd2KhiVcJnO7sRzTBbhSQwIIP0zUrnLkMT04pFDZC/e44bH9Kl6FJMjkjAf5Rg4qnIgLEqM1feNmKtk8DrVaSMghhkAdMdzWZaRFzgYwPoabIPmIGAD/npUyjJGVA9SaVwUfdhSB2PFMNbjdg2YUjIpY1wQOhHSk81NvIwTzwKQTRFgS20ds0E2ZaC5bCgAEYwa0NNkOx41UbfvfMMfr2rPs3SRiGbjBII7H6Vchl8ptxAJORnuOKaJe1jXjeFtoWNiwHOTnmmSiPzAGCoMZ+bjmso3isSW4OOQ2OPf6U24v4wjhHaUbeMjmquRyWNPexLui/ISFLKc803dibDuAoO0gdj3Nc9Lfk58mDauMKWbkGoJLu4CEeYCB7dc0uaw+W50fmwtgxn5icIo9PWqVzKNpbO0sxyD047msZXmZtzSseNuOmKXywSrsSw9DRzE8lupotexrjlSw6E9DUsN/Eq5SVTjg5PNZgiDEZQcHp6U9UhUZCqeOg60rlXSNiS8jcK8ckIUnaxB5P1pTPEU/c/LGOCc1zp2qpATknqO1TRbSg4K/TjNFy1FG/Lt+yRzNhtrY46Dis2/2RTkqu0YDLketV85glUSP1Bx24qC782by2Z2K4xljQ2XGJa84mPgE+uatQyqsa7znPaspt/yg7ig4wPWpo2QN3GfWlcbgrF+Qqy5Az/WonlwBjC/56UjsRHgMCOxBoiiGQWHA7EcUXFypE6AnaePcelWETsv51XcbHAIwTT4Z13FSCB7dKpMTg9xZFfBxkMOvuKdEvyDd979am3YbC4OBkE1JGN33htc9PenoGy1GqSX6/7o6AVKGGD0znjnr9KURYBzjNBRQoPHHakybXHvgYJxkjkdcVIGUIFHHGOMmqruCMfr60sbBlGSSfX1pWHyllZDwQxCKc564NWDjcCAASc5x1x7Vnna7bVIAXv2NWWGF2tnIxnnkZppktE/mkgrkr3IYfepu8M2GXGfWoY3JdVc5z0J7KOlWpkJUIflK9DjIOaLkNWK7JgM24ksec9DTWBZCrDDBuVI6/8A1qsnKLgqSD2qOWMbWKkbcZ3dMD/GjYTKLx5JJyo7MR1FUZUAA7+taUrOeDkcZY/yFVp49y5AFUiNmYV9b5GU4I549K5zUgSCuzPOMEcfWuwuEKISQD9K5++i81nYKuTS5balx95WZzeiXg0zUGimcfZpnwT2Vh0b/GuylDphQdwPII5BHrXMXllA21ZcKuMcDrVjStRfTymn37hoRgRS54Un+E16GGrr4ZHjZhgmm6kDeaPKHGc+1MgkCtgk8VeijXOWbtwKpyoVmIHQmu654zJpYorlSD96qqL9mnIbpQC6vu7GrQiWfBY5zQItRFPKBGMHvUbrg88ioiGt/lb7p4xTJZCy7VIP40DI1lPmtHGx8tyAwHetq/2QSpHJq92j8bsKSF9jzXMDdHKWHGK6SSL7dGLi40+QyuAflmCCQ+uDz+VTMdO+qX6jrmz2mWRbh55Y9vmeYvO09CD3FFQtqDFLlJYPLnkIV8/wKvRQKKIruOT/AJTzqAJjew3MR+QrQtSBxwAR6VlWbAKc9fWtGHPBJx9a8Jn2adzXiGQoUjFaFsFVcMMmsmOQLjng9xV+3csoI/A0RHY144gVyo6VKibWwQcnnimWDhiobr9Otaiom1TgDGTgdTVpGfwsZbQ7wMZDjrtG41KkQIbCnOe43FafbtlsHvyVyWx+VTyf65VZi2f4c4GPcCmTfUz5YQ0nAxjtnNN8nMvzZC4yAOcVfuF2oMhuM8D5fp9apIcE9wegPFTY1i7jZ4g2eG49B0/CqcqYkC5JOO3FX3cGMLtPJwcH/OKz5MByuTtzg+1Syou5XeM7lVjkevp7VJJCu3Cgk9yaR2cnngA1JGxbAYbfQH+tJFNFQqBgY6VXliz/AHQeuK0LhTtyo696h8tcgkFh696mwKT3KALwMHjYg+gpyTuDne7buR7GrjRqy5wcHn61VmhMZyBwevtS1QXvuCgn5jyTxk1KibCMd/1pkbDZgqeD1FWFXfCrjlh1IoTGJtEnQLtHXPUUzyVVgx3deMdqniT96cqRuAxViZQIOMszHaMVauZsoqgY7uwPSpxCDgAkY7moEyPQKOKcZCy/KOegOO1BLiK5MbFQctng9qdFGW4K4zyDnrTApwAOvepAjgMcDb3oDlInt1BO0EDuOtNAAYAg+2anVWIJOc9aCgZTj7w5pGi0K6N5bkkYB6j1qZELxsMfMpBGBwRSIMNkDPpmng4JKkjIwcdKSVirjnQsVKgAY7CkdFJO8ZUDkj1qW2mUKN4Zsjbg/wBKdJGWJ6Hnknr0/WmMprHgfe59KminkQ4+VwOlNCYYDHAOCe1PG4tkdBxkUDFkkZ5AACg75qSMKCTkfSnRLgEMevrTkCbyCAcdh3oKvoWYozsLAA4HQ1LnayAkEjrjvVZCyMQGIBzweakQ5GcYx3pksuR4KgDrnJFMkVlIUsemKkglXZ94E9AQOanEZkjLDDFR09KrczvZmZIrggYBB56dqscwoFbDMw/zir6w5iYkBSDkjrgVAtqSxkA4Y8c5+uKLDcyARAQjjlRnr1qxCmBltzLzz3Bx0q0tsAOUOMce+R1poi2g/wAWQenAzQ0RzXImQq+Rl06ZA9KtPlYVDn5Txn070xx5bMSrBcgHB46ZzSK25APvKTgE9s8mpYnqQrI7Ku3pnAz1Bx1H4UksoKkhcDO5g3X0H+NOdCMAjgjPHbNMaMFlCHcp+Ye3ahA0iEqJCoPPqff1qJ0IEu7O0DAPStCRVC8L09PSqkqhsbeF6/WqRKsZVzl0CgEdvpWbOEUbYzvbvxxWjODcKIIsghsufWo3gSEBFILDrjtVXHaxg3NtwpPOayryzDMRJGHTnC4xz611TWzSDkgL6etU7mzKDOcDpnrS21CTTVjF0rVXsmhtr/d5OQsU3Yexz2966aSMsFkyCue1c9c2KzrslO5V6DsKg0zUptG3Wd3++sWOVYctF/iK76GIT92R4eMwVvfpnQzkFMBRmokmK4AzgU0ss0UbwyB435Vl6GhyQcZFdqd0eRK6ZbmcTxckBsVnorCQqT0HFN84q+AcjNOmcHDAfNTJb1GykqwZlzWlqdmdRuTdwXkCxSAH95JtaPjpj29qpxxS3IJSJ3ZeTtUn+VILO6KENazHj/nmf8KTWu4L0LGoTJNemSFzJGqqm/8AvkDGaKn1KJRf7cBdsUfGMY+UUUR2RT3PPrJwVGB0rVjXIGMc9axLMkkDjPUZFakUnzZznPByM4PtXhs+wpu5qRRgnggCr0KhRlRWZBMhbaW+nbFals25RyPxNQdCNCxYq4PrxittJNiESYJ7DPH44rGjAjIAPz59OlXIXAwuCfqe9WmRNXNWF22ZAJHQgA4qU43KVXDd8VTgzj5+R23A4zV1Sp7q2DkkKetWZWIJUMcYAxluc9Tn3JoWP5NoAIXpnofxp4y2S5PzemBxSMyxAbdv51FyrlSReckYxyM1UZf3rN275q1JKWY53H5s888en0qBm3dehGPp7UpGkLlVlEgXkgZ4+tP8v5R3Pc+tSwRgxnIwo5zUipgFecdM0JFNlKXcXYk57EYpjHkjsR0q68QClQORyKiWJiVY8HHepaGmiusTE4JwKW4iODwSMdatCIscsNvqBQwyoyenTPaixD3Ml49oz15qe0HLA8b/AMqJupIUY9MVEh2SYPHcVD3LRaZDjLFtyc8dxRdAs8ZBJUfkT3xTwrGInjDc9OvtTBhUZT8x/hGelVcCm2d2B90VYBBjHBWkZSMgKPYkZFMLAKCpz6j0oJa1JkcFtoX/AOvUhYAkDOO4qOFFIVhwQc4FSlGyMlSeo56e1MTQgkwuAPlpMcbQRzThE3GQfr6ULGyO2DjufeixV0Nnj4G4nI6ntShDwcjacc9ql3FiMdAM596eDlMYx2Ap2FcpHhXGOVOc1Yt5WC469+tNli/eZTn1pFRQN2cEHBHpUdS1qPPD8rsz/nmlLICoPTHPP3vpUka7lDbgSTk+tVdv74FW+YevencuKuWwNzYb5eOtPhyq8cjP+Qf8aRDgFSVOTjrTo9ySkBgMde9NCY5m2MSODjikt+WYsCOMkDtUiYbOcKevIzmm7dvLcL2PpnvV2JT6F+OON4SQenXParkSnYMMS3XaeeB2qhGzABQFHpmtK0y3yunfZg9eKEZS2Hy9VSM5ZudwNO8tYiWJAQDhT396Ihl2yPbA9vSpkjBTG44++wHQ1VjNsVBvUBuvOB0HHNNmcInJGGyA2PbipYl6MfnBPB9P8inXUaspcE/XGc4/lQyU7MozOJExnGSAMDrx1FQRRlm6BgQeRwDxilDNE5XhioGN305pVJYgK+PlIbHHSs+pvYmZNoCrgsMD6DFQoBucAD1Jz/KrDKSDv+UZ+8PYVEYsOwDZzwPfinYkkOGJzHlCOAOo9KqSQpsmfIQRjv2960Io85VQCCc89QBWHrdw0kklvC22IkM+O/tVLQSV3Yzot0hdYwVj6lj1NO+RSN4OT0A6/jUySgwmKEYT+L1IqHnIwvHuam47DQCRyep6CoJYwR82OegFTSHkjPHTApzRkRjH50rk8pjXluGztwT1P+FZN3bq6FXUsMdMdfaugkjZnLY46VVmiVfvDB64ouJxOSgNxpVw72wJhY5aJuhHt71sRXsd7EJIScj7yn7yfWrM1vG0eTkc8EGsW8091m+0WrGOUdR/jXZQxDhpLVHl4vBRqXlHRmqgGMk4qcFRg4H0rLtb9Z/3c6+VcdMHox9quPFJ0zg+nevSjJSV0eDOEoO0i8kssaE2k0kRPXa3WlF7fbf+Pmf/AL7NP0aNRb3E9xGZVhUYjzgMScc1ca3ivbdprJDHLGMyQZzx6r/hSbVxpO2jKKGWZy0js7nqzHJNFbFzHFDd7IlCjYhAHTkc0U07ofKeO2k/yAMcH61qQTq4UD5iPeuW01jIFLE4Irfs12pkdQa8R6n1lM2rY/OD09q2rPdywyfQVjWfIGe9a8LqpG04x6VGzOlS0NmLlV3ZBYevenwSENncRVOGXHGc55qVZF8wEgc8YpgjWhmAGV5wcseRn2qeOXdkFipJ7E8VlrJtPU4B9KtLM3G0AZ69jTuLlLjybVIXJPc98VFHOW4OfTriopZDg8kcUhJPQZ46dqQ+XSxM3yw4UnjvnNUW3qeeflq0A2wBDyeo9qrFyD/KpuaRWhKMfNgjAKjFPVgqLgHJyaYu0jOMMFB571IXG4L2BwPancTQydsqMA5xupIyDjOCOgzTnjGDt44HFOt4mKkYB7570WYOyRKwByw4ycU1owwJ5z7dqRx8pHIx60pUAEZ6GkTYzbqPEmV5AHaq24ZAbJ75NX5+pyevQ1RU8kEDHaoZaWhdik/depFR3CDBUEg46ikt2yCH6+op0o75+TFO4dTOjGGzg8cYPcU9HOcAdTt+lThVlBBHzDpimFMZC8c84p9Lg/IuxKFGBlR0yKtRAcZ57VSikYJhs4x609JCo44J9apMzcblqYDnAz9KjRNxIA6c81F5hDbgfz7e1TW/zAHJH0phyNIqTbllJ5x3wOKs2+SwDjGeg9qtNEH9D9KiK7duTxQx3TQ2SEx52gFPftTY1BUtgEHjNTzFZVKsML3qJ4ggG0kAnHFSwSYsIXDDg544pn2dHY5yMenJqWBAFPA2nhc0633JKMDp3HUfSkaJjGt3Uht2ewPrVeQYbqRjtjpWuxXcMsvzDp6fhVOZN8bBv4eB7UCi29yC2kfa3mD5egB6EVKGYFcHIGSoPOKaqA4BwRjgdwfUU/YRnafTnFWhz01RONu0H7gBxz0H/wBatC3kwQVcl8Ekk/oayPNIJDDbt/h7j/61OsLomR+Btz0bsKdzFxbRtQTCMgMCoPRgckf/AKqvxspUkNh8fdPTr0FY7TAkk8Z5+X1/wNTJKxkOXYg8fNzihMhxvqaLugUEBgR0x0OD0pplCoV5ICEA+vPFQu0iBsLnB6g+3PHvUNwy/I3GTwcccUOQ1Er3UwaZlA+bcPwp0YeAjacDjLjncajtCXkeRgCfvYWrYjVQxAzF2DHoaRq3bQmt2cnY52sc/ePUUpYblOSAWPWq24I+2QHZk4J5K1KZmXbsAYk9+ePanczsPmufstm0gH7xsKqg55PeuZuSd7hsgjlsVqSzefIuTmND09TVCVfOuJXKlVYnC9vxpSbKiuXUr7tq4UHb25xUjYB4xu9PSlCgoSSN3YDtTVUhdx249fWp2HuInVdy8DvVgjcpCcE0yMh0G/0H0qRc7VGOQKCWVZYzGct3PaopLdZVyANx6n1q8/zcnt60iRDcSBg9eKBMy5rVQuMcAdKzJ7faG2nr3x1rp5YVZcJ19+fyqjJbZUggkA8imZM47UII5VwyAe/qf8aLHVDbbbe/OUziKbufZv8AGtu9sPnO1cqecHtWPdWWcpMBt9a2o1pQehy4jDQrI6TT5LlJTJaRs4xhgq7wQfX1FTpBewyrJDbXCuDkMENcfpd3faBeIVEk9pux5YySFPbFdC6Xrr5sCXaQtyuSxwK9KFRVFdHg1qMqLtIm1G5uGvGe6Qxy4AZQuOMcUVXkV2Tc7Fm9ScmitlorGDd9TxPR5vMVSD8tdZYOCFBxzxXnnhu5DRKuQTiu201yVU/yrxmfUUWdUijywVByOauRZJGB25qhY3G6MJnitK3OSBk1idsS5Cozwcd+vWrMZXJLcj6VFAmTk4GPerCYJHTJoKLKMhQE4A7Vat2HIIx6cZNU4ztYgAEDnFWiwxuyFJHUdqLlFvYCQzgZxSkjGNu32HB//VUVq3mx4bOB1Kjn8qtKu8BvfOCP84p3JIZVEaMTtPGPY1FAB5QJjzngD3qe7/eBEH3m5O6lMQeaONHJVBzkYOaRaIfKUryc9qY0bZYnGRj8qvJGSEz0zk8d6e9uF+YEkEgYPUDFOxPNYqxp/e5OM8U8PswynjmpNgBVT1K5x9OtIsYJXP3TgjBzmqIuMRTI67jwec0Sg9uQB6d6t+UE28dgT+tNaJlj6HeW9c9qTQKVzHu0ff2I9u1VWjIGWBHrxW1cwfKS4AI/CqsiKpIOQO+azsaxnoZ5XYvTg96mYAjHVe2aZjc+Mke9SN90f5xUssgjDA7hn64qcgfN2PXnoaaDiQHkgj5sUj4ZjyQCMZ9PamnoS463GkhGOemenc0NhgCCSfftUcisBjPy+opsSu2CRk+9O40u5oKI2QK/J61aSPagNUYVOTkHd7elXkVhwWA9+xNarUlliCMgYXgnk5olhB9PQ1Zs/uA7snGcU+WLnaPnI4OKdjFy1MjyQDuGcdfqKReuD07ZrSli2yBug9P1qvNGDlyAAT61Ni+YiXhCByR1FAB/gHHHFKmTKVXGCT0704gbd27n0qWgiSlS64+UYOajfaWBGBu4JPTNTRMBgjlm6DHP51BPl0YAEkc+4peZa10BkDIDjBGTkGnxnJKsDuYdfXHr61DCzSKuSpGDnnkVKIyQnXPTnvTTBor3UQJJXIPdRnI/OqySBCFI2+hxwR6/X2rSZWWRHIY9uuaiubdGkJiyCOcmqEn0EQANjkgDoO9XEkGFJzuA+8PSs5ZdvDDBHSj7VkHHA74oIdzVW8JfBYhsdSOtVr263Ku4jI4yO4rLnu0ALbmBx94CsbU9dWEpHIyHJ7HBqXJDUdTr7VnhVU6b+efSrhuduCpUFhhkP8VchpviCOdW2SDaeOe1bEV7HKoxgkYOaE7jlF9TfEbPHz2OdpPT/Co5HjSJdw2gfdbtUFveAAO5yOm4dQKW5uEkH3QI34LEcHnrVmN3exVnZbWyEnHmsTtx0565qvEwECseST196LhtzNyrLGMDnnnvUKuAmeMJj8aljvdWI7lj5hAwD2I70QA8Z6+hpzJuySOMZyTT4cNkdD6ipKT0JYogVO/PPHHerB45AAGMACmRYU7TyoHT1qVNqZ3YAPpTAjeMs3yjJOKjlQqTHu+YdWFSs5YhU4BPWmurHkAF84x61LYIYFcqADwPunFJJGQDkZbvVqNtp2vwR+lSyr8qHv2NNESMd1UZ2j5TwRWXc2+SuAMHkE1u3EOATyeazp0bB+U49KpMOS5V05cC5WCRYrtkxExOMHPOCehIrNSy8RWF351tJIFY5cS3ACfXJNbFvBAySzXILxQqCEBwWJOACfSqWoaZb39s89msimIbngZtxT/aHqK1jNrVHJVoqV09hdQ1C2vbiR7KVZCuBJt6bgOSPbNFYmu2LafqLHT1EYWON+O/ygmiu+niY8vvHjVcBU5rw2PnjQLjy5+WwPSvRdJuFKjng15RbSeVKpBIHSu30bUR5agHNcLPUpSPR7CUDHQVr28g3qR19c1xtjfAso5JNdBbTFdpMmG9KykjvhK51FrINwC4yeDk1d4boBn6VzXmuCjFtvPWtKG73J8o3c9alGjXY2UCsSEIJxxSopPG0/j3+lULa43Nh2257YzWnG43jYr+/erSuLUmhAQgZJzzn/CrCy4IUDBPUZ6VAsqNIQmN3XaRyfpUkZ3AsQeDzxzUM1XmW41/eK+eemKmiRfNb+91z6e1Z8srbPlIB9fSpkmClsMCcjIPrTTCSZNM+wEHilExK44U4xj3qlJJkMUbC5zg9/X8qjMu5xuyOwI9aFuHKi+cmUs2CMgnH61KMJGiqC23I+oHIrOWfLZB56dKtJMVfBGcnNVuZSVi7Gy5ySFww6+lPTbJk59Du9zk1VYgqWUbhnoRSJt8vjIOTn+VUiF6jmC+UzH5gRwDWZI27KHBJH5VpOuIG65Izn6dKzhHtZyQd361ElY1plQqVU45BHUUkZwSDjJ6Z6VakjJTco2+tVcggZHU1kzoi0J3K9upqMLvHXkHtViSKRyo2gN3welPWFmzhQAozz/M0Cc0Vo+oSQc5xUjpszx0HFTpDgHdk/73GKWSPMbbThgOMc0IzcuxBASducuSelaMKAICxBUnAyDz7VnWvChm6nkNnpWlaYIdCcZ5BPrWsBSdjUgiIUKuAMBh71aQAq2AMrjn3qnBMDFEVB2n5SM9KtK48rcSN+7k46dv8K1SOd3I5lLLjsD1PfH/AOuqA3IDu5wMmtBpFKHJ3DO4A8dqgmKps54IAKgdcg1LHFlGVSWJyB71DwCof7tSMpc9BjABFPEHylTyRxmsmbRdtxsXMmVUqM9jVgqJAGPDZ5GMmp7WzGA3QsMj3Hr7U+W354yFblc9/wD61CTBy10M1lMc3IBRvl5HQ1MP3YU4BA6LjH61d8nMMisEYnGAexHcVCiKroPmwgJPfPpTSDmI/K85AD8u44DZ4qCUvtAAzt4wKtum8nyiAfvMc4FZ9zKIZXXqRzx3qiU9SpOwbHoe1Zk0rIG5yBVuSZ5vurt3ZBJ4FYF5K6NIjdQPXioZpfuRalfLDCzuSAOTk8AV414o8VTXeokWbhbeI4VsfePf8K7nXo7jUoJYMlYypGQ3TNeM3SNBM8Mgw8bbGHv/AJFXGN9zgxFV3sjobLxReW7gs24E9jjFddovj+SMqGk/Bjj9a8r3cdQBnFLvA6c96bppmUcROK1PpDSfG1vdbVMiqT1BPeulXWFMCmNlMXZSc4r5bsNUltWGTvj4+Unn8K7PSNfDLlJWZT1Ut92paaOiFaMz3ouDbBEb5ZOQe4qMSFRtHUdfcVynhrXY7uALuzg55NdGJtyB0BJx83bipZqXDJgZjBKnt6VJASTx0HBqraOSG3EYFWYiqZPYjpSGmXo+FI7etNy3fkURNuXipZYTjkDPtSadroExFAKAqfnz09KsRLkqp+8erCo7eFViKgfOTktVmJfKBXIJPAY0IbIxHulA25JPJNOwyMeQcdDU6ZVGwow3eoW3cgDNVYV7laaTg7sBvUd/aqcq+djDEN6nmrUihmYHsOahJBUAArjvTsapWKi+ZbTMyqrBhtZWGQw9xVIrJBOs0L7ZF6Aen9a2rZBNuZhv2kAKTjcx4APtTNzSzSQyCCRVBwojxvx2BHIqkZyS1Od1N2vpGlkVRIQFKqMDjiirF7beTOwU7kIDIx6gEZGaKdyeXsfIK9c1s6JMVYAHIHQVlBF2n5R+VX9KADjAA4qzyoPU9B0uY7R2Y966axUhufmOciuT0n+Cuus+oqWd1N6GooOQCwOe1aNpnG1VJ5z0qhZAHbn1rYThFx6Vn1OlFiOKcYYbFQnrWnF5IAIZ5JMcgcCsmInzF5NdBajFvkcHfVoTdh1taM6GRo9iD+MnFWIvJhY4Y+g28/jVKR2N0VLMV54J4q5YgYX6mpKTZXJeV2Ej+Wp5XPemNaTxzZjeOVduTt/wqxfgHzMjoF/nVUEh1wSPmqTbZDDKduU+VlOcAdfrUakncynJ68dqk1HiIEdc1Xh6uO1CE9EWY2UL9TjmrkLZcBRkHnOeayk6xVfi6rVxMZ9jRR1O1GZ1PbNSI48s+Yo3dQfxrOiJKjJz1q8P9QfqKsxegTOzbWZ8AnGBUMg8yVm3EN296jn/ANbH/nvSXBIC4qWaQehLMS+7ovrgdKa9sHi3xrgAZPt7VW3He3J6Cppnbyh8x+6O9ZGqdmLayARHPODg+vPpUqqvJyFHq3T/APXVQdfw/rVleWXP94/ypoJIbcMMt/DnvtySf6VFGC5BLcdwDT+sbZ9f61LMBmTgdRSQdDGlAguiMYRvmGBnNbFknmRYBCvjOWOR9Pasy84trTH97+tXbf8A10g7baumKewit5N3IrBgGHK+/c1eivH2Hvnq2OcjvWdqBO1Tnn5eakiJA49f6VSeo5JWRrLMAcrgD7o/HpTZAq4BcsCRkdO1U07fSnW3M0eeeR/I02zLYRXUHD5GRjPXircPBXzFyPXuQKz+x+v9a0Yf9TH/ALg/nUFy2uXllQEgjJxnCj8hSAg7QEySMA9PqfpVdP8AVn8f50jE8cnpQJIueYBYTPJIFKcKowc/SqBmZoSkEXHYk459/akdiWuQScBelZcrN5LDccbvWqK5bXJZYwHLGUykn7qVFeRiONWPy56Y61as/ltGK8H1FVxyy55+Y9aCbmZLumfcxKjrtHQ/WsXU4FLNySwPT2roLv7zfSsq7/16fQVEnoV1MMQA7hjBOOD0NeQfEzSmsNZW6CgR3Aw2P74/+tXtE3/Hy31P864X4tIraCpKgnzByRVwOPEpHkLdz703P+1UgUYPA60ED0FWcRHkA+p9KnguHicOhII/X61W7j/eqWMAycjvQF7HY+F9fNvdLyQD1XPevY9J1NLqFCrZ3AZr5xteJ1xxzXrHgsnyIuT1rKWj0PQpSbjqeoLKV7nHp6VftmMidOvrWRacqua0bInzBzSe5t0NW1wDgE9PwFWsFQATkVRg6n6Veg+6tDIvqPTjg8r6VcUqUwBg8ciqafeqaL71SXuTupcDbkIpznrk0Ehfde571KeIosetRr9xvrVXEUpVTcWB4x8vvTI4wVOf4uo9Kmf/AFg/3KfH/qVpml2kVEQQs4Z8IcEPjO1geDj0qbagjYssETEEGRH3de6j1pq9D9aozcdOPmNUgcb6lPU3EshITCKAqg9Qo6ZoplyT5ZooZS2P/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Dyshidrotic hand eczema",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_18_41258=[""].join("\n");
var outline_f40_18_41258=null;
var title_f40_18_41259="Etiology of diastolic dysfunction";
var content_f40_18_41259=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F55751&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F55751&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Physiologic mechanisms and causes of diastolic dysfunction",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"3\" width=\"33%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Physiologic abnormality",
"       </td>",
"       <td class=\"subtitle1\">",
"        Alteration in parameter of assessment",
"       </td>",
"       <td class=\"subtitle1\">",
"        Common etiology",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Abnormal (delayed or incomplete) relaxation",
"       </td>",
"       <td>",
"        <p>",
"         Increased tau",
"        </p>",
"        <p>",
"         Increased IVRT",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         LV hypertrophy",
"        </p>",
"        <p>",
"         Myocardial ischemia",
"        </p>",
"        <p>",
"         LV dyssynchrony",
"        </p>",
"        <p>",
"         Abnormal loading",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Early diastolic filling abnormalities",
"       </td>",
"       <td>",
"        <p>",
"         Reduced peak filling rate",
"        </p>",
"        <p>",
"         Increased time to peak filling",
"        </p>",
"       </td>",
"       <td>",
"        Abnormal relaxation (see above)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Increased LV passive stiffness",
"       </td>",
"       <td>",
"        <p>",
"         Abnormal diastolic P/V relationship",
"        </p>",
"        <p>",
"         Increased stiffness constant",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Concentric LVH",
"        </p>",
"        <p>",
"         Increased collagen and fibrosis",
"        </p>",
"        <p>",
"         Myocardial infiltration (eg, amyloid)",
"        </p>",
"        <p>",
"         Increased vascular turgor",
"        </p>",
"        <p>",
"         Post myocardial infarction hypertrophy and fibrosis",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     LV: left ventricular; tau: time constant of isovolumic pressure decay; IVRT: isovolumic relaxation time; abnormal diastolic pressure/volume relationship: upward shift and/or increased slope of LV diastolic pressure/volume relationship.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_18_41259=[""].join("\n");
var outline_f40_18_41259=null;
var title_f40_18_41260="Pain management in EB";
var content_f40_18_41260=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F87169&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F87169&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Pain management in epidermolysis bullosa (EB)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"5\" width=\"20%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Daily activities",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dressings and baths",
"       </td>",
"       <td class=\"subtitle1\">",
"        Acute injury",
"       </td>",
"       <td class=\"subtitle1\">",
"        Perioperative",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        <strong>",
"         Topical therapy",
"        </strong>",
"       </td>",
"       <td>",
"        <p>",
"         Occlusive and protective dressings",
"        </p>",
"        Skin grafts",
"       </td>",
"       <td>",
"        <p>",
"         Occlusive dressings",
"        </p>",
"        <p>",
"         Bath additives (salt)",
"        </p>",
"        Adhesive removers",
"       </td>",
"       <td>",
"        <p>",
"         Occlusive dressings",
"        </p>",
"        <p>",
"         Skin grafts",
"        </p>",
"        <p>",
"         Topical lidocaine",
"        </p>",
"        Topical morphine",
"       </td>",
"       <td>",
"        <p>",
"         Operative preparation",
"        </p>",
"        <p>",
"         Lubrication",
"        </p>",
"        Padding",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        <strong>",
"         Traditional systemic therapy",
"        </strong>",
"       </td>",
"       <td>",
"        <p>",
"         Paracetamol",
"        </p>",
"        <p>",
"         Ibuprofen",
"        </p>",
"        Low-strength opioids",
"       </td>",
"       <td>",
"        <p>",
"         Paracetamol",
"        </p>",
"        <p>",
"         Ibuprofen",
"        </p>",
"        Low-strength and high-strength opioid combinations",
"       </td>",
"       <td>",
"        <p>",
"         Paracetamol",
"        </p>",
"        <p>",
"         Ibuprofen",
"        </p>",
"        Low-strength and high-strength opioid combinations",
"       </td>",
"       <td>",
"        <p>",
"         Paracetamol",
"        </p>",
"        <p>",
"         Ibuprofen",
"        </p>",
"        <p>",
"         Low-strength and high-strength opioid combinations",
"        </p>",
"        <p>",
"         Anti-anxiolytics",
"        </p>",
"        <p>",
"         Ketamine",
"        </p>",
"        <p>",
"         Nerve blocks",
"        </p>",
"        Propofol",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        <strong>",
"         Non-traditional systemic therapy",
"        </strong>",
"       </td>",
"       <td>",
"        <p>",
"         Tricyclic antidepressants",
"        </p>",
"        <p>",
"         Anticonvulsants",
"        </p>",
"        <p>",
"         Tetrahydrocannabinol",
"        </p>",
"        Dronabinol",
"       </td>",
"       <td>",
"        <p>",
"         Tricyclic antidepressants",
"        </p>",
"        <p>",
"         Anticonvulsants",
"        </p>",
"        <p>",
"         Tetrahydrocannabinol",
"        </p>",
"        Dronabinol",
"       </td>",
"       <td>",
"        <p>",
"         Tricyclic antidepressants",
"        </p>",
"        <p>",
"         Anticonvulsants",
"        </p>",
"        <p>",
"         Tetrahydrocannabinol",
"        </p>",
"        Dronabinol",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Psychological techniques",
"        </strong>",
"       </td>",
"       <td>",
"        <p>",
"         Relaxation",
"        </p>",
"        <p>",
"         Visualization",
"        </p>",
"        Yoga, meditation",
"       </td>",
"       <td>",
"        <p>",
"         Relaxation",
"        </p>",
"        <p>",
"         Visualization",
"        </p>",
"        Self-hypnosis",
"       </td>",
"       <td>",
"        <p>",
"         Relaxation",
"        </p>",
"        <p>",
"         Visualization",
"        </p>",
"        Self-hypnosis",
"       </td>",
"       <td>",
"        <p>",
"         Relaxation",
"        </p>",
"        <p>",
"         Visualization",
"        </p>",
"        Self-hypnosis",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Original figure modified for this publication. Goldschneider KR, Lucky AW. Pain management in epidermolysis bullosa. Dermatol Clin 2010; 28:273. Table reproduced with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_18_41260=[""].join("\n");
var outline_f40_18_41260=null;
var title_f40_18_41261="Antimicrob activity abx A";
var content_f40_18_41261=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F54268&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F54268&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Antimicrobial activity of topical antibiotics used for external otitis: Part A",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Organism",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\" rowspan=\"1\">",
"        Quinolones",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\" rowspan=\"1\">",
"        Tetracycline",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\" rowspan=\"1\">",
"        Sulfonamides",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Ciprofloxacin",
"       </td>",
"       <td class=\"subtitle2\">",
"        Ofloxacin",
"       </td>",
"       <td class=\"subtitle2\">",
"        Tetracycline",
"       </td>",
"       <td class=\"subtitle2\">",
"        Oxytetracycline",
"       </td>",
"       <td class=\"subtitle2\">",
"        Sulfacetamide",
"       </td>",
"       <td class=\"subtitle2\">",
"        Sulfisoxazole",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"7\" rowspan=\"1\">",
"        Gram-positive",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Corynebacterium diphtheriae",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Staphylococcus sp",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Staphylococcus aureus",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Staphylococcus epidermidis",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Streptococcus sp",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Streptococcus pneumoniae",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Streptococcus pyogenes (group A beta-hemolytic)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"7\" rowspan=\"1\">",
"        Gram-negative",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Bacteroides fragilis",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Citrobacter sp",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Enterobacter aerogenes",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Enterobacter sp",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Escherichia coli",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Haemophilus influenzae",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Klebsiella pneumoniae",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Klebsiella sp",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Proteus sp",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pseudomonas aeruginosa",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Bojrab DI, Bruderly T, Abdulrazzak Y, Otolaryngol Clin North Am 1996; 29:761.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_18_41261=[""].join("\n");
var outline_f40_18_41261=null;
var title_f40_18_41262="Tachygastria";
var content_f40_18_41262=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F66624&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F66624&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Tachygastria",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 373px; height: 128px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Electrogastrography of the gastric antrum shows a brief period of tachygastria between six and seven minutes, followed by a compensatory pause, and then return of normal pacemaker function with three contractions per minute.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Chen JD, Pan J, McCallum RW. Dig Dis Sci 1995; 13:275.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_18_41262=[""].join("\n");
var outline_f40_18_41262=null;
var title_f40_18_41263="Pediatric tachycardia without shock";
var content_f40_18_41263=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F58268&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F58268&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 605px\">",
"   <div class=\"ttl\">",
"    Pediatric tachycardia without shock",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 585px; height: 530px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     ARF: acute rheumatic fever.",
"     <br>",
"      * Signs of cardiac disease equals murmur, gallop, hepatomegaly.",
"      <br>",
"       &bull; For example, illicit drugs, cyclic antidepressants, diet supplements with caffeine, or herbal preparations.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_18_41263=[""].join("\n");
var outline_f40_18_41263=null;
